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Di(2-ethylhexyl) phthalate (DEHP) is a plasticizer used to confer flexibility and stability 
in common polyvinyl chloride products. DEHP can be found in numerous consumer products 
and is a ubiquitous chemical. Humans are exposed to DEHP daily due to its widespread use and 
ability to leach from out of products. DEHP and its bioactive metabolites are found in human 
tissues such as amniotic fluid, cord blood, breast milk, and human follicular fluid. Exposure to 
DEHP is a public health concern because DEHP is a known endocrine disrupting chemical and 
reproductive toxicant in females. The presence of DEHP in tissues vital for reproduction and 
development suggests that DEHP exposure occurs at various developmental stages; thus, posing 
as a potential toxicant for several generations. 
Multiple organs are required to facilitate healthy reproduction. Organs within the 
hypothalamic-pituitary-ovary axis consist of the hypothalamus, anterior pituitary, and the ovary 
and are vulnerable to toxicant exposure. Specifically, the ovary is a heterogeneous organ 
composed of follicles, oocytes, corpora lutea, and interstitial tissue. The primary roles of the 
ovary are to produce sex steroid hormones and maintain a steady stream of growing follicles. 
Normal sex steroid hormone production by the mature follicles is essential for the maintenance 
of normal menstrual/estrous cyclicity, reproductive tract tissues, and non-reproductive tissues 
such as bones, the heart, and the brain. In addition, the mature antral follicle is the only follicle 
type capable of ovulating and releasing an oocyte for potential fertilization. Therefore, female 
fertility is dependent on the maintenance of a constant stream of growing follicles and sex steroid 
hormone secretion throughout the reproductive lifespan. 
The ability of endocrine disruptors to cause disease and infertility is a major concern, but 
even more troubling is that some of the effects of DEHP may be multigenerational or 
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transgenerational in nature. To obtain a multigenerational or transgenerational effect, the 
phenotype or the effect must be passed from one generation to a subsequent generation. During 
prenatal exposure, the F0 generation is exposed to DEHP during pregnancy. The F1 generation is 
exposed as a developing fetus and the F2 generation is exposed as the developing germ cells 
inside the fetus. Both the F1 and F2 generations are directly exposed and effects observed in 
these generations are considered multigenerational effects. The subsequent generation, the F3 
generation, is the first generation that is not directly exposed to DEHP and any effects observed 
are considered transgenerational effects. The transgenerational phenomena does not involve 
direct exposure and usually involves epigenetic changes induced in the germline. 
Limited information is available on the effects of environmentally relevant DEHP 
exposure on female reproduction and even less information is available on the effects of DEHP 
on female reproduction across generations. Therefore, the goal of my doctoral dissertation work 
was to investigate the multigenerational and transgenerational toxicant effects of DEHP on 
female reproduction. Specifically, I investigated the effects of prenatal and ancestral DEHP on 
ovarian steroidogenesis and folliculogenesis and how DEHP exposure affects female 
reproductive outcomes in the F1 – F3 generation of mice. Additionally, I investigated how 
prenatal and ancestral DEHP exposure disrupts gene expression and DNA methylation in 
juvenile mouse ovaries across generations. 
First, I tested the hypothesis that prenatal and ancestral exposure to environmentally 
relevant doses of DEHP decreases folliculogenesis and impairs steroidogenesis in the F1 – F3 
generations. Folliculogenesis is the process in which follicles in the ovary develop and mature 
towards ovulation to release the oocyte for fertilization. Steroidogenesis involves the production 
of sex steroid hormones by the mature follicle type. I found that prenatal DEHP exposure 
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decreased folliculogenesis and the percentage of atretic follicles in adult ovaries the F1 
generation. DEHP exposure disrupted folliculogenesis in adult ovaries in the F2 generation. 
Ancestral DEHP exposure accelerated germ cell transition into primordial follicles in neonatal 
ovaries in the F3 generation. I also found that prenatal DEHP exposure increases serum 17β-
estradiol levels in the F1 generation and altered serum progesterone levels in the F2 generation.  
Next, I tested the hypothesis that prenatal and ancestral DEHP exposure to 
environmentally relevant doses impair reproductive outcomes in the F1 – F3 generations of 
female mice. Sex organs are particularly sensitive to endocrine disruptors and during a 
developmental window of exposure. I found that prenatal and ancestral DEHP exposure caused 
precocious puberty and disrupted normal estrous cyclicity in all three generations of mice. I also 
observed changes in birth outcomes such as increased litter size in the F2 generation and 
increased percentage of female pups per litter in the F3 generation. Additionally, I found that 
prenatal DEHP exposure decreased fertility in the F1 and F2 generations. Specifically, prenatal 
DEHP exposure decreased the mating index and pregnancy rate in the F1 generation and 
decreased the gestational index in the F2 generation.  
Further, I tested the hypothesis that prenatal and ancestral exposure to environmentally 
relevant doses of DEHP differentially expressed genes in pathways critical for ovarian functions 
and increased DNA methylation in whole ovaries in the F1 – F3 generations. I found that 
prenatal and ancestral DEHP exposure disrupted gene expression in various pathways in the 
ovary. In the F1 generation, prenatal DEHP exposure increased the expression of Dnmt1 and 
increased the percentage of 5-mC in the whole ovary. In the F2 generation, DEHP exposure 
decreased the expression of Tets. In the F3 generation, ancestral DEHP exposure decreased the 
expression of Dnmts, Tets, and decreased the percentage of 5-mC in the whole ovary. 
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Collectively, my doctoral dissertation work shows that prenatal and ancestral exposure to 
environmentally relevant doses of DEHP cause multigenerational and transgenerational 
impairment of ovarian health and function, female reproductive outcomes, ovarian gene 
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Phthalates are synthetic endocrine disrupting compounds commonly used as plasticizers 
to confer flexibility and stability in consumer products including children’s toys, food containers, 
furniture, personal care products, medical devices, and housing materials [1, 2]. Phthalate 
exposure is associated with multiple adverse health effects in humans [3-5] and experimental 
animals [6]. DEHP is a commonly used phthalate, di(2-ethylhexyl) phthalate (DEHP), and a 
known developmental and reproductive toxicant [7-9]. Specifically, in females, DEHP exposure 
reduces folliculogenesis and steroidogenesis in vitro [10], and DEHP exposure in adulthood 
alters estrous cyclicity, accelerates follicle recruitment [11], and accelerates reproductive aging 
in mice [8].   
DEHP and its bioactive metabolites are found in human tissues such as amniotic fluid, 
cord blood, breast milk, and human follicular fluid [2]. The presence of DEHP in tissues vital for 
reproduction and development suggests that DEHP exposure occurs at various developmental 
stages; thus, posing as a potential toxicant for several generations. Numerous studies have 
examined the effects of prenatal exposure to DEHP and its metabolites on the offspring. In 
animal studies, prenatal exposure to DEHP induces premature reproductive senescence in male 
offspring [9] and leads to cryptorchidism in male rats [12]. Human studies show that DEHP 
exposure in pregnant women is associated with adverse outcomes in the offspring [13-16]. 
Specifically, prenatal DEHP exposure is negatively associated with birth weight [16] and head 
circumference [17] and with increased odds of male newborn genital anomaly [14]. These 
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studies demonstrate that prenatal exposure to DEHP and its metabolites negatively impact the 
next generation. 
Despite the importance of fertility in females across generations, little is known about the 
mechanism by which exposure to environmental chemicals impacts female reproduction in each 
generation. Previous studies in male rodents suggest that epigenetic changes in DNA methylation 
can induce transgenerational effects. In male rats, prenatal exposure to DEHP induces epigenetic 
transgenerational inheritance of cryptorchidism by increasing differentially methylated DNA 
sequences in the testes [12]. Disruption of DNA methylation is an inheritable epigenetic 
modification and can be passed to future generations. In females, however, the epigenetic 
mechanism of action of DEHP is not known. It is critical to elucidate the epigenetic mechanisms 
underlying the DEHP-induced transgenerational effects in females to better understand the 
impacts of chemical exposure in future generations. 
Therefore, the goals of these studies were to investigate effects of prenatal and ancestral 
exposure to DEHP on female reproductive functions and the underlying mechanisms by which 
DEHP exposure impacts the ovary in each generation. This was done by testing the hypothesis 
that prenatal and ancestral exposure to DEHP causes transgenerational effects on 
folliculogenesis, steroidogenesis, fertility, and the epigenome of the ovary the F1, F2, and F3 
generations of female mice. To test this hypothesis, I completed the following specific aims: 
Specific Aim 1: Determine if prenatal and ancestral exposure to DEHP reduces the number 
of healthy ovarian follicles and serum sex steroid hormone levels in the F1, F2, and F3 
generations.  
To complete this aim, I orally dosed pregnant CD-1 mice with vehicle control 
(tocopherol-stripped corn oil) or DEHP (20 µg/kg/day, 200 µg/kg/day, 500 mg/kg/day, or 750 
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mg/kg/day) daily from gestation day 10.5 until birth. Following dosing, pregnant mice gave birth 
to the F1 generation and females were used to produce the F2 generation. The F2 females were 
used to produce the F3 generation. I then examined the effects of prenatal and ancestral DEHP 
exposure on folliculogenesis and sex steroid hormone levels. On postnatal days 1, 8, 21, and 60, 
ovaries were collected and used for histological evaluation of follicle numbers and sera were 
used to measure progesterone, testosterone, estradiol, luteinizing hormone, and follicle 
stimulating hormone levels.  In the F1 generation, prenatal exposure to DEHP disrupted organ 
weights (20 µg/kg/day, 200 µg/kg/day, and 750 mg/kg/day), decreased folliculogenesis (200 
µg/kg/day and 750 mg/kg/day), and increased serum estradiol levels (20 µg/kg/day, 500 
mg/kg/day, and 750 mg/kg/day). In the F2 generation, exposure to DEHP decreased body 
weights (20 µg/kg/day) and organ weights (200 µg/kg/day), dysregulated folliculogenesis (20 
µg/kg/day, 200 µg/kg/day, and 750 mg/kg/day), and disrupted serum progesterone levels (20 
µg/kg/day, 200 µg/kg/day, 500 mg/kg/day, 750 mg/kg/day). In the F3 generation, DEHP 
exposure accelerated folliculogenesis (500 mg/kg/day and 750 mg/kg/day). These data suggest 
that prenatal exposure to DEHP leads to adverse multigenerational and transgenerational effects 
on ovarian function. These data are presented in Chapter 3. 
Specific Aim 2: Determine if prenatal exposure to DEHP leads to infertility or reproductive 
complications in the F1, F2, and F3 generations.  
To complete this aim, I orally dosed pregnant CD-1 mice with vehicle control 
(tocopherol-stripped corn oil) or DEHP (20 µg/kg/day, 200 µg/kg/day, 500 mg/kg/day, or 750 
mg/kg/day) daily from gestation day 10.5 until birth. Following dosing, pregnant mice gave birth 
to the F1 generation and females were used to produce the F2 generation. The F2 females were 
used to produce the F3 generation. In the F1 – F3 generations, the onset of puberty, estrous 
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cyclicity, time for mice to become pregnant, birth outcomes, and fertility related indices were 
collectively measured from 3 to 9 months of age. In the F1 generation, prenatal DEHP exposure 
accelerated the onset of puberty (200 µg/kg/day), caused abnormal estrous cyclicity (200 
µg/kg/day and 500 mg/kg/day) and disrupted fertility-related indices (20 µg/kg/day and 200 
µg/kg/day). In the F2 generation, DEHP exposure accelerated the onset of puberty (500 
mg/kg/day), caused abnormal estrous cyclicity (20 µg/kg/day and 200 µg/kg/day), increased the 
litter size (20 µg/kg/day and 500 mg/kg/day), and disrupted fertility-related indices (500 
mg/kg/day). In the F3 generation, DEHP exposure accelerated the onset of puberty (20 
µg/kg/day, 500 mg/kg/day, and 750 mg/kg/day), caused abnormal estrous cyclicity (20 
µg/kg/day), and decreased female pup anogenital index (750 mg/kg/day). Collectively, the data 
show that prenatal DEHP exposure at environmentally relevant doses accelerates the onset of 
puberty, disrupts birth outcomes, and disrupts fertility-related indices; thus, suggesting that 
DEHP causes female reproductive problems in a multigenerational and transgenerational 
manner. These data are presented in Chapter 4. 
Specific Aim 3: Determine if prenatal and ancestral exposure to DEHP reduces mRNA of 
key ovarian regulators and induces differential methylation in the F1, F2, and F3 ovaries.  
To complete this aim, I orally dosed pregnant CD-1 mice with vehicle control (tocopherol-
stripped corn oil) or DEHP (20 µg/kg/day, 200 µg/kg/day, 500 mg/kg/day, or 750 mg/kg/day) 
daily from gestation day 10.5 until birth. Following dosing, pregnant mice gave birth to the F1 
generation and females were used to produce the F2 generation. The F2 females were used to 
produce the F3 generation. At postnatal day 21 for each generation, mice were euthanized and 
ovaries were removed for gene expression analysis of various ovarian pathways via qPCR and 5-
mC quantification. In the F1 generation, prenatal DEHP exposure disrupted the expression of 
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cell cycle regulators (20 µg/kg/day, 200 µg/kg/day, 500 mg/kg/day, and 750 mg/kg/day), 
decreased the expression of peroxisome-proliferator activating receptors (20 µg/kg/day and 750 
mg/kg/day), and increased the percentage of 5mC in the ovary (20 µg/kg/day) compared to 
control. In the F2 generation, exposure to DEHP decreased the expression of steroidogenic 
enzymes (20 µg/kg/day, 500 mg/kg/day, and 750 mg/kg/day), dysregulated the expression of 
PI3K-pathway factors (20 µg/kg/day, 200 µg/kg/day, and 750 mg/kg/day), decreased the 
expression of apoptosis factors (20 µg/kg/day), and decreased the expression of Tet (20 
µg/kg/day, 200 µg/kg/day, 500 mg/kg/day, and 750 mg/kg/day) compared to controls. In the F3 
generation, ancestral DEHP exposure decreased the expression of steroidogenic enzymes (20 
µg/kg/day, 200 µg/kg/day, 500 mg/kg/day, and 750 mg/kg/day), decreased the expression of 
PI3K-pathway factors (20 µg/kg/day, 200 µg/kg/day, 500 mg/kg/day, and 750 mg/kg/day), 
decreased the expression of cell cycle regulators (20 µg/kg/day, 200 µg/kg/day, and 750 
mg/kg/day), decreased the expression of apoptosis factors (20 µg/kg/day, 200 µg/kg/day, 500 
mg/kg/day, and 750 mg/kg/day), decreased the expression of Esr2 (20 µg/kg/day, 200 µg/kg/day, 
and 750 mg/kg/day), decreased the expression of DNA methylation factors (20 µg/kg/day, 200 
µg/kg/day, 500 mg/kg/day, and 750 mg/kg/day), and decreased the percentage of 5mC (500 
mg/kg/day and 750 mg/kg/day) compared to controls. Overall, the data show that prenatal and 
ancestral DEHP greatly suppresses gene expression of pathways required for folliculogenesis 
and steroidogenesis in the ovary in a transgenerational manner and that gene expression may be 
influenced by DNA methylation. These results provide insight into some of the mechanisms of 
DEHP-mediated toxicity in the ovary across generations.  These data are presented in Chapter 5. 
Collectively, this work determined that prenatal and ancestral exposure to DEHP disrupts the 
expression of pathways important for normal ovarian function and it causes epigenetic changes 
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in the ovary of subsequent generations. This study provides a better understanding of how DEHP 
exerts transgenerational effects on reproduction. 
In summary, Chapter 1 provides an overview of my dissertation. Chapter 2 provides 
background information on phthalates, endocrine disruption, transgenerational epigenetic 
inheritance, female reproduction, and the epigenetic effects of endocrine disruption on female 
reproduction. Chapter 3 describes the work that tests the hypothesis that prenatal exposure to 
DEHP disrupts ovarian function in a transgenerational manner in female mice. Chapter 4 
describes the work that tests the hypothesis that DEHP exposure during prenatal development 
causes adverse transgenerational effects on female fertility in mice. Chapter 5 describes the work 
that elucidates the mechanisms by which DEHP exposure disrupts ovarian function across three 
generations. Finally, Chapter 6 summarizes the findings presented in the dissertation and outlines 
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The Epigenetic Impacts of Endocrine Disruptors on Female Reproduction Across 
Generations 
2.1 Abstract 
Humans and animals are repeatedly exposed to endocrine disruptors, many of which are 
ubiquitous in the environment. Endocrine disruptors interfere with hormone action, thus causing 
non-monotonic dose responses that are atypical of standard toxicant exposures. The female 
reproductive system is particularly susceptible to the effects of endocrine disruptors. Likewise, 
exposures to endocrine disruptors during developmental periods are particularly concerning 
because programming during development can be adversely impacted by hormone level changes. 
Subsequently, developing reproductive tissues can be predisposed to diseases in adulthood and 
these diseases can be passed down to future generations. The mechanisms of action by which 
endocrine disruptors cause disease transmission to future generations are thought to include 
epigenetic modifications. This review highlights the effects of endocrine disruptors on the female 




2.2 Endocrine Disruptors 
Synthetic chemicals have become a part of people’s everyday lives and some of these 
chemicals have been identified as endocrine disruptors. Endocrine disruptors are exogenous 
chemicals, mixtures of chemicals, or non-chemical exogenous factors that interfere with the 
body’s normal endocrine system, leading to adverse effects on hormonally controlled functions 
[1]. Endocrine disruptors are heterogeneous and vary from synthetic to natural chemicals. 
Specifically, synthetic chemicals such as polychlorinated biphenyls, plasticizers, pesticides, 
fungicides, and pharmaceutical agents are known endocrine disruptors [1]. Natural chemicals 
such as phytoestrogens found in food are also known endocrine disruptors. These chemicals 
serve various purposes and are ubiquitous in the environment [1]. Endocrine disruptors interfere 
with hormone actions by mimicking hormones, promoting inappropriate responses at improper 
times, or by blocking hormone action, leading to alterations in the hormonal and homeostatic 
systems and interfering with the ability of the body to communicate with and respond to the 
environment [1]. Endocrine disruptors tend to have a low binding affinity for hormone receptors 
and their ability to activate or block hormone receptors may vary. Although it is often difficult to 
define adverse effects, some researchers consider any biological response to an endocrine 
disruptor to be an adverse event [2]. 
Endocrine disruptors are prevalent in the environment. These disruptors are found in 
food, consumer products, water, soil, and in wildlife and people who are exposed through 
ingestion, inhalation, dermal contact, or injection [1]. Examples of endocrine disruptors vary 
from chemical to non-chemical exogenous factors [1, 3]. Chemical endocrine disruptors can be 
categorized into three major groups: pesticides, chemicals in consumer products, and food 
contact materials [4]. Examples of pesticides that induce endocrine disruptive activities include 
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glyphosate, dichlorodiphenyltrichloroethane, atrazine, chlorpyrifos, and methoxychlor [4-6]. 
Endocrine disruptors found in consumer products include, but are not limited to, brominated 
flame-retardants, phthalates, parabens, heavy metals, polychlorinated biphenyls, nonylphenols, 
diethylstilbestrol, and perfluorochemicals [4, 7-9]. Additional endocrine disruptors described as 
food contact materials are bisphenol A, phthalates, and phenols [4, 8]. Non-chemical endocrine 
disruptors include light at night, improper nutrition, stress, and diet [3, 10-13]. 
Numerous endocrine disruptors exist, but this review will focus on several well-
documented endocrine disruptors (Table 2.1). Specifically, bisphenol A (BPA) is a well 
described endocrine disruptor [14]. BPA is a synthetic chemical used mostly in polycarbonate 
plastics, epoxy resin liners in aluminum cans, and thermal receipts. It can act through various sex 
steroid hormone receptors, including estrogen receptors 1 and 2, androgen receptors, and thyroid 
hormone receptors [15]. Phthalates, like BPA, are a class of chemicals that serve as plasticizers 
and act as endocrine disruptors [16, 17]. Diethylstilbestrol (DES) is another example of an 
endocrine disruptor [16]. It was a pharmaceutical agent used as an anti-abortive drug until the 
1970s, but it is no longer used due to its reproductive toxicity [16]. 
Dichlorodiphenyltrichloroethane (DDT) and its metabolite dichlorodiphenyldichloroethylene 
(DDE) are organochlorine insecticides and are well known endocrine disruptors [16, 18, 19]. 
Methoxyclor is another organochlorine pesticide and endocrine disruptor that was intended to 
replace DDT, but is now banned in many countries due to its toxicity [19]. Vinclozolin is a 
dicarboximide fungicide used in agriculture, but more specifically in the viniculture industry, and 
it exhibits endocrine disrupting effects [20]. Further, 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD) is a potent polychlorinated dibenzodioxin and endocrine disruptor. It is formed as a by-
product of organic combustion and was a major component of the Agent Orange that was used 
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during the Vietnam War. It also was a major environmental contaminant from an industrial 
explosion in Seveso, Italy [16, 21]. 
Endocrine disruptors cause nonmonotonic dose responses such as sigmoid, U-shaped, or 
inverted-U-shaped curves [1, 22]. For example, xenobiotics that mimic estrogen stimulate MCF-
7 human breast cancer cell proliferation at low doses, but saturate the cell growth response and 
do not increase proliferation at high doses [23]. Although the mechanisms behind such 
nonmonotonic effects are not fully understood, they may be due to receptor type and abundance 
in specific cells or tissues [24], receptor down-regulation and desensitization [25, 26], and 
endocrine feedback loops [27, 28]. 
Endocrine disruptors also have been shown to act at low levels and in the range of normal 
human exposure [1]. This is not surprising because endocrine disruptors mimic endogenous 
hormones, which act at low concentrations. Therefore, studies that utilize environmentally 
relevant and low doses are important for understanding the effects of endocrine disruptors in the 
body. 
Recently, several studies have linked exposure to endocrine disruptors to adverse 
reproductive outcomes. For example, the incidence and prevalence of diseases involving 
reproductive tissues such as breast cancer, prostate cancer, and polycystic ovarian syndrome 
have increased over time [29-31]. These diseases are influenced by both genetic and 
environmental factors, but dramatic increases in incidence and prevalence suggest that these 
diseases are largely due to environmental factors. An analysis of about 44,800 pairs of twins 
from Sweden, Denmark, and Finland shows that the environment, and not genetics, substantially 
influenced the rates of sporadic prostate and breast cancers [30]. Another study demonstrates that 
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exposure to bisphenol A, an endocrine disruptor, plays a major role in polycystic ovarian 
syndrome pathogenesis [29].  
The reproductive system is especially vulnerable to endocrine disruptors during 
development. The developmental origins of health and disease (DOHaD) is a paradigm in which 
environmental exposures during development can lead to health and disease risk later in 
childhood and adult life [32]. The concept is that environmental stressors including malnutrition 
and exposure to environmental endocrine disruptors during critical periods of development cause 
subtle changes in  gene expression that lead to permanent alterations in an organ, tissue, or 
structure. The alteration will then lead to a health and disease risk later in life [32-34]. In 
addition, DOHaD disease risk can be transmitted across generations [32].  
Endocrine disruptors act through multiple pathways to influence developmental 
programming. For example, during early development, the fetus is protected from exogenous 
estrogens by a plasma protein, α-fetoprotein, which binds estrogens and protects the fetus [35]. 
Some endocrine disruptors bypass α-fetoprotein due to weak binding affinity, subsequently 
rendering the fetus vulnerable to toxicity [36]. Further, other hormone-binding proteins circulate 
through the blood and endocrine disruptors may bind to these proteins, disrupting the balance 
between hormone-binding proteins and endogenous hormones [37]. Further, endogenous 
hormones may be less bioavailable, whereas the endocrine disruptors are physiologically 
available, causing inappropriate hormone signaling [37, 38]. The ability of endocrine disruptors 
to interfere with hormone levels during development is of concern because cell differentiation 
and tissue development can be adversely impacted by hormone level changes. Subsequently, 
these tissues can be predisposed to diseases in adulthood and disease can be passed down to 
future generations [39].  
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2.3 Epigenetic Mechanisms 
The ability of endocrine disruptors to cause disease and infertility is a major concern, but 
even more troubling is that some of the effects of endocrine disruptors may be multigenerational 
or transgenerational in nature. To obtain a multigenerational or transgenerational effect, the 
phenotype or the effect must be passed from one generation to a subsequent generation. Multiple 
exposure paradigms produce multigenerational and transgenerational effects.  
The first paradigm is by adult life exposure. The F0 generation is exposed to an endocrine 
disruptor during adult life. During this window, the F1 generation experiences preconception 
exposure as the germ-line. Once the F0 generation produces the F1 generation, any effects 
observed in the F1 generation are due to multigenerational effects of endocrine disruptor 
exposure. To observe a transgenerational effect from adult exposure, the subsequent generation, 
the F2 generation, must be produced. This is the first generation that is not directly exposed to 
the endocrine disruptor and any effects observed in this generation are considered 
transgenerational effects [40-42]. 
The second exposure paradigm is by prenatal exposure (Figure 2.1). The F0 generation is 
exposed to an endocrine disruptor during pregnancy. During this exposure window, the F1 
generation is exposed as a developing fetus and the F2 generation is exposed as the developing 
germ cells inside the fetus. Both the F1 and F2 generations are directly exposed and effects 
observed in these generations are considered multigenerational effects. The subsequent 
generation, the F3 generation, is the first generation that is not directly exposed to the chemical 
and any effects observed are considered transgenerational effects [40-42]. The transgenerational 
phenomena does not involve direct exposure and usually involves epigenetic changes induced in 
the germline [39, 43-45]. 
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Epigenetics are mitotically and meiotically heritable changes in gene function without 
changing DNA sequences [46, 47]. Broadly, these heritable changes in the epigenome define and 
control cell and tissue development by controlling gene expression [48]. Multiple molecular 
mechanisms alter the epigenome, including changes DNA methylation, chromatin modification, 
and noncoding RNAs (Figure 2.2). Epigenetic modifications must be transmitted through the 
germline to the unexposed generation to cause a transgenerational phenomenon [41]. 
DNA methylation is a commonly studied epigenetic mechanism [49]. Specifically, 
methylation of DNA is a highly dynamic modification that occurs on the cytosine residue in 
“CpG” dinucleotides [50]. CpG indicates cytosine-phosphate-guanine and that these nucleotides 
are in sequence next to each other as opposed to CG base pairs across the DNA strand [49]. CpG 
sites are frequent in the promoter regions of some genes and are defined as CpG islands. 
Cytosines in 5’ promotor region that are methylated hinder the transcription of the gene, thus 
causing gene silencing. This is because DNA methylation is associated with providing a physical 
barrier, which impedes transcription factor binding, resulting in a downregulation of gene 
expression [51, 52]. Downregulation of gene expression can be due to a steric hindrance of the 
transcription factor binding to the promotor region of the gene or a secondary recruitment of 
DNA binding proteins that prevent transcription factors from binding to the DNA [49]. However, 
cytosine nucleotides may be demethylated. Demethylation of cytosine nucleotides in CpG 
islands allows access of transcription factors to the promoter region, typically resulting in an 
upregulation of gene expression [51, 52].  
DNA methylation is performed by a group of enzymes named DNA methyltransferases 
(DNMTs). The main classes of DNMTs are DNMT1 and DNMT3 [53, 54]. DNMT1 is the 
maintenance DNMT because it maintains the original DNA methylation pattern in a cell lineage. 
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It primarily serves to methylate CpG sites during DNA replication so that both daughter cells 
have the same DNA methylation patterns [54-56]. DNMT3a and DNMT3b are 
methyltransferases that methylate CpG sites on naked DNA outside of DNA replication. These 
DNMTs are critical for early development. Besides tissue distribution, little difference exists 
between DNMT3a and DNMT3b. DNMT3a is ubiquitously distributed, whereas DNMT3b is 
restricted to the thyroid, testes, and bone marrow [53, 57, 58]. DNMT3s methylate DNA by two 
interlinked mechanisms. Specifically, DNMT3a and DNMT3b may be recruited to promoters by 
specific transcription factors or the DNMTs may methylate all CpG sites not protected by a 
transcription factor in the genome [57, 59, 60]. 
The covalent bond between a methyl group and the 5’ position of cytosine is one of the 
strongest bonds in nature. It is nearly impossible to break this bond; thus, DNA methylation can 
be a permanent epigenetic modification passed to future generations. However, DNA 
methylation is not always permanent and the DNA can undergo demethylation. In fact, DNA 
demethylation is important in the early stages of development, in highly specialized postmitotic 
cells, and occurs as a response to extrinsic signals [61]. DNA demethylation can occur through 
passive or active action. Passive DNA demethylation occurs through an absence of active 
DNMT1 proteins during DNA synthesis. Without the maintenance DNMT, DNA in dividing 
cells will not pass the methylation pattern on to the daughter cells. This will result in a 
progressive loss of methylated CpGs and consequently reduce the methylation markers on 
cytosines following each cell division. Passive demethylation occurs in activing dividing cells, 
but does not occur in terminally differentiated cells or during active demethylation in the zygote 
[62, 63].  
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Active DNA demethylation may generally occur by one of two methods. The first is by 
chemically modifying the 5-methyl cytosine by deamination and/or oxidation and converting it 
into a thymine. A guanine/thymine DNA mismatch occurs and induces the base excision repair 
(BER) pathway to correct the base into a naked cytosine [57, 61]. The second active DNA 
demethylation method is mediated by the ten-eleven translocation (TET) enzymes. TET enzymes 
add a hydroxyl group onto the 5’-methylcytosine and convert it to 5’-hydroxymethylcytosine. 
The methylated cytosine is converted into a naked cytosine by one of two routes. The first 
method is that the 5’-hydroxymethylcytosine is further oxidized to 5’-formylcytosine and then 
into 5’-carboxycytosine [64].The BER pathway is activated and the 5-carboxycytosine is cleaved 
by thymine DNA glycosylase (TDG) and is replaced with a naked cytosine [65]. The second 
method of TET DNA demethylation is by deaminating 5’-hydroxymethylcytosine by activation-
induced cytidine deaminase (AID) and apolipoprotein B mRNA-editing catalytic polypeptides 
(APOBECs) to form 5’-hydroxymethyluracil [61, 66]. The BER pathway is activated and the 5’-
hydroxymethyluracil is cleaved by TDG and is replaced with a naked cytosine [67]. DNA 
demethylation occurs through multiple pathways, utilizing numerous enzymes and proteins and 
resulting in a dynamic, complex process. 
In addition to epigenetic modifications occurring by DNA methylation, they can occur 
due to chromatin modifications. Chromatin modifications are epigenetic modifications that 
directly regulate the packaging of DNA. Over 3 billion base pairs are contained in chromosomes 
and need to fit inside the nucleus. Chromatin serves to compact the DNA while allowing 
transcription factor access to relevant DNA sequences. Chromatin is made of DNA, histone 
proteins, and nucleosomes. DNA is wound around an octamer of histone proteins. Histone 
octamers consist of four core histones: H4, H3, H2a, and H2b. H4 and H3 pair together and H2a 
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and H2b pair together. Each histone is found in duplicate. A fifth histone, H1, links the histone 
cores to each other. DNA wrapped around an octamer of histones is referred to as the 
nucleosome. The most important epigenetic role of chromatin is to regulate gene expression by 
controlling the access of transcription factors to DNA. Chromatin may be tightly compacted, 
blocking transcription factor access to DNA, and reducing gene transcription. Alternatively, 
chromatin may become loose, allowing transcription factor access to DNA, and allowing gene 
transcription [49]. 
Histones are critical for condensing DNA and their functions are primarily controlled by 
modifying the N-terminus, also known as histone tail domains. These histone tails are modifiable 
by nonhistone proteins and these modifications reflect DNA compaction. The type of 
modification on the specific histone and the position of the modification influences gene 
expression. Histone tail modifications include acetylation, methylation, proline isomerization, 
SUMOlyation, ubiquitination, phosphorylation, ADP ribosylation, and deamination [68]. Post-
translational modifications interact with the histone tails to modify the transcriptional regulatory 
readout and may occur on any of these histones [68]. Further, the position of the post-
translational modification can influence the transcriptional regulatory readout. For example, two 
post-translational modifications on the same histone may provide a different readout compared to 
the same post-transcriptional modifications on two adjacent histones [69]. The two most well-
known post-transcriptional modifications are acetylation and methylation. 
Histone acetyltransferases (HATs) and histone deacetyltransferases (HDACs) are 
enzymes that facilitate acetylation onto the lysine residues on the histone tail. Generally, 
acetylation of histone tails enhances gene transcription by neutralizing the charge of the lysine 
residue. Further, removal of the acetyl group represses gene transcription [70]. Histone 
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methyltransferases (HMT) and histone demethyltransferases (HDMT) are enzymes that facilitate 
methylation on the lysine, histidine, and arginine residues on the histone tail. Histone 
methylation generally leads to repressed gene transcription. However, methylation can be both 
activating and repressing, depending on which residue is modified and how many methyl 
modifications occur [70]. For example, trimethylation of the lysine 27 residue of histone H3 
silences genes, whereas methylation and trimethylation of the lysine 4 residue on histone H3 
activate enhancers [71]. 
Another type of epigenetic modification involves noncoding RNA. Noncoding RNAs 
(ncRNA) are forms of epigenetic modifications that serve housekeeping and regulatory functions 
and are involved in chromatic function. Noncoding RNAs are a large group of RNAs that fall 
into two main classes based on size or function. The main classes are long noncoding RNAs 
(lncRNAs), which are greater than 200 nucleotides in length and short noncoding RNAs, which 
include microRNA (miRNA), transferRNA (tRNA), piwi-interactingRNA (piRNA), and short-
interferingRNA (siRNAs) [49, 72]. 
Long noncoding RNAs are longer than 200 nucleotides in length, do not encode protein, 
and mediate gene expression. Long noncoding RNAs and mRNAs are similar to each other. Both 
are transcribed by RNA polymerase II from genomic loci and both are biochemically similar 
except that lncRNA lack codons that encode proteins [73]. However, a major difference between 
lncRNA and mRNA is that lncRNA serve as epigenetic modifiers. The mechanisms by which 
lncRNAs exert their epigenetic effects are diverse. Long noncoding RNA have the ability to 
interact with genomic loci and chromatin by forming stable domains for protein binding and 
chromatin localization. Therefore, the lncRNA interactions allow sequence specific localization 
of chromatin-modifying complexes and the lncRNAs direct the chromatin-modifying complexes 
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to target genes, thus regulating transcriptional activity [74, 75]. Further, lncRNAs can directly 
interact with DNMT1 and affect global methylation patterns [76]. Finally, lncRNAs have been 
shown to interact with other noncoding RNAs such as miRNA. Specifically, lncRNA can bind 
and sequester miRNA and prevent them from binding to their target mRNAs [77, 78]. 
MicroRNA are ~22 nucleotides in length and regulate protein-coding genes. MicroRNA 
are first synthesized in the nucleus and then mature within the cytoplasm. Genes encoding 
miRNAs are transcribed into primary miRNAs (pri-miRNA) by RNA polymerase II. Pri-
miRNAs are cleaved by a nuclear microprocessor complex and exported from the nucleus into 
the cytoplasm as pre-miRNA. Pre-miRNAs are cleaved by the protein DICER, generating a 
small miRNA duplex. The miRNA duplex is loaded onto an argonaute family protein (AGO) to 
form an effector complex called RNA-induced silencing complex (RISC) [79]. The RISC 
complex regulates gene expression by hybridizing to sequence-specific target mRNA and 
regulates transcriptional and translational functions and mRNA stabilization [80]. MicroRNAs 
can post-transcriptionally regulate epigenetic-related genes and can act in the nucleus by 
stimulating or repressing gene transcription [81]. Post-transcriptional modifications can modulate 
protein level independently from correlating mRNA levels [82]. MicroRNAs regulate post-
transcriptional epigenetic factors such as DNMTs, PRC1 and PRC2, heterochromatin protein 1 
(HP1), and HDACs [81]. PRC1 and PRC2 are polycomb group proteins that cooperate with 
DNMTs to silence target genes [83]. HP1 proteins are critical mediators of heterochromatin gene 
silencing and gene activation [84]. Further, miRNAs stimulate or repress gene transcription. 
MicroRNAs can silence gene transcription with the use of AGO1, AGO2, and small interfering 
RNAs that recognize the target promoter region [85, 86]. MicroRNAs can target promoter 
elements and active RNA with the use of AGO1, AGO2, Drosha, and Dicer [87].  
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2.4 Female Reproduction 
Multiple organs are required to facilitate healthy reproduction. Organs within the 
hypothalamic-pituitary-ovary axis (HPO) consist of the hypothalamus, anterior pituitary, and the 
ovary. The HPO axis facilitates healthy reproduction in mammals and normal development 
throughout the body. The hypothalamus, pituitary, and ovary secrete endogenous hormones 
critical for the differentiation, development and action of the brain, ovary, pituitary, reproductive 
tract, physiology, and behaviors [27, 88]. In adulthood, the HPO axis displays rhythmic patterns 
that vary from minutes to weeks depending on the organ and hormonal feedback between all of 
the organs [95]. 
Hypothalamus 
 The hypothalamus in mammals is a small region of the brain. It is near the base of the 
brain adjacent to the pituitary gland. In adulthood, the hypothalamus secretes gonadotropin-
releasing hormone (GnRH) to the pituitary as part of a feedback mechanism for reproductive 
functions. The hypothalamus contains two discrete regions critical for fertility: the anteroventral 
periventricular nucleus-periventricular nucleus continuum (AVPV/PeN) and the arcuate nucleus 
(ARC) [96]. Neurons in these regions express Kiss1 genes, which encode for the neuropeptide 
kisspeptin [96]. Kisspeptin neuropeptides are proximal agonists of GnRH secretion from GnRH 
neurons [96, 97]. The hypothalamus secretes GnRH into the median eminence and then into the 
hypothalamo-hypophyseal portal circulation to the anterior pituitary [89]. GnRH is a 
hypothalamic peptide that mediates central control of reproduction. GnRH peptide release is 
pulsatile and the rhythmic nature of GnRH is critical for proper gonadotropin secretion from the 
anterior pituitary [98]. 
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 The secretion of GnRH in adult females is mediated by a feedback mechanism of gonadal 
sex steroid hormones. Specifically, the sex steroid hormones interact with neurons in the ARC to 
inhibit Kiss1 expression, whereas the sex steroid hormones increase Kiss1 expression in the 
AVPV [99]. The direct effect on Kiss1 expression translates to GnRH secretion. The differential 
effects of sex steroid hormones on Kiss1 secretion in the ARC and the AVPV translates the sex 
steroid hormone mediated positive and negative feedback mechanism of reproduction [96]. 
Specifically, the ARC is responsible for the negative sex steroid hormone feedback loop for 
GnRH secretion [100]. Conversely, the AVPV is responsible for the positive feedback effects of 
estrogen on GnRH secretion, and subsequently, the preovulatory LH surge [101]. 
Pituitary 
The anterior pituitary consists of five different endocrine cell types: gonadotropes, 
lactotropes, somatotropes, thyrotrope, and adrenocorticotropes. The gonadotropes are endocrine 
cells that in response to GnRH pulses, produce gonadotropin peptides critical for reproduction 
[89]. The two gonadotropin peptides secreted by gonadotropes are follicle-stimulating hormone 
(FSH) and luteinizing hormone (LH). Both FSH and LH activate the gonads and are critical for 
normal steroidogenesis and gametogenesis. In females, LH stimulates ovulation as well as corpus 
luteum formation and function, whereas FSH stimulates ovarian follicle formation as well as 
estrogen secretion [89].  
The pulse frequency of GnRH causes differential gonadotropin secretion by the 
gonadotropes. Specifically, increasing GnRH frequencies result in preferential secretion of LH 
and decreasing GnRH frequencies result in preferential FSH release [102]. The gonadotrope cells 
respond to GnRH through the GnRH receptor (GnRHR). The ability for the gonadotrope cell to 
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differentially respond to varying GnRH pulse frequencies may due to changes in the number of 
cell surface receptor numbers [102, 103].  
The gonadotropin peptides, FSH and LH, are heterodimeric glycoprotein hormones that 
share a common α-glycoprotein hormone subunit (αGSU) and have distinct β subunits (LHβ and 
FSHβ) [89]. FSH consists of αGSU and FSHβ and LH is composed of αGSU and LHβ. The 
transcription of the β-subunits are dependent on the GnRH pulse frequency whereas αGSU is 
produced in excess and not dependent on GnRH pulse frequency [104]. However, the 
mechanism by which gonadotrope cells decode the pulsatile GnRH signal to produce either FSH 
or LH remains largely unknown [102]. 
Ovary 
The ovary is a heterogeneous organ composed of follicles, oocytes, corpora lutea, and 
interstitial tissue. The primary roles of the ovary are to produce sex steroid hormones and 
maintain a steady stream of growing follicles. Normal sex steroid hormone production by the 
mature follicles is essential for the maintenance of normal menstrual/estrous cyclicity, 
reproductive tract tissues, and non-reproductive tissues such as bones, the heart, and the brain 
[105-108]. In addition, the mature antral follicle is the only follicle type capable of ovulating and 
releasing an oocyte for potential fertilization. Therefore, female fertility is dependent on the 
maintenance of a constant stream of growing follicles and sex steroid hormone secretion 
throughout the reproductive lifespan [109].  
Primordial germ cell specification and migration 
In mice, the ovary begins to form during embryonic development. Primordial germ cells 
are precursors of gametes that develop as sperm or eggs in the gonads. Primordial germ cells are 
first detected at embryonic day (ED) 6.0 – 6.5 by the exclusive expression of the protein 
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BLIMP1 [110]. Primordial germ cells are pluripotent stem cells that migrate during embryonic 
development to the place of gonadal development. During migration, the primordial germ cells 
undergo mitosis to increase primordial germ cell population. Primordial germ cells actively 
traverse through the developing embryo by receiving cues from the somatic cells, such as the 
chemokine SDF-1 [111]. At ED 10.5 in the mouse, a large population of primordial germ cells 
finish migration to the genital ridge and begin to form the ovary [112, 113]. The primordial germ 
cells continue to proliferate, but around ED 12, primordial germ cells enter meiosis and begin 
differentiating into germ cells [113]. Germ cells are connected by intracytoplasmic bridges and 
form large clusters. The germ cells begin to arrest in meiotic prophase and some germ cells begin 
to undergo apoptosis around ED 14.5 [112, 113]. The apoptotic process is necessary to eliminate 
abnormal or unhealthy germ cells unable to produce viable oocytes.  
Germ cell nest breakdown 
Following birth, pups experience a dramatic decrease in circulating estrogen and 
progesterone. The dramatic change of hormones initiates germ cell nest breakdown [114, 115]. 
Germ cell nest breakdown is the process that germ cells undergo apoptosis or differentiate into 
primordial follicles through a variety of signaling pathways such as the NOTCH2 signaling 
pathway [114, 116]. Only a third of the total germ cells survive to become primordial follicles 
[117, 118]. The primordial follicle consists of a single oocyte surrounded by a single layer of 
squamous somatic granulosa cells and subsequently becomes the finite pool of available follicles 
during the reproductive lifespan [113]. The B-cell lymphoma/leukemia-2 (Bcl-2) family of 
proteins is critical for the regulation of apoptosis in reproductive tissues and during germ cell 
nest breakdown. This family of proteins contains pro-apoptotic proteins and anti-apoptotic 
proteins. Proper regulation of these proteins leads to healthy and normal apoptosis during germ 
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cell nest breakdown [117, 119, 120]. Germ cell nest breakdown is complete around postnatal day 
6 in the mouse [117]. Once the germ cell nest breaks down and individual germ cells are 
surrounded by somatic granulosa cells, the structure is a primordial follicle. Primordial follicles 
remain quiescent until activation through folliculogenesis [121]. 
Follicle recruitment, selection, and maturation 
At one single time in the adult mouse ovary, all stages of follicle growth are present. 
Follicles are quiescent, constantly growing, or undergoing atresia. The manner in which a follicle 
remain quiescent, is recruited for growth, or undergoes atresia is a complex process. Specifically, 
primordial follicles are the most immature follicle type in the ovary. Primordial follicles may 
remain quiescent in the ovary and maintain the ovarian reserve through repressive signals. 
Specifically, phosphatase and tensin homolog (PTEN), a protein that antagonizes the 
phosphoinositide 3-kinase (PI3K) pathway, is critical to maintain primordial follicle dormancy 
[122]. It is critical to maintain primordial follicle dormancy so that primordial follicles may 
activate at different points throughout the reproductive lifespan of a female.  
Primordial follicle may activate and grow into primary follicles through a variety of 
pathways. Specifically, proteins from the (transforming growth factor beta) TGFβ super family 
are critical to initiate follicle activation [123] and in vitro studies show that kit ligand, basic 
fibroblast growth factor, and bone morphogenetic protein 4 and 7 increase primary to primordial 
follicle ratio [124-127]. It is critical for primordial follicles to activate, grow, and potentially 
ovulate; however, studies show that the most common fate for ovarian follicles is atresia [17, 
128]. A balance of pro- and anti-apoptotic factors regulates follicular atresia. The signaling 
pathway responsible for follicle death in the ovary includes the BCL2 family of proteins [117, 
119, 120, 129], whereas the signaling pathways that help prevent follicle death include 
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gonadotropins, insulin-like growth factor-I, and estrogens [17, 130, 131]. Follicle atresia is 
important to remove unhealthy or poor quality oocytes from the germ cell pool. 
Ovarian follicles mature through a process called folliculogenesis. Primordial follicles 
may activate and grow into primary follicles. Primary follicles are composed of a single oocyte 
surrounded by a single layer of cuboidal granulosa cells [121, 132]. Primary follicles then grow 
into preantral follicles, which consist of a single oocyte surrounded by at least two layers of 
cuboidal granulosa cells and a layer of thecal cells [121, 132]. Preantral follicles are composed of 
a single oocyte surrounded by numerous layers of granulosa cells, at least two layers of thecal 
cells, and a fluid filled space called the antrum [121, 132]. Preantral follicles subsequently grow 
into antral follicles. Antral follicles are the only follicle type that are capable of synthesizing sex 
steroid hormones such as progesterone, androgens, and testosterone and they are the only follicle 
type capable of ovulating for fertilization [133]. 
Gonadotropin signaling and ovarian follicles 
The ovary receives gonadotropin signals from the pituitary. Ovarian follicles are 
stimulated by both FSH and LH to produce sex steroid hormones. Both FSH and LH bind to cell 
surface protein receptors and through complex signaling pathways coordinate gene expression 
critical for the many functions of the ovary [134]. Simply, FSH is critical for follicle maturation 
and LH is required for ovulation. 
FSH regulates the expression of over 500 target genes in granulosa cells, which are 
somatic cells that support follicle maturation [135]. Relatively low, but constant levels of FSH 
are required to promote granulosa cell differentiation. FSH binds to the seven membrane-
spanning G protein-coupled receptor, FSH receptor [134]. FSH signals and activates the PI3K 
pathway, which can signal for cell survival, granulosa cell differentiation and proliferation, and 
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promotes gene expression. Subsequently, FSH regulates apoptosis, proliferation, steroidogenesis, 
and promotes granulosa cells to respond to the LH surge largely through protein kinase A (PKA) 
[134]. FSH is critical for the growth and maturation of the ovarian follicles. 
LH stimulates sex steroid hormone production in follicles, regulates thecal cell functions, 
and is critical for ovulation. LH enhances mRNA expression of transcription factors necessary 
for sex steroid hormone synthesis. Specifically, LH induces 17α-hydroxylase/C17-20-lyase 
(CYP17), which is the rate-limiting enzyme for androgen biosynthesis [136]. Further, LH signals 
through a pathway involving the orphan nuclear receptor NR4A1 to increase mRNA levels of 
steroidogenic acute regulatory protein (Star), cytochrome P450 family 11 subfamily A member 1 
(Cyp11a1), 3β-hydroxysteroid dehydrogenase (Hsd3b1), and cytochrome P450 family 17 
subfamily A member 1 (Cyp17a1) in theca cells, which are enzymes necessary for sex steroid 
hormone synthesis [137]. 
Ovarian follicle steroidogenesis 
In addition to follicle production and growth, the ovary is the major site of sex steroid 
hormone synthesis. Antral follicles are responsible for the primary production of estradiol 
because they contain the combination of theca cells, granulosa cells, and a series of enzymes 
[17]. Further, the corpus luteum is responsible for the primary production of progesterone 
because corpora lutea contain enzymes and luteal cells that specialize in progesterone production 
[138]. 
Within the antral follicle, the coordination between the theca and granulosa cells and 
signaling by FSH and LH are required for successful production of 17B-estradiol. Cholesterol is 
the precursor of all the sex steroid hormones produced in the ovary. The first conversion is of 
cholesterol to pregnenolone and it is the rate-limiting step subjected to acute regulation. The 
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protein StAR mediates the transfer of cholesterol from the outer mitochondrial membrane across 
the intercisternal space, and into the inner mitochondrial membrane of granulosa and theca cells 
[133, 139]. The enzyme CYP11A1 accesses cholesterol from the inner mitochondrial membrane 
and converts cholesterol to pregnenolone through three monooxygenations [140]. Pregnenolone 
diffuses from the mitochondria and transported to the smooth endoplasmic reticulum where it is 
further converted by CYP17A1 to dehydroepiandosterone (DHEA) or converted by HSD3B to 
progesterone. DHEA is catalyzed by HSD3B into androstenedione and progesterone is cleaved 
by CYP17A1 into androstenedione within the smooth endoplasmic reticulum. Androstenedione 
is a weak androgen that can be converted into a potent androgen, testosterone, by HSD17B [141] 
or aromatized by CYP19A1 into estrone [140]. Testosterone is aromatized by CYP19A1 and 
converted into 17B-estradiol, a potent estrogen [140]. Estrone is a weak estrogen that is 
converted by HSD17B into 17B-estradiol, [141]. 
Ovulation and corpora lutea formation and function 
The corpus luteum is a transient organ that forms following follicle ovulation in 
preparation for pregnancy. The theca and granulosa cells left behind after ovulation luteinize to 
form a corpus luteum. Luteinization is composed of cell proliferation, cell differentiation, and 
tissue remodeling. Specifically, proliferation of theca and granulosa cells ceases and the cells 
undergo rapid hypertrophy and differentiate into luteal cells. In addition, during luteinization, 
blood vessels rapidly grow into the previously-granulosa layer of the corpus luteum [138, 142]. 
This highly vascular corpus luteum sequesters bloodborne sources of cholesterol as substrate for 
the steroidogenic pathway [138]. Luteinization of granulosa and theca cells increases the 
expression and/or activity of CYP11A1, the enzyme responsible for converting cholesterol or 
pregnenolone. Further, an increase in HSD3B expression and decrease in CYP17A1 and 
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CYP19A1 facilitates an increase of progesterone expression [138, 143]. The corpus luteum 
specializes in the production of progesterone to maintain a pregnancy following ovulation. 
Reproductive senescence 
Reproductive senescence is a normal process of reproductive aging that occurs in women. 
Over time, the ovarian reserve depletes and is the major contributor of reproductive senescence. 
The age of reproductive senescence in women is based on the size of the initial primordial 
follicle pool and the rate of follicle depletion. Normal ovarian functions decline and cease 
leading to a feedback cascade to the hypothalamus and pituitary [144]. The lack of estrogens and 
progesterone from the ovary removes the negative feedback on the hypothalamus and pituitary. 
Specifically, GnRH secretion increases and leads to an increase in serum FSH and LH levels. 
Additionally, the ovary does not produce inhibin and is also associated with dramatic increases 
of FSH and LH levels [145]. 
Uterus 
 The uterus is an organ critical for fertility in females. It functions as an endocrine 
sensitive organ that facilitates embryo implantation and delivery of the infant. The uterus is 
divided into three sections from anterior to posterior: the fundus, the corpus (body), and the 
isthmus (cervix). Further, the uterus is composed for three tissue layers: functionalis 
endometrium, basalis endometrium, and myometrium [108, 146]. The development of the uterus 
is complex, but simply, the paramesonephric or Müllerian ducts develop and give rise to the 
female reproductive organs through a series of growth pathways and hormone signals [147]. 
 The three uterine tissue layers serve different purposes. The functionalis endometrium is 
the superficial tissue layer in the uterus that lines the lumen and it is sensitive to sex steroid 
hormones and critical for implantation. The functionalis endometrium, in response to sex steroid 
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hormones, undergoes dramatic changes in cell appearance and function throughout the menstrual 
and estrous cycle. The basalis endometrium is adjacent to the functionalis endometrium. This 
layer is critical for the regeneration of the functionalis endometrium following menses in women. 
The menstrual and estrous cycles are divided into two different phases. During the follicular or 
proliferative phase in women, the endometrium thickens approximately 12 – 14 mm due to the 
increasing levels of serum estradiol [108]. The endometrial glands also become larger and more 
tortuous and the stroma proliferates. The uterus is preparing for a pregnancy. During the 
follicular or proliferative phase in rodent models, the uterine width is at the greatest and 
endometrium growth occurs due to high levels of estrogen and low levels of progesterone [148]. 
During the luteal or secretory phase in women, the primary sex steroid hormone is progesterone. 
During this phase, the uterus enters a “window of receptivity” in which glycogen accumulates 
near the basalis endometrium and the epithelial cells of the endometrium expel proteins into the 
glandular lumen, endothelial cells proliferate, and edema occurs [149]. An embryo is supported 
by the endometrium during this period, however in women, if a pregnancy is not achieved, the 
endometrium undergoes apoptosis and the vascular basement membraned breaks down and the 
functionalis endometrium splits from the basalis endometrium and is discarded through the 
vagina [108, 150]. The women reenters the follicular or proliferative phase and the functionalis 
endometrium is regenerated by the basalis endometrium [151].  
The myometrium contains smooth muscles and is the outer most layer of the uterus [146]. 
Similar to the endometrium, the myometrium is influence by sex steroid hormones. The 
myometrium is important for uterine contractions and aid in functions such as sperm transit, 
placement of the blastocyst to the luminal epithelium of the functionalis endometrium, 
contractions during menstruation, and parturition [108, 150, 152]. 
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2.5 Epigenetic Effects of Endocrine Disruptors on Female Reproduction 
The hypothalamus 
 Studies indicate that endocrine disrupting chemicals can target the hypothalamus in the 
brain, leading to epigenetic changes and transgenerational effects. For example, bisphenol A 
(BPA), a plasticizer with well-known endocrine disrupting effects, has been shown to cause 
transgenerational inheritance in the hypothalamus [90]. Prenatal BPA exposure reduces ERα-
immunoreactivity in brain regions important for reproductive function in female mice in a 
transgenerational manner [90]. Further, perinatal BPA exposure increases the expression of 
Meg3, a maternally expressed lncRNA, in the female hypothalamus of the F3 generation [91]. 
The expression of Meg3 is important because it is correlated with the central control of 
precocious puberty [92] and increased levels of BPA are associated with precocious puberty in 
women [93] and in laboratory animals [94]. The increase in Meg3 is significant because it is an 
epigenetic modifier and mRNA expression is increased in the generation that was ancestrally 
exposed to BPA.  
The ovary 
Endocrine disruptors can affect several processes in ovary, including the formation of a 
healthy primordial follicle pool, maintenance of a constant stream of growing follicles, and 
normal steroidogenic capacity, all of which are required for normal female fertility [17, 109, 144, 
153, 154]. Any chemical that interferes with these processes can cause severe reproductive 
outcomes. Specifically, chemicals that target the formation of the primordial follicle pool cause 
infertility because they deplete the finite follicle reserve used for the growth of ovulatory 
follicles [153, 154]. Additionally, an increased loss of primordial follicles leads to an early onset 
of reproductive senescence [144]. This is of concern because early onset of reproductive 
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senescence is associated with increased risk of chronic diseases [106, 144, 155-157]. Chemicals 
that specifically target primary, preantral, and antral follicles may lead to temporary infertility or 
permanent infertility. Temporary infertility may occur when the toxicant only targets the mature 
population of follicles, but not immature follicles. Thus, when the toxicant is removed, the 
immature follicle types can grow and replenish the mature population of follicles, restoring 
fertility. Permanent infertility occurs when the toxicant is not removed and continuously targets 
the growth and function of ovarian follicles [109]. Permanent infertility is more likely to occur in 
humans because chemical exposure occurs on a daily basis and it is difficult to remove chemical 
exposure. Chemicals that target the production of sex steroid hormones from the ovary may lead 
to infertility and other non-reproductive disorders [106, 109, 158-160]. 
Exposure to diethylstilbestrol (DES) has been associated with multigenerational effects 
on the ovaries in women. In particular, one case study describes small cell carcinoma of the 
ovary in a 15 year old girl whose maternal grandmother had taken DES during her pregnancy 
[161]. This study demonstrates that prenatal DES exposure is associated with a multigenerational 
increase in ovarian cancer in the F2 generation. Similarly, another study has shown that prenatal 
exposure to DES is associated with ovarian cancer in the F2 generation [162]. Unfortunately, the 
epigenetic mechanisms for these ovarian effects have not been fully investigated across 
generations. 
Methoxyclor (MXC) is a banned insecticide that was once used as a replacement for 
dichlorodiphenyltrichloroethane (DDT). It is an endocrine disruptor shown to directly affect 
ovarian functions. Studies have shown the exposure to MXC causes various ovarian-related 
diseases in both multigenerational and transgenerational manners. Direct MXC exposure inhibits 
growth and induces atresia of antral follicles by altering the expression of regulators of apoptosis 
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and the cell cycle [163]. Additional evidence shows that MXC exerts these effects via the aryl 
hydrocarbon receptor [164]. Further, MXC exposure causes ovarian disease in the F1 generation 
of rats and ancestral MXC exposure increases polycystic ovarian-like syndrome in the F3 
generation of rats [165]. Epigenetic analyses show that MXC hypermethylates CpGs in the ERβ 
promoter of the ovary. Further, MXC hypermethylates multiple loci critical for ovarian signaling 
pathways and concurrently decreases gene expression [166, 167]. MXC exposure also increases 
expression of DNMT3B in the ovaries, suggesting that DNMT3B plays a critical role in DNA 
hypermethylation [166].  
Phthalates are a class of chemicals commonly used as plasticizers, but are also known 
endocrine disrupting chemicals. Previous studies show that prenatal exposure to a mixture of 
phthalates that mimics human exposure causes multigenerational effects on mouse ovaries [168, 
169]. Specifically, prenatal phthalate exposure induces cystic ovaries in the F1 and F2 
generations [168, 169]. Further, exposure to a mixture of plastic derivatives (BPA, di(2-
ethylhexyl) phthalate, and dibutyl phthalate) causes polycystic ovaries in both the F1 and F3 
generations [170]. Exposure a single phthalate, di(2-ethylhexyl) phthalate (DEHP), also causes 
adverse transgenerational effects on the ovary in mice. Specifically, prenatal DEHP exposure 
dysregulates folliculogenesis, alters sex steroid hormone levels, and increases the presence of 
ovarian cysts in a multigenerational manner [171, 172]. Further, ancestral exposure to DEHP 
accelerates early folliculogenesis in a transgenerational manner [172]. Although studies 
demonstrate that phthalate exposure causes transgenerational effects on the ovary, the 
mechanisms causing these effects are not well understood. A few studies suggest that DEHP 
exposure causes multigenerational effects through both the estrogen receptor 1 (ESR1) and the 
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peroxisome proliferator-activated receptor alpha (PPARα) [173-176]. However, further studies 
are necessary to investigate the effects of phthalate exposure on the epigenome of the ovary.  
BPA, a plasticizer with known endocrine disrupting abilities, causes both 
multigenerational and transgenerational effects on the ovary. Prenatal exposure to BPA decreases 
serum testosterone levels in the F2 generation and dysregulates steroidogenic enzymes in the F2 
ovaries of mice [177]. Ancestral exposure to BPA dysregulates gene expression of ovarian 
apoptotic factors, oxidative stress factors, and autophagy factors in mice [178]. Interestingly, a 
few studies have linked BPA exposure to DNA methylation across generations in females [170, 
179]. Specifically perinatal exposure to BPA altered DNA methylation at a differentially 
methylated region that regulates expression of Igf2 gene in F1 and F2 generations, however, this 
was found only in male mice [179]. Another study has demonstrated that prenatal exposure to a 
mixture of BPA and phthalates promotes epigenetic transgenerational inheritance of disease. 
However, this study only showed that the plasticizer mixture affected the differentially 
methylated regions in sperm. Epigenetic analyses were not performed on the females [170]. 
Vinclozolin, a fungicide used on fruits, acts as an endocrine disruptor and causes 
transgenerational effects [180, 181]. Prenatal vinclozolin decreases primordial follicle counts in 
both the F1 and F3 generations of rats at one year of age [181]. In addition, ancestral exposure to 
vinclozolin causes small and large cysts in the ovaries and increases circulating androstenedione 
levels in the F3 generation [181]. The observed phenotype in the F3 generation is similar to the 
clinical phenotype in women with polycystic ovarian syndrome [181]. Further, vinclozolin 
causes differential gene expression in the F3 ovaries. These genes are associated with ovarian 
diseases such as polycystic ovarian syndrome. Ancestral vinclozolin exposure also alters DNA 
methylated regions in promoter regions of the granulosa cells; however, the DNA methylation 
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changes do not overlap with the promoters of the differential gene expression in the F3 
generation [181]. Instead, the DNA methylation changes may influence distal gene expression 
through ncRNA, which may regulate the differential gene expression in the granulosa cells of the 
F3 ovaries [181]. Further investigations reveal that the purified rat granulosa cells from 
ancestrally exposed F3 generation have differentially expressed lncRNA and sncRNAs and that 
these changes contribute to the vinclozolin-induced dysregulation of the ovary [182]. 
Although studies demonstrate that environmental chemicals can induce transgenerational 
effects on the ovary, diet has also been shown to cause endocrine disruption and alter the 
epigenome in the ovary. Specifically, exposure to low-protein diet during pregnancy in the F0 
generation accelerates ovarian aging in a multigenerational manner (F1-F2 generations) in 
female rats. Exposure to the low-protein diet during pregnancy reduces ovarian telomere length, 
primordial follicle numbers, and serum anti-Müllerian hormone levels in the F1 and F2 
generation rats [183]. These reductions in the F1 and F2 generations are due to an increase in 
oxidative stress markers such as increased mitochondrial DNA copy numbers and 4-hydroxy-
nonenal levels in rat ovaries [183]. Unfortunately, epigenetic modifications were not quantified 
in this study [183]. However, a different study examined the transgenerational effects of 
supplementing polyunsaturated fatty acids (PUFAs) in the diet of female mice from the F0 – F3 
generations [184]. Exposure to n-3 PUFAs reduced the number of ovulated oocytes, increased 
the percentage of oocytes trapped in luteinized follicles, and decreased litter sizes in the F3 
generation [184]. Further, increased PUFA exposure decreased concentrations of prostaglandins 
in the F3 generation [184].  
Another study examined the transgenerational effects of a restricted diet during 
pregnancy on epigenetic markers in the offspring [185]. In this study, the F0 rats were fed half of 
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the typical food intake during pregnancy. The rats with prenatal restricted diet exposure 
exhibited changes in epigenetic markers across the generations. Specifically, mRNA levels of 
Hdac1, a histone modification gene, were upregulated in the F1 and F2 generations and 
downregulated in the F3 generation [185]. DNA methylation specific genes such as Dnmt1 was 
altered across the generations. Although these epigenetic changed were not specifically observed 
in the ovary, it is worth noting that poor diet during pregnancy causes epigenetic changes that are 
inherited in the maternal germline, causing a transgenerational phenotype [185]. 
The uterus 
 The uterus is critical for fertility in females; it acts as an endocrine sensitive organ that 
facilitates both embryo implantation and parturition. Studies indicate that endocrine disruptors 
can affect the uterus and that these changes may lead to epigenetic and transgenerational 
inheritance of diseases. The prescription of diethylstilbestrol (DES) to pregnant women is one of 
the best examples of multi- and transgenerational impact because it is associated with fetal 
endocrine disruption and adverse reproductive health outcomes in subsequent generations in 
humans [186]. Women who were exposed to DES as a fetus, also known as “DES daughters”, 
have more frequent benign reproductive tract problems, including reproductive organ 
dysfunction, abnormal pregnancies, structural changes of the uterus, and reduced fertility [187]. 
These women have an increased risk of a rare clear-cell cervicovaginal adenocarcinoma and 
squamous-cell and cervicovaginal carcinoma [188]. Further, these “DES daughters” report that 
their in utero exposure led to cancer in their daughters, the F2 generation [189]. Effects seen in 
this F2 generation demonstrate a multigenerational effect of prenatal DES exposure on the uterus 
in humans [189]. Animal studies further demonstrate multigenerational effects of DES. 
Specifically, prenatal DES exposure decreases fertility in the F1 generation of female mice and 
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increases the incidence of malignant reproductive tract tumors such as adenocarcinomas in the 
F2 generation of female mice [190]. Additional studies show that prenatal and perinatal exposure 
to DES increases the susceptibility of uterine developmental abnormalities and cancer in both the 
F1 and F2 generations of female mice [191]. 
Currently, the mechanisms explaining the multigenerational effects of DES exposure on 
the uterus are not understood. However, studies in mice suggest epigenetic alterations in DNA 
methylation involving hormone responsive families of genes including lactoferrin, homeobox, 
wnt signaling pathway, and epidermal growth factor genes are involved with the reproductive 
tract developmental changes in a multigenerational manner [162, 192]. Another study 
demonstrates that neonatal DES exposure alters the expression of chromatin-modifying proteins 
in the adult mouse uterus, causing persistently altered epigenetic marks [193]. Further, neonatal 
DES exposure also decreases Dnmt gene expression and alters DNA methylation in the mouse 
uterus [194]. Although these epigenetic markers are observed from neonatal exposure within the 
same generation and not from prior generation exposures, these epigenetic changes may help 
contribute to the multigenerational effects of DES exposure. 
Another endocrine disruptor that targets the uterus is 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD). TCDD is a byproduct of incomplete combustion of a variety of products such as fossil 
fuels, wood, and industrial wastes. Perinatal TCDD exposure causes endometriosis-like 
reproductive phenotypes in F1 – F4 generations of female mice, indicating both multi- and 
transgenerational effects [195]. Further, TCDD exposure reduces uterine progesterone 
responsiveness and causes subfertility [195]. TCDD exposure also causes endometriosis-like 
histological and functional phenotypes in mice [195]. TCDD exposure increases both stromal 
cell and epithelial cell ERS2 protein expression in the F1 – F3 generations and causes 
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adenomyosis in the F3 generation [196].  Interestingly, ancestral exposure to TCDD causes 
hypermethylation of Pgr, which is associated with the development of the endometriosis-like 
histological and functional phenotypes [197]. 
Female reproduction outcomes 
 Plasticizers that act as endocrine disruptors interfere with female reproductive outcomes. 
Some of these reproductive outcomes are due to impacts on the hypothalamus, pituitary, ovary, 
and uterus. For example, prenatal BPA exposure reduces the ability of mice to maintain 
pregnancies in a multigenerational manner and it delays the onset of puberty and compromises 
the ability of mice to become pregnant in a transgenerational manner [198]. BPA has been shown 
to interfere with brain and ovarian functions in a transgenerational manner, likely contributing to 
altered reproductive outcomes [91, 198]. A study of offspring to Chinese textile workers shows 
that in utero serum dichlorodiphenyldichloroethylene (DDE) levels were associated with an early 
menarche in the offspring [199]. Both prenatal and ancestral exposure to a mixture of phthalates 
cause pregnancy complications in the F2 and F3 generations of mice [168]. Further, ancestral 
exposure to a phthalate mixture reduces total litter size and the percentage of dams that produce 
live litters in the F3 generation [168], whereas exposure to DEHP, a single phthalate, causes 
multi- and transgenerational effects on reproductive outcomes [172, 200]. Specifically, prenatal 
DEHP exposure increases litter size and decreases the percentage of dams that give birth in the 
F2 generation [200]. Ancestral DEHP exposure accelerates the onset of puberty and reproductive 
senescence in the F3 generation of female mice [171, 200]. Phthalates interfere with ovarian 




 Overall, the literature shows that several endocrine disrupting chemicals cause 
reproductive dysfunction in females in a multigenerational and transgenerational manner and that 
some of these effects are due to epigenetic changes. Epidemiological data show that exposure to 
endocrine disruptors is associated with adverse ovarian and uterine health outcomes in women 
across generations [161, 189, 199]. Experimental data demonstrate that endocrine disruptors 
cause female reproductive abnormalities in the hypothalamus, ovary, and uterus in 
multigenerational and transgenerational manners [91, 165, 168, 171, 172, 190, 200, 202]. 
Generally, the consensus is that epigenetic changes are induced by chemical exposures and are 
inherited through the germline, thus causing transgenerational phenotypes in reproductive 
functions in the generation that was not directly exposed to the endocrine disruptor. However, it 
is critical that future studies continue to investigate the epigenetic basis of transgenerational 
inheritance and demonstrate that the epigenetic changes are inherited through the germline. It is 
crucial to fill the gap in knowledge about how endocrine disruptors affect the epigenome so that 







2.7 Table, Figures, and Legends 
Figure 2.1 Multigenerational and transgenerational effects 
 
Exposure to endocrine disruptors during prenatal development causes multigenerational effects 
in the F1 and F2 generations and transgenerational effects in the F3 generation. The F1 and F2 
generations are directly exposed to the endocrine disruptor as a fetus and germ cell, respectfully. 
The F3 generation is not directly exposed and the mechanisms governing the effects in the F3 




Figure 2.2 Epigenetic mechanisms 
 
An overview of epigenetic mechanisms including chromatin modifications, DNA methylation, 
and noncoding RNA interactions. Chromatin is made of DNA, histone proteins, and 
nucleosomes and regulates gene expression by controlling the access of transcription factors to 
DNA. DNA methylation creates a physical barrier that generally impedes transcription factor 
binding. Noncoding RNA interact with DNA in many ways as a form of epigenetic modification. 
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Table 2.1 Endocrine disruptors and their chemical structures 
Endocrine Disruptor Name Chemical Structure 
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Prenatal Exposure to Di(2-ethylhexyl) Phthalate Disrupts Ovarian Function in a 
Transgenerational Manner in Female Mice1 
3.1 Abstract 
 Di(2-ethylhexyl) phthalate (DEHP) is a plasticizer found in polyvinyl chloride products 
such as vinyl flooring, plastic food containers, medical devices, and children’s toys. DEHP is a 
ubiquitous environmental contaminant and is a known endocrine disrupting chemical. Little is 
known about the effects of prenatal DEHP exposure on the ovary and whether effects occur in 
subsequent generations. Thus, we tested the hypothesis that prenatal exposure to DEHP disrupts 
ovarian functions in the F1, F2, and F3 generations of female mice. To test this hypothesis, 
pregnant CD-1 mice were orally dosed with corn oil (vehicle control) or DEHP (20 and 200 
µg/kg/day and 200, 500, and 750 mg/kg/day) daily from gestation day 10.5 until birth (7-28 
dams/treatment group). F1 females were mated with untreated males to obtain the F2 generation, 
and F2 females were mated with untreated males to produce the F3 generation. On postnatal days 
1, 8, 21, and 60, ovaries were collected and used for histological evaluation of follicle numbers 
and sera were used to measure progesterone, testosterone, 17β-estradiol, luteinizing hormone, 
and follicle stimulating hormone levels. In the F1 generation, prenatal exposure to DEHP 
disrupted body and organ weights, decreased folliculogenesis, and increased serum 17β-estradiol 
levels. In the F2 generation, exposure to DEHP decreased body and organ weights, dysregulated 
folliculogenesis, and disrupted serum progesterone levels. In the F3 generation, DEHP exposure 
accelerated folliculogenesis. These data suggest that prenatal exposure to DEHP leads to adverse 
multigenerational and transgenerational effects on ovarian function. 
1. This is a pre-copyedited, author-produced version of an article accepted for publication in Biology of Reproduction following peer review. The 
version of record S. Rattan, E. Brehm, L. Gao, S. Neirmann, and JA. Flaws. Prenatal exposure to di(2-ethylhexyl) phthalate (DEHP) disrupts 





Phthalates are a family of synthetic chemicals that are additives and act as plasticizers to 
confer flexibility and prevent plastics from becoming brittle [1]. Many types of phthalates exist, 
but di(2-ethylhexyl) phthalate (DEHP) is a common plasticizer found in polyvinyl chloride 
products such as consumer products, medical equipment, and building products [2]. DEHP is 
incorporated into a multitude of products including personal care products, medical equipment 
(i.e., blood and I.V. bags), car upholstery, food and beverage containers, and building materials 
[3]. On average, 300 million pounds of DEHP are produced annually in the United States [1]. 
DEHP is noncovalently bound; therefore, it readily leaches from products and into the 
environment after repeated use, heating, and cleaning [4]. Humans are exposed to DEHP by oral 
ingestion, inhalation, and dermal contact at an average range between 3 – 30 µg/kg/day [3, 5]. 
Studies show that 100% of human urine samples test positively for DEHP and its metabolites, 
indicating that humans are repeatedly and continuously exposed to DEHP [6]. This is supported 
by the frequent detection of DEHP in various human tissues such as blood, amniotic fluid, 
umbilical cord blood, breast milk, and ovarian follicular fluids in humans [3, 7-10]. This is of 
concern because a pregnant mother and her developing offspring can be exposed to DEHP, and 
DEHP is a known endocrine disrupting chemical (EDC) [1]. 
Numerous studies demonstrate that exposure to DEHP exerts adverse effects on the male 
reproductive system. Specifically, prenatal exposure to DEHP causes testicular dysgenesis 
syndrome [11-14], which is characterized by testicular cancer, low or declining semen quality, 
high frequencies of undescended testis, and hypospadias [15, 16]. In addition, prenatal exposure 
to DEHP shortens anogenital distance (an indicator of in utero sex steroid hormone level 
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disruption) [17], decreases circulating serum testosterone levels [13], and causes pubertal 
abnormalities [18].  
In females, the effects of prenatal exposure to DEHP are less understood than in males. 
However, experimental studies show that prenatal exposure to DEHP decreases litter size and 
pup body weight [19], disrupts sex determination, causes precocious puberty in females [20], and 
decreases circulating estradiol levels in females [21]. Further, studies indicate that prenatal 
exposure to DEHP increases the time for females to become pregnant and increases pup death in 
mice [2] and that it is associated with reduced uterine size [22], reduced testosterone:estradiol 
ratio and progesterone levels [23], and advanced age of pubic hair development in young girls 
[24]. 
Studies have examined the effects of DEHP exposure on the ovary because it is an 
important organ for reproductive processes. Further, a previous study has shown that DEHP 
metabolites reach the ovary [25]. Specifically, the bioactive metabolite of DEHP, mono(2-
ethylhexyl) phthalate (MEHP), has been detected at approximately 9.34 ng/mL in human antral 
fluid [25]. 
The ovary is a heterogeneous organ composed of different follicle types, oocytes, corpora 
lutea, and interstitial tissue. Any chemical exposure that interferes with the development and 
function of the ovary can cause severe reproductive abnormalities. Specifically, chemicals that 
target the formation of the primordial follicle pool cause infertility because it depletes the finite 
follicle reserve used for the production of ovulatory follicles [26, 27]. Chemicals that specifically 
target primary, preantral, and antral follicles may lead to temporary infertility or permanent 
infertility. Permanent infertility may occur when the toxicant is not removed and it continuously 
targets the growth and function of ovarian follicles [28]. Chemicals that target the antral follicles 
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also may interfere with the production of sex steroid hormones, leading to infertility and other 
reproductive disorders [28-32]. Our laboratory has previously shown that in vitro exposure to 
MEHP reduces follicle growth in antral follicles and decreases sex steroid hormone biosynthesis 
[33]. Further, we have shown that DEHP exposure (20, 200, and 750 mg/kg/day) during 
adulthood for 10 days accelerates primordial follicle recruitment [34] and reduces the primordial 
follicle pool at 9 months [27]. In addition, studies indicate that postnatal exposure to DEHP (20 
and 40 µg/kg) reduces the ovarian primordial follicle pool, accelerates ovarian follicular 
recruitment [19], and decreases ovarian concentrations of progesterone, 17β-estradiol, and 
androstenedione [35].  
Although the direct effects of DEHP are fairly well documented on the ovary, the effects 
of DEHP exposure across generations are not as well understood. Previous studies have shown 
that maternal DEHP exposure (0.05 mg/kg/day) reduced embryo viability over several 
generations in female mice [36] and prenatal exposure to a mixture of plasticizers, including 
DEHP, increased the presence of small and large cysts in the ovary [37]. 
Although previous studies have shown that DEHP exposure adversely affects the ovary, 
they have not assessed the impact of prenatal DEHP exposure on follicle numbers in detail, sex 
steroid hormone production over time, and the impact of DEHP on the ovary in subsequent 
generations over time. Therefore, the current study was designed to evaluate the potential effects 
of prenatal exposure to DEHP during the second half of pregnancy on ovarian functions in the 
F1, F2, and F3 generations of mice. Specifically, this study tested the hypothesis that prenatal 
DEHP exposure adversely affects folliculogenesis, gonadotropin hormone levels, and sex steroid 




3.3 Materials and Methods 
Chemicals 
DEHP (99% purity) was purchased from Sigma-Aldrich (St. Louis, MO). Stock solutions 
of DEHP (0.022, 0.224, 560, and 840 mg/mL) were prepared by diluting the chemical in 
tocopherol-stripped corn oil (MP Biomedicals, Solon, OH). These stock solutions were diluted to 
achieve the desired doses of 20 µg/kg/day, 200 µg/kg/day, 200 mg/kg/day, 500 mg/kg/day, and 
750 mg/kg/day. DEHP concentrations were chosen based on previous studies and their 
environmental relevance [2, 12, 26, 27, 33, 34]. Specifically, DEHP at 20 µg/mg/day was 
selected based on the United States Environmental Protection Agency published reference safe 
dose (https://www3.epa.gov/airtoxics/hlthef/eth-phth.html) and falls within the estimated human 
exposure range based on urinary metabolite levels [5]. DEHP at 200 µg/mg/day was used 
because adult exposure causes abnormal estrous cyclicity and accelerates primordial follicle 
recruitment in female CD-1 mice [34]. DEHP 200 mg/kg/day was chosen because adult exposure 
has been shown to accelerate primordial follicle recruitment in females [34]. DEHP 500 
mg/kg/day was selected because this dose causes abnormalities in spermatogonial stem cells 
across multiple generations in male CD-1 mice [12]. DEHP 750 mg/kg/day was selected because 
it causes in abnormal estrous cyclicity and accelerates primordial follicle recruitment in adult 
female CD-1 mice [34]. 
 
Animals and study design 
Adult female and male CD-1 mice (Charles River, USA) were housed at 25 °C in 
conventional polysulfone, ventilated cages on 12L:12D cycles. The mice were provided Teklad 
Rodent Diet 8604 (Harlan) and highly purified water (reverse osmosis filtered) in polysulfone 
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water bottles ad libitum. All animal procedures were approved by the University of Illinois 
Institutional Animal Care and Use Committee and abide by the guidelines set forth by the 
National Institute of Health for the Care and Use of Laboratory Animals. Investigations using 
experimental animals or subjects were conducted in accordance with the Society for the Study of 
Reproduction's specific guidelines and standards. 
At 8 weeks of age, 83 female mice (F0) were mated with control mice of the same age. 
The female mice were monitored twice a day for the presence of a copulatory vaginal sperm plug 
to confirm mating. Once a copulatory vaginal sperm plug was confirmed, the presence of which 
was considered gestational day (GD) 0.5, the females were weighed and individually housed. 
Subsequently, mice were weighed twice a week to confirm successful pregnancy. From GD 10.5 
until birth of the pups, pregnant dams (F0) were orally dosed once a day with the vehicle control 
(tocopherol-stripped corn oil), or with DEHP (20 µg/kg/day, 200 µg/mg/day, 200 mg/kg/day, 
500 mg/kg/day, 750 mg/kg/day) by placing a pipette tip with the dosing solution into the cheek 
pouch of the mouse. This dosing regimen was selected to mimic oral exposure to DEHP in 
humans [1, 27, 34]. The doses were calculated and adjusted based on daily body weights, and 
delivered in 25 – 33 µL of tocopherol-stripped corn oil. The treatment window was chosen 
because it is a critical time period of ovarian development. Specifically, this is when primordial 
germ cells arrive at the gonad [38, 39], sex determination occurs [40], and when global 
demethylation and imprint erasure of primordial germ cells occur [41]. 
Pregnant mice were allowed to deliver naturally and the day of birth was considered 
postnatal day (PND) 0. Mice born from the F0 generation were labeled the F1 generation. 
Female mice from the F1 generation were mated with non-treated male CD-1 mice at 3 months 
of age to produce the F2 generation. Females from the F2 generation were mated with non-
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treated male CD-1 mice at 3 months of age to produce the F3 generation. The 200 mg/kg/day 
treatment group was not continued past the F2 generation. Body weights in all generations were 
measured from PND 1 – 60, and at 3, 6, and 9 months of age during the collection of organs and 
during set intervals during adulthood. Mice were euthanized on PNDs 1 and 8 by decapitation, 
and on PNDs 21 and 60 by carbon dioxide asphyxiation followed by cervical dislocation. 
 
Histological evaluation of follicle numbers 
Ovaries from F1, F2, and F3 females at PND 1, 8, 21, and 60 were collected, oviducts 
and surrounding tissues were removed, weighed in pairs, and placed in Dietrich’s fixative. Fixed 
ovaries were placed in paraffin and serial sectioned at 5 µm for PND 1 ovaries or at 8 µm for 
PND 8, 21, and 60 ovaries. The sections then were mounted on glass slides, stained with 
Weigert’s hematoxylin and picric-acid methyl blue, and covered with a glass coverslip. Every 5th 
section of the ovary at PND 1 or every 10th section of the ovary at PND 8, 21, and 60, was used 
to count the numbers of germ cells, primordial follicles, primary follicles, preantral follicles, 
antral follicles, and atretic follicles as described [2, 42]. Germ cells were defined as round in 
appearance with a nucleus. Primordial follicles were defined as follicles with an oocyte, 
surrounded by a single layer of squamous granulosa cells. Primary follicles consisted of an 
oocyte, surrounded by a single layer of cuboidal granulosa cells. Preantral follicles contained an 
oocyte, surrounded by multiple layers of cuboidal granulosa cells, and theca cells. Antral 
follicles consisted of an oocyte, surrounded by numerous layers of cuboidal granulosa cells, 
theca cells, and a fluid filled antrum. Preantral and antral follicles were only counted if they 
contained a nucleus in the oocyte to avoid “double counts” due to the large follicle size that can 
span multiple sections. Follicles that were transitioning between stages were counted as the more 
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immature stage. Atretic follicles were counted as preantral or antral follicles that contained 10% 
or greater number of apoptotic bodies. The total numbers of all follicles, total numbers of each 
healthy follicle type, percentages of follicle types, and percentages of atretic preantral and antral 
follicles were recorded. To calculate the percentages of follicle types, the number of the follicle 
type was divided by the total number of all follicles multiplied by 100. This calculations allow us 
to identify shifts in follicle pools, which may indicate either accelerated or inhibited 
folliculogenesis. To calculate the percentage of atretic follicles, the number of atretic preantral 
and atretic antral follicles were combined, divided by the number of healthy preantral and antral 
follicle types, and multiplied by 100. Corpora lutea were quantified at PND 60 by inspecting the 
individual progression of the corpora lutea throughout the ovary in all serial sections [43]. This 
was done to avoid double counting of corpora lutea because they do not have a landmark such as 
nuclear material in the oocyte observed in antral follicles. All sections were examined without 
knowledge of treatment group.  
 
Analysis of sex hormone levels 
Tissues and sera were collected and analyzed as described below. Mice do not cycle at 
PNDs 1 – 21; therefore, serum samples were collected at exactly 1, 8, or 21 days. Mice at PND 
60 are cycling; therefore, serum samples were collected when the mice were in 
diestrus/metestrus to minimize fluctuations due to cycle day. All serum samples were submitted 
to the University of Virginia Center for Research in Reproduction Ligand Assay and Analysis 
Core lab without knowledge of treatment groups to measure progesterone, testosterone, and 17β-
estradiol using enzyme-linked immunosorbent assays (ELISAs) and to measure follicle 
stimulating hormone (FSH) and luteinizing hormone (LH) using radioimmunoassay (RIAs). The 
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lowest limit of detections were 0.15 ng/mL for progesterone, 10 ng/dL for testosterone, 3 pg/mL 
for 17β-estradiol, 1.17 ng/mL for FSH, and 0.04 ng/mL for LH. If the assays measured less than 
the lowest limit of detection, the value was substituted with the lowest limit of detection/√2. The 
intra- and inter-assay coefficients of variability were less than 10% 
(https://med.virginia.edu/research-in-reproduction/wp-content/uploads/sites/311/2016/08/2016-
INTRA-INTER-ASSAY-CVs__032316.pdf). At PND 21, low quantities of serum prevented 
measurements of serum progesterone levels for the F1 generation. 
 
Statistical analyses 
Data were expressed as the mean ± standard error of the mean (SEM). In all generations, 
data from multiple female pups originating from the same litter were averaged and combined as 
n = 1, and data from at least 3 separate litters were used in the analyses. If samples were less than 
3, then statistical tests were not performed, but data were presented. Data were analyzed by 
comparing treatment groups to control using SPSS software (SPSS Inc., Chicago, IL). Outliers 
were removed using the GraphPad outlier calculator for the Grubb’s test (GraphPad Software 
Inc., La Jolla, CA). To test for cohort differences, data were tested using a general linear model 
univariate test. If there was an interaction effect between treatment and cohort in the tests of 
between-subjects effects, then the data from the first two cohorts were analyzed. If no interaction 
effect between treatment and cohort occurred, then all three cohorts were analyzed as one. Data 
that were continuous were assessed for normal distribution by Shapiro-Wilk analysis. If data met 
assumptions of normal distribution and homogeneity of variance, data were analyzed by one-way 
analysis of variance (ANOVA) followed by Dunnett (2-sided) post-hoc comparisons. If data 
were not normally distributed, were presented as a percentage, and/or did not meet homogeneity 
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of variance assumptions, the independent sample Kruskal-Wallis H followed by Mann-Whitney 
U non-parametric tests were performed. For all comparisons, statistical significance was 
determined by a p-value ≤ 0.05. In instances in which p-values were greater than 0.05, but less 
than 0.1, data were considered to exhibit a trend towards significance. 
 
3.4 Results 
Effects of DEHP exposure on body weights 
In the F1 generation, DEHP exposure did not significantly affect body weight at any time 
point (Table 3.1). In the F2 generation, exposure to the 20 µg/kg/day dose of DEHP significantly 
decreased body weight at PNDs 8 and 21 compared to the control (Table 3.1, n = 7 – 20 
dams/treatment group; p ≤ 0.05), but DEHP did not affect body weights at other time points. In 
the F3 generation, DEHP exposure did not significantly affect body weight at any time points 
(Table 3.1). 
 
Effects of DEHP on ovarian weights 
In the F1 generation, the 20 µg/kg/day and 750 mg/kg/day doses of DEHP significantly 
decreased ovarian weight, but the 200 µg/kg/day dose of DEHP significantly increased ovarian 
weight at PND 21 compared to the control (Table 3.2, n = 3 – 15 dams/treatment group; p ≤ 
0.05). Exposure to the 200 mg/kg/day dose of DEHP increased ovarian weight at PND 21, but 
this increase only trended towards significance compared to the control (Table 3.2, n = 8 – 15 
dams/treatment group; p = 0.076). In the F2 generation, exposure to the 20 µg/kg/day dose of 
DEHP decreased ovarian weight at PND 21, but this decrease only trended towards significance 
(Table 3.2, n = 8 – 9 dams/treatment group; p = 0.072). Exposure to the 200 µg/kg/day dose of 
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DEHP significantly decreased ovarian weight at PND 60 compared to the control (Table 3.2, n = 
7 – 9 dams/treatment group; p ≤ 0.05). In the F3 generation, DEHP exposure did not 
significantly affect ovarian weight at any time points (Table 3.2). 
 
Effects of DEHP on uterine weights 
In the F1 generation, exposure to DEHP did not significantly affect uterine weight at 
PND 8, but the 200 µg/kg/day dose of DEHP significantly increased uterine weight at PND 21 
compared to the control (Table 3.3, n = 4 – 16 dams/treatment group; p ≤ 0.05). In the F2 
generation, exposure to the 500 mg/kg/day dose of DEHP significantly increased uterine weight 
at PND 8 (Table 3.3, n = 3 – 14 dams/treatment group; p ≤ 0.05). In contrast, the 200 mg/kg/day 
dose of DEHP decreased uterine weight at PND 8, but only trended towards significance (Table 
3.3, n = 7 – 14 dams/treatment group; p = 0.084). At PND 21, exposure to the 20 µg/kg/day dose 
of DEHP significantly decreased uterine weight compared to the control (Table 3.3, n = 7 – 15 
dams/treatment group; p ≤ 0.05). In the F3 generation, exposure to DEHP did not significantly 
affect uterine weight at any of the time points (Table 3.3). 
 
Effects of DEHP on liver weights 
In the F1 generation, the 500 mg/kg/day dose of DEHP significantly increased liver 
weight at PND 1 compared to the control (Table 3.4, n = 5 – 17 dams/treatment group; p ≤ 0.05) 
and the 200 mg/kg/day dose of DEHP significantly increased liver weight at PND 8 compared to 
the control (Table 3.4, n = 8 – 15 dams/treatment group; p ≤ 0.05). In the F2 generation, the 500 
mg/kg/day dose of DEHP significantly increased liver weight at PND 8 compared to the control 
(Table 3.4, n = 10 – 17 dams/treatment group; p ≤ 0.05). The 20 µg/kg/day dose of DEHP 
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significant decreased liver weight, and the 500 mg/kg/day dose of DEHP significantly increased 
liver weight at PND 21 compared to the control (Table 3.4, n = 3 – 15 dams/treatment group; p ≤ 
0.05). In F3 generations, exposure to DEHP did not significantly affect liver weight at any doses 
(Table 3.4). 
 
Effect of DEHP exposure on F1 ovarian morphology 
At PND 1, prenatal exposure to DEHP did not significantly affect the numbers of germ 
cells, or primordial, primary, and total follicles compared to the control (Figure 3.1A). Similarly, 
at PND 8, DEHP exposure did not significantly affect the numbers of primordial, primary, 
preantral, or total follicles compared to the control (Figure 3.1B). In contrast, at PND 21, the 200 
µg/kg/day and 750 mg/kg/day doses of DEHP significantly decreased the numbers of antral 
follicles compared to the control (Figure 3.1C, n = 4 – 10 dams/treatment group; p ≤ 0.05). At 
PND 60, both the 20 µg/kg/day and the 200 µg/kg/day doses of DEHP decreased the number of 
primary follicles, but only trended towards significance (Figure 3.1D, n = 5 – 13 dams/treatment 
group; p = 0.071 and 0.064, respectfully). Further, the 20 µg/kg/day dose of DEHP decreased the 
number of preantral follicles but only trended towards significance (Figure 3.1D, n = 5 – 13 
dams/treatment group: p = 0.084). 
At PND 1, prenatal exposure to DEHP did not significantly affect the percentage of germ 
cells, or primordial, primary, and atretic follicles compared to the control (Figure 3.2A). In 
contrast, at PND 8, exposure to the 500 mg/kg/day dose of DEHP increased the percentage of 
primordial follicles and the 200 mg/kg/day dose of DEHP increased the percentage of preantral 
follicles, but both increases trended towards significance compared to the control (Figure 3.2B, n 
= 5 – 14 dams/treatment group; p = 0.085 and p = 0.076, respectfully). At PND 21, the 20 
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µg/kg/day dose of DEHP significantly increased the percentage of primary follicles and the 750 
mg/kg/day dose of DEHP significantly decreased the percentage of antral follicles compared to 
the control (Figure 3.2C, n = 5 – 12 dams/treatment group; p ≤ 0.05). Further, the 500 mg/kg/day 
dose of DEHP decreased the percentage of antral follicles, but the decrease only trended towards 
significance (Figure 3.2C, n = 5 – 12 dams/treatment group; p = 0.079). At PND 60, the 200 
µg/kg/day dose of DEHP decreased the percentage of primary follicles, but the decrease only 
trended towards significance (Figure 3.2C, n = 5 – 13 dams/treatment group; p = 0.068). Further, 
the 200, 500, and the 750 mg/kg/day doses of DEHP significantly decreased the percentage of 
atretic follicles compared to the control (Figure 3.2D, n = 4 – 12 dams/treatment group; p ≤ 
0.05).  
 
Effect of DEHP exposure on F2 ovarian morphology 
At PND 1, exposure to DEHP did not significantly affect the number of germ cells, or 
primordial, primary, and total follicles compared to the control (Figure 3.3A). In contrast, at 
PND 8, the 200 mg/kg/day dose of DEHP significantly decreased the numbers of primordial, 
primary, and total follicles compared to the control (Figure 3.3B, n = 5 – 7 dams/treatment 
group; p ≤ 0.05), but the decrease in primary follicle type only trended towards significance 
(Figure 3.3B, n = 5 – 7 dams/treatment group; p = 0.062). At PND 21, the 200 mg/kg/day dose 
of DEHP significantly decreased the number of primordial, primary, and total follicles compared 
to the control (Figure 3.3C, n = 5 – 7 dams/treatment group; p ≤ 0.05). Further, the 500 
mg/kg/day dose of DEHP decreased the number of primordial follicles, but the decrease only 
trended towards significance (Figure 3.3C, n = 4 – 7 dams/treatment group; p = 0.09). Both the 
20 µg/kg/day and the 750 mg/kg/day doses of DEHP significantly decreased the number of 
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antral follicles at PND 21 compared to the control (Figure 3.3C, n = 5 – 7 dams/treatment group; 
p ≤ 0.05). At PND 60, both the 200 µg/kg/day and the 750 mg/kg/day doses of DEHP decreased 
the number of antral follicle numbers compared to the control (Figure 3.3D, n = 6 – 
11dams/treatment group; p ≤ 0.05). Further, the 20 µg/kg/day dose of DEHP decreased the total 
number of follicles, but the decrease only trended towards significance (Figure 3.3D, n = 8 – 11 
dams/treatment group; p = 0.075). 
At PND 1, the 200 µg/kg/day dose of DEHP decreased the percentage of germ cells and 
increased the percentage of primordial follicles types, but these changes only trended towards 
significance (Figure 3.4A, n = 3 – 4 dams/treatment group; p = 0.077 and p = 0.077, 
respectfully). At PND 8, exposure to both the 20 µg/kg/day and the 200 mg/kg/day doses of 
DEHP decreased the percentage of primordial follicles, but the decreases only trended towards 
significance (Figure 3.4B, n = 4 – 7 dams/treatment group; p = 0.088 and p = 0.062). Further, the 
200 mg/kg/day dose of DEHP significantly increased the percentage of preantral follicles 
compared to controls (Figure 3.4B, n = 5 – 7 dams/treatment group; p ≤ 0.05). At PND 21, the 
200 mg/kg/day of DEHP decreased the percentage of primordial follicles compared to the 
control, but the decrease only trended towards significance (Figure 3.4C, n = 5 – 7 
dams/treatment group; p = 0.058), whereas the 500 mg/kg/day dose of DEHP significantly 
decreased the percentage of primordial follicles compared to the control (Figure 3.4C, n = 6 – 7 
dams/treatment group; p ≤ 0.05). The 200 and 500 mg/kg/day doses of DEHP significantly 
increased the percentage of preantral follicles compared to the control, with the increase in the 
500 mg/kg/day trending towards significance (Figure 3.4C, n = 4 – 7 dams/treatment group; p ≤ 
0.05 and p = 0.086, respectfully). The 20 µg/kg/day significantly decreased the percentage of 
antral follicles and the 200 mg/kg/day doses of DEHP significantly increased the percentage of 
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antral follicles compared to the control (Figure 3.4C, n = 4 – 7 dams/treatment group; p ≤ 0.05). 
At PND 60, the 750 mg/kg/day dose of DEHP increased the percentage of primary follicles and 
decreased the percentage atretic follicles, but it only trended towards significance (Figure 3.4D, n 
= 5 – 11 dams/treatment group; p = 0.070 and p = 0.066, respectfully). Further, the 200 
µg/kg/day dose of DEHP significantly decreased the percentage of preantral and antral follicles 
compared to controls, but the decrease in preantral follicles only trended towards significance 
(Figure 3.4D, n = 7 – 11 dams/treatment group; p = 0.094 and p ≤ 0.05, respectfully).  
 
Effect of DEHP exposure on F3 ovarian morphology 
At PND 1, the 500 mg/kg/day dose of DEHP significantly decreased the number of germ 
cells and total number of oocytes compared to the control (Figure 3.5A, n = 5 – 7 dams/treatment 
group; p ≤ 0.05). At PND 8, the 200 µg/kg/day and the 500 mg/kg/day doses of DEHP increased 
the number of primordial, preantral, and total follicles compared to the control (Figure 3.5B, n = 
4 – 5 dams/treatment group; p ≤ 0.05, except 500 mg/kg/day preantral p = 0.088). At PND 21, 
the 20 µg/kg/day dose of DEHP significantly decreased the number of primordial and total 
number of follicles compared to the control (Figure 3.5C, n = 4 – 6 dams/treatment group; p ≤ 
0.05). The 750 mg/kg/day dose of DEHP decreased the number of preantral follicles, but the 
decrease only trended towards significance (Figure 3.5C, n = 5 dams/treatment group; p = 
0.068). At PND 60, exposure to DEHP did not significantly affect the numbers of primordial, 
primary, preantral, antral, and total follicles compared to the control (Figure 3.5D). 
At PND 1, both the 500 mg/kg/day and the 750 mg/kg/day doses of DEHP significantly 
decreased the percentage of germ cells and increased the percentage of primordial follicle types 
compared to the control (Figure 3.6A, n = 5 – 7 dams/treatment group; p ≤ 0.05). At PND 8, the 
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20 µg/kg/day dose of DEHP significantly increased the percentage of preantral follicles 
compared to the control (Figure 3.6B, n = 5 – 7 dams/treatment group; p ≤ 0.05). At PNDs 21 
and 60, DEHP exposure did not significantly affect the percentage of primordial, primary, 
preantral, antral, or atretic follicles compared to the control (Figures 3.6C and 3.6D).  
 
Effect of DEHP on corpora lutea in all generations 
At PND 60, exposure to DEHP did not significantly affect the number of corpora lutea in 
the F1 generation (Figure 3.7). Similarly, DEHP exposure did not significantly affect the number 
of corpora lutea in the F2 and F3 generations (Figure 3.7). 
 
Effect of DEHP exposure on serum 17β-estradiol levels 
At PND 8, the 20 µg/kg/day, 500 mg/kg/day, and 750 mg/kg/day doses of DEHP 
significantly increased serum 17β-estradiol levels compared to the control in the F1 generation 
(Figure 3.8A, n = 5 – 8 dams/treatment group; p ≤ 0.05, except for 500 mg/kg/day p = 0.057). In 
contrast, the 750 mg/kg/day dose of DEHP decreased serum 17β-estradiol levels in the F2 
generation and  only trended towards significance (Figure 3.8A, n = 5 – 10 dams/treatment 
group; p = 0.09). DEHP exposure did not significantly affect serum 17β-estradiol levels in the F3 
generation (Figure 3.8A).  
At PND 21, exposure to DEHP did not significantly affect serum 17β-estradiol levels in 
the F1 generation. In contrast, exposure to DEHP decreased serum 17β-estradiol levels in the 20 
µg/kg/day treatment group in the F2 generation, but the decrease only trended towards 
significance (Figure 3.8B, n = 7 – 9 dams/treatment group; p = 0.074). Exposure to DEHP did 
not significantly affect serum 17β-estradiol levels in the F3 generation (Figure 3.8B)   
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At PND 60, exposure to the 500 mg/kg/day dose of DEHP significantly increased serum 
17β-estradiol levels compared to the control in the F1 generation (Figure 3.8C, n = 7 
dams/treatment group; p ≤ 0.05). In contrast, DEHP exposure did not significantly affect serum 
17β-estradiol levels in the F2 and F3 generations (Figure 3.8C). 
 
Effect of DEHP exposure on serum progesterone levels 
At PND 21, exposure to 20 µg/kg/day and 500 mg/kg/day doses of DEHP significantly 
increased serum progesterone levels compared to the control in the F2 generation (Figure 3.8D, n 
= 5 – 8 dams/treatment group; p ≤ 0.05 except 20 µg/kg/day p = 0.057). In contrast, DEHP 
exposure did not significantly affect serum progesterone levels in the F3 generation (Figure 
3.8D).  
At PND 60, serum progesterone levels were not significantly affected by DEHP exposure 
in the F1 generation (Figure 3.8E). In contrast, exposure to 200 µg/kg/day, 500 mg/kg/day, and 
750 mg/kg/day dose of DEHP significantly decreased serum progesterone levels compared to the 
control in the F2 generation (Figure 3.8E, n = 3 – 10 dams/treatment group; p ≤ 0.05 except 200 
µg/kg/day p = 0.091). DEHP exposure did not significantly affect progesterone levels in the F3 
generation (Figure 3.8E). 
 
Effect of DEHP exposure on serum testosterone levels 
At PND 60, exposure to 200 µg/kg/day of DEHP significantly decreased serum 
testosterone levels compared to the control in the F1 generation (Figure 3.8F, n = 4 – 7 
dams/treatment group; p ≤ 0.05). In contrast, DEHP exposure did not significantly affect serum 
testosterone levels in the F2 and F3 generations. 
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Effect of DEHP exposure on serum gonadotropin hormone levels 
Exposure to DEHP did not significantly affect serum LH and serum FSH levels in the F1 
generation. (Figures 3.9G and 3.9H). Similarly, DEHP exposure did not significantly affect 
serum LH and FSH levels in the F2 and F3 generations (Figures 3.9G and 3.9H). 
 
3.5 Discussion 
We have shown that prenatal exposure to DEHP during the second half of pregnancy 
disrupts ovarian function across generations through the maternal lineage in mice. Specifically, 
we provide evidence that DEHP exposure adversely affects body weights in the F2 generation, 
tissue weights in the F1 and F2 generations, ovarian morphology in the F1, F2, and F3 
generations, and serum sex steroid hormone levels in the F1 and F2 generations. Further, to our 
knowledge, we are the first to show adverse transgenerational effects of prenatal DEHP exposure 
on ovarian morphology in detail. 
Interestingly, the effects caused by DEHP exposure were not the same in each generation 
and many effects were non-monotonic in nature. This is likely because during prenatal exposure 
to DEHP, the F1, F2, and F3 generations received DEHP during different developmental 
windows. Specifically, the F1 generation was exposed to DEHP as the developing pup. The F2 
generation was exposed to DEHP as the developing ovaries within the pup. The F3 generation 
was not directly exposed to DEHP. Further, DEHP is a known endocrine disrupting chemical 
(EDC), and characteristic of an EDC is that the adverse effects of a toxicant are not proportional 
to the dose and therefore, often do not follow a linear relationship [44]. Further, because DEHP 
is rapidly metabolized and excreted with a half-life between 2 – 8 hours [45], it is important to 
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note that the exposure window to DEHP is limited. Thus, it is unlikely that DEHP levels during 
gestation continued into the F1, F2, and F3 generations. 
Our data showed that DEHP exposure decreased body weight in the F2 generation at 
PNDs 8 and 21, but it did not affect body weight in the F1 and F3 generations. This is in contrast 
to a previous study in which prenatal exposure to a phthalate mixture (200 µg/kg/day and 200 
mg/kg/day) increased body weight in the F2 generation of female mice [46]. The reasons why 
our results differ may be because the phthalate mixture contained multiple phthalates in addition 
to DEHP and the different phthalates could have affected the body weight differently than DEHP 
alone. In addition, the dose of DEHP in the phthalate mixture was different than the doses we 
used in this study (approximately 41 µg and 41 mg/kg/day in the mixture vs. 20 µg – 750 
mg/kg/day in this study) [46].  
The mechanism by which DEHP exposure decreased body weight in our study is not 
known. However, phthalates such as DEHP have been shown to act on peroxisome proliferator-
activated receptors (PPARs) and these receptors are important for the regulation of glucose 
homeostasis and in turn, body weight [47]. Therefore, it is possible that DEHP may have acted 
on PPARs to dysregulate body weight in our study. It is interesting to note that the decrease in 
body weight was observed only with the lowest dose of DEHP (20 µg/kg/day), suggesting that 
different doses of DEHP may act on the body differently. This possibility is supported by another 
study that showed that prenatal DEHP exposure caused different effects on body weight at 
different doses. Specifically, prenatal DEHP increased body weight at 200 µg/kg/day and 
decreased body weight at 500 mg/kg/day in male mice [13]. 
In addition, our data showed that prenatal DEHP exposure affected ovarian weight in the 
F1 and F2 generations. Specifically, in the F1 generation, the 20 µg/kg/day and 750 mg/kg/day 
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doses of DEHP increased ovarian weight and the 200 µg/kg/day dose decreased ovarian weight 
at PND 21. In the F2 generation, DEHP exposure at 20 µg/kg/day decreased ovarian weight. The 
reasons why DEHP causes ovarian weight changes are unknown. We speculate that DEHP 
exposure may alter the granulosa cell size, the granulosa cell number, or affect the interstitial 
cells, leading to alterations in ovarian weight. The DEHP-induced decrease in ovarian weight is 
similar to the DEHP-induced decrease in testes weight observed after prenatal exposure to 325 
µL/L of DEHP in drinking water [48]. However, this level of DEHP in drinking water is 
equivalent to 30 – 35 mg/kg/day of DEHP and is much higher than the dose at which we 
observed a decrease in ovarian weight [48]. Our data differ from another study showing that 
prenatal DEHP exposure (0.015 – 405 mg/kg/day) from gestation day 6 to lactation day 21 did 
not affect ovarian weight [49]. The difference in results between our study and this study may be 
due to the different windows of exposure (during second half of gestation vs. through lactation), 
different doses of DEHP, different animal models (mice vs. rats), and different methods of 
exposure (gavage vs oral). 
Prenatal DEHP exposure also increased uterine weight at PND 21 in the F1 generation, 
but it did not significantly affect uterine weight at any time points in the F2 or F3 generations. 
An increase in uterine weight may correlate with an increase in 17β-estradiol production. 
However, our data showed that at PND 21, DEHP exposure did not increase serum 17β-estradiol 
levels compared to controls. Thus, the DEHP-induced increase in uterine weight in the F1 
generation at PND 21 may be due to developmental effects independent of 17β-estradiol levels. 
In contrast to our data, a study reported that in utero and lactational exposure to DEHP (0.015 – 
405 mg/kg/day) did not alter uterine weight in the F1 generation of rats [49], suggesting the 
existence of species differences in the impact of prenatal DEHP exposure on uterine weight. 
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In our study, we counted follicle numbers and calculated the percentage of follicles at 
each stage of development. By examining the follicle numbers, we were able to quantify DEHP-
induced changes in the number of available primordial follicles or the growth of follicles to more 
mature stages. By calculating the percentage of follicle types, we were able to quantify shifts in 
follicle pools, which may indicate either accelerated or inhibited folliculogenesis. Our data 
showed that the DEHP treatment disrupted ovarian follicle numbers in all three generations. In 
the F1 and F2 generations, exposure to DEHP decreased follicle numbers. However, in the F3 
generation, DEHP exposure both decreased and increased follicle numbers, depending on the 
time point. Previous studies have reported that DEHP exposure during adulthood decreases the 
primordial follicle pool [34, 50]. These findings indicate that both prenatal and adult exposure to 
DEHP impact follicle numbers. The impact of prenatal exposure to DEHP is especially 
concerning because the DEHP-induced decrease in follicle numbers occurs across generations. It 
is possible that DEHP-induced losses in the finite number of primordial follicles may cause 
primordial follicle ovarian insufficiency, leading to declining fertility with age, and an early age 
of reproductive senescence. Loss of follicles was also observed in another study. Specifically, 
prenatal exposure to a plasticizer mixture including DEHP (750 mg/kg/day) reduced the number 
of primordial follicles in the F1 and F3 generations of female rats [37]. Taken together, these 
results suggest that prenatal DEHP exposure may lead to primary ovarian insufficiency, which is 
the premature loss of ovarian follicles caused by either atresia of follicular destruction [51]. 
Thus, future studies should examine the impact of DEHP-induced follicle losses on fertility. 
Our data showed that DEHP exposure decreased folliculogenesis in adult ovaries in the 
F1 generation, disrupted folliculogenesis in adult ovaries in the F2 generation, and accelerated 
the transition of germ cells to primordial follicles in the neonatal ovary in the F3 generation. The 
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mechanism by which DEHP exposure accelerates folliculogenesis, however, is not completely 
known. Our laboratory has previously demonstrated that adult exposure to DEHP (20 and 200 
µg/kg/day and 20 and 750 mg/kg/day) for ten days accelerated primordial follicle recruitment in 
mouse ovaries, and that this acceleration was mediated through the phosphatidylinositol 3-kinase 
(PI3K) signaling pathway [34]. The PI3K pathway is a critical regulator of folliculogenesis, 
specifically for primordial follicle activation, survival, and quiescence [34]. Thus, it is possible 
that prenatal exposure to DEHP activated the PI3K signaling pathway in our study. In addition, 
another study showed that impaired folliculogenesis correlated with reduced progesterone levels 
during diestrus and thus, DEHP may impair folliculogenesis by interfering with progesterone 
levels [52]. This possibility is supported by our data indicating that DEHP exposure both reduced 
serum progesterone levels in the F2 generation and accelerated folliculogenesis. Further, studies 
show DEHP exposure (10 and 100 µM) in vitro impairs primordial follicle assembly by 
increasing the mRNA expression levels of pro-apoptotic gene Bax in oocytes [53]. Given that 
Bax plays an important role in follicle growth, it is possible that the mechanism by which DEHP 
impacts folliculogenesis involves Bax [54]. 
In addition, our data showed that prenatal exposure to DEHP decreased the percentage of 
atretic follicles in the F1 generation. Although the reasons for the DEHP-induced reduction in 
atresia is unknown, a previous study showed that a mixture of phthalates containing DEHP 
caused the antral follicles to become arrested in the G1 state of the cell cycle [55]. At this stage, 
the cells are relatively resistance to apoptosis [56]. Therefore, the DEHP-induced reduction in 
the percentage of atretic follicles may be due to an ability of DEHP to arrest granulosa cells in 
the antral follicles in the G1 stage.  
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Our data showed that prenatal DEHP exposure did not affect the number of corpora lutea 
in the ovaries in any generation. This is in contrast to previous studies that have shown that 
DEHP exposure at much higher doses (3,000 mg/kg) decreased the number of new corpora lutea 
in adult rats [57] and that DEHP exposure (125, 250, and 500 mg/kg/day) reduced the number of 
corpora lutea in pregnant mice [58]. Interestingly, one study showed that DEHP exposure (25 
and 50 mg/kg/) reduced the size of corpora lutea, but increased plasma progesterone levels in 
sheep [59]. The reasons for differences in study results likely stem from differences in exposure 
windows (pregnancy vs. adulthood), species (mice vs. ewes), and timing of evaluation (pregnant 
dams vs. offspring). 
Our data showed that DEHP exposure disrupted sex steroid hormone levels in the F1 and 
F2 generations. Specifically, in the F1 generation, prenatal DEHP exposure increased serum 17β-
estradiol levels at PNDs 8 and 60. At PND 8, the increase in serum 17β-estradiol levels occurred 
at a time in which the ovary contained no antral follicles and because antral follicles are the 
primary produces of 17β-estradiol. These data suggest that the DEHP-induced increase in serum 
17β-estradiol at PND 8 is not due to a significant increase in antral follicle numbers and that 
DEHP affects follicle numbers and sex steroid hormone levels via different mechanisms. One 
study has shown that disruption of FSH production can signal to the immature ovary and 
promote the synthesis of 17β-estradiol without stimulating follicular growth [60]. Therefore, it is 
possible that DEHP may promote FSH production and elevate serum 17β-estradiol levels. At 
PND 60, the ovary contains many antral follicles, but it is unlikely that the DEHP-induced 
increase in 17β-estradiol levels at this time point is due to a change in antral follicle numbers 
because we did not observe any effects of DEHP on antral follicle numbers or atresia at PND 60. 
Instead, it is possible that DEHP exposure may dysregulate the biosynthesis of 17β-estradiol in 
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the ovary. Previous studies have shown that in vitro DEHP exposure (1 – 100 µg/mL) decreases 
17β-estradiol production [33] and decreases mRNA expression of aromatase, a key steroidogenic 
enzyme necessary for the conversion of cholesterol to 17β-estradiol in antral follicles [61]. 
Therefore, DEHP exposure in vivo may affect the levels of steroidogenic enzymes, increasing the 
levels of serum 17β-estradiol.  
Our data showed that in the F2 generation, exposure to DEHP increased serum 
progesterone levels at PND 21 and decreased serum progesterone levels at PND 60. It is 
interesting that in the F2 generation, exposure to DEHP increased serum progesterone levels 
even though corpora lutea are not present at PND 21. One study has shown that FSH stimulation 
can promote progesterone synthesis and output from granulosa cells without luteinization by 
upregulating enzymatic activity of 3B-hydroxysteroid dehydrogenase (3BHSD) [62]. Although 
we did not measure FSH or 3BHSD levels in the F2 generation at PND 21, it is possible that 
DEHP exposure stimulated FSH production leading to elevated progesterone levels. At PND 60, 
serum progesterone levels were decreased in DEHP treated mice. Similarly, previous studies 
showed that in vitro DEHP exposure (1 – 100 µg/mL) decreased progesterone levels in antral 
follicles [33]. Further, DEHP exposure throughout lactation (1 – 100 mg/kg/day) decreased 
serum progesterone levels in adult female rats [63]. In addition, DEHP exposure has increased 
plasma progesterone levels by metabolic clearance and not by the level of secretion from the 
corpora lutea in sheep [58]. Further, DEHP exposure is associated with reduced hepatic estrogen 
metabolism and may contribute to the altered hormone levels observed in our study [64]. 
Therefore, hormone synthesis and clearance may contribute to the altered hormone levels 
observed in this study and should be further explored in future studies. 
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It is likely that DEHP exposure affects folliculogenesis and steroidogenesis through 
separate mechanisms. Our data show that DEHP exposure interferes with follicle numbers, but 
not sex steroid hormone levels or vice versa at corresponding time points. One possible 
mechanism that may explain the change in sex steroid hormone levels may be a disruption of 
FSH and LH action either directly on the follicles or through the hypothalamus-pituitary-ovary 
axis. Further, an alteration of the steroidogenic enzyme expression or activity in the follicles may 
also contribute to the altered hormone levels as demonstrated by a previous study [65]. A 
different mechanism to explain the change in follicle numbers, but not sex steroid hormone 
levels may be through an oxidative stress pathway. A previous study focusing on DEHP 
exposure in antral follicles has shown that DEHP (10 µg/mL) significantly increases reactive 
oxygen species levels and decreases antioxidant enzymes to inhibit antral follicle growth [66]. 
Collectively, these data provide evidence that prenatal exposure to DEHP during the 
second half of gestation causes body weight and organ weight changes, dysregulates serum sex 
steroid hormone levels, and causes adverse transgenerational changes in ovarian morphology. 
However, further work is needed to elucidate the mechanisms underlying the effects of DEHP on 
folliculogenesis and steroidogenesis across generations. The mechanisms underlying the direct 
effects of DEHP on the F1 and F2 generations may be very different compared to the effects of 
DEHP on the F3 generation. In the F1 and F2 generations, it is possible that the mechanisms 
involve direct effects of DEHP on peroxisome proliferator-activated receptor alpha, proliferator-
activated receptor gamma, or estrogen receptors [67-69]. In the F3 generations, however, it is 
possible that the mechanism involves epigenetic modifications to the DNA, such as DNA 
methylation and histone modifications [18, 37, 70-72]. Normal folliculogenesis and 
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steroidogenesis are required for normal fertility. Therefore, future studies should also examine 
the fertility of mice prenatally exposed to DEHP in the F1, F2, and F3 generations.
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3.6 Tables, Figures, and Legends 
Table 3.1 Effects of prenatal exposure to DEHP on body weights, measured in grams, in the 
F1, F2, and F2 generations of female mice.  
      GENERATION 
TIME 
POINT Treatment Group 
Sample 





Control 4 - 17 1.792 ± 0.039 1.942 ± 0.142 1.851 ± 0.046 
DEHP 20  
µg/kg/day 3 - 10 1.853 ± 0.065 1.786 ± 0.113 1.751 ± 0.048 
DEHP 200 
µg/kg/day 3 - 10 1.886 ± 0.072 1.697 ± 0.124 1.751 ± 0.028 
DEHP 200 
mg/kg/day 9 1.800 ± 0.062 no data no data 
DEHP 500 
mg/kg/day 3 - 10 1.861 ± 0.029 1.728 ± 0.054 1.790 ± 0.117 
DEHP 750 





Control 15 - 20 6.300 ± 0.217 4.818 ± 0.115 5.116 ± 0.312 
DEHP 20  
µg/kg/day 5- 9 6.200 ± 0.321 
4.238 ± 0.195 
* 5.038 ± 0.210 
DEHP 200 
µg/kg/day 3 - 10 6.142 ± 0.345 5.027 ± 0.209 4.839 ± 0.145 
DEHP 200 
mg/kg/day 8 - 9 5.580 ± 0.268 4.382 ± 0.191 no data 
DEHP 500 
mg/kg/day 4 - 10 5.936 ± 0.192 5.125 ± 0.149 4.789 ± 0.363 
DEHP 750 





Control 8 - 16 15.33 ± 0.414 12.38 ± 0.444 12.43 ± 0.758 
DEHP 20  
µg/kg/day 4 - 7 14.00 ± 1.408 8.84 ± 0.703 * 11.78 ± 0.521 
DEHP 200 
µg/kg/day 3 - 8 14.68 ± 0.757 12.43 ± 0.618 11.81 ± 0.876 
DEHP 200 
mg/kg/day 6 - 8 14.81 ± 0.814 11.50 ± 0.440 no data 
DEHP 500 
mg/kg/day 3 - 5 13.94 ± 0.496 15.40 ± 1.567 13.02 ± 0.766 
DEHP 750 
mg/kg/day 5 - 6 14.75 ± 0.618 12.58 ± 1.363 13.60 ± 0.726 
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Table 3.1 (cont.) 
 
      GENERATION 
TIME 
POINT Treatment Group 
Sample 





Control 7 - 24 29.66 ± 0.527 27.92 ± 1.056 29.01 ± 0.872 
DEHP 20  
µg/kg/day 6 - 8 29.08 ± 1.177 26.99 ± 0.726 26.75 ± 0.492 
DEHP 200 
µg/kg/day 4 - 7 28.92 ± 1.517 27.57 ± 0.961 28.29 ± 1.331 
DEHP 200 
mg/kg/day 9 30.30 ± 0.513 no data no data 
DEHP 500 
mg/kg/day 3 - 11 27.93 ± 0.938 29.72 ± 2.752 29.70 ± 1.688 
DEHP 750 







Control 8 - 14 32.45 ± 1.105 29.47 ± 1.308 32.15 ± 0.742 
DEHP 20  
µg/kg/day 7 - 8 31.66 ± 1.385 29.30 ± 0.510 29.59 ± 0.719 
DEHP 200 
µg/kg/day 4 - 10 31.35 ± 0.684 29.15 ± 0.519 30.05 ± 0.484 
DEHP 200 
mg/kg/day 0 no data no data no data 
DEHP 500 
mg/kg/day 3 - 13 30.96 ± 1.030 30.88 ± 0.392 31.25 ± 1.273 
DEHP 750 







Control 7 - 14 39.63 ± 1.505 39.97 ± 1.379 41.48 ± 1.461 
DEHP 20  
µg/kg/day 6 - 8 39.94 ± 1.757 36.71 ± 1.309 36.92 ± 0.414 
DEHP 200 
µg/kg/day 3 - 10 37.76 ± 1.302 39.70 ± 1.841 38.07 ± 1.784 
DEHP 200 
mg/kg/day 0 no data no data no data 
DEHP 500 
mg/kg/day 3 - 13 37.18 ± 1.169 40.48 ± 0.273 40.33 ± 2.497 
DEHP 750 




Table 3.1 (cont.) 
 
      GENERATION 
TIME 
POINT Treatment Group 
Sample 







Control 7 - 14 41.21 ± 1.377 42.28 ± 2.319 46.10 ± 2.120 
DEHP 20  
µg/kg/day 6 - 8 41.19 ± 1.824 39.83 ± 2.255 41.70 ± 0.817 
DEHP 200 
µg/kg/day 3 - 10 40.61 ± 1.524 42.54 ± 2.205 45.27 ± 2.739 
DEHP 200 
mg/kg/day 0 no data no data no data 
DEHP 500 
mg/kg/day 3 - 13 39.26 ± 1.201 44.93 ± 1.282 47.90 ± 3.731 
DEHP 750 
mg/kg/day 6 - 7 43.61 ± 1.691 40.21 ± 1.316 43.73 ± 2.312 
 
Note: Table represent means ± standard error of the mean from 3 – 24 dams per treatment group. 
*p ≤ 0.05 (significant difference compared to the control) 
94 
 
Table 3.2 Effects of prenatal exposure to DEHP on ovarian weights, measured in 
milligrams, in the F1, F2, and F3 generations of female mice.  











Control 8 - 15 6.7 ± 0.5 5.0 ± 0.4 4.6 ± 0.5 
DEHP 20 
µg/kg/day 3 - 7 3.9 ± 0.3 * 4.2 ± 0.4 4.1 ± 0.2 
DEHP 200 
µg/kg/day 3 - 8 34.3 ± 5.9 * 5.1 ± 0.5 5.1 ± 0.3 
DEHP 200 
mg/kg/day 6 - 8 32.8 ± 16.4 ^ 5.3 ± 0.9 no data 
DEHP 500 
mg/kg/day 3 - 5 6.1 ± 1.0 6.2 ± 0.8 4.5 ± 0.3 
DEHP 750 





Control 7 - 24 15.4 ± 0.8 20.7 ± 1.8 16.9 ± 1.6 
DEHP 20 
µg/kg/day 6 - 7 14.0 ± 1.2 16.0 ± 1.2 ^ 14.2 ± 1.4 
DEHP 200 
µg/kg/day 4 - 7 14.1 ± 1.7 15.0 ± 0.8 * 16.0 ± 1.3 
DEHP 200 
mg/kg/day 9 14.2 ± 1.4 no data no data 
DEHP 500 
mg/kg/day 3 - 11 14.6 ± 1.0 17.6 ± 2.0 17.3 ± 1.4 
DEHP 750 
mg/kg/day 5 - 6 14.5 ± 0.4 19.9 ± 1.6 15.3 ± 1.3 
 
Note: Ovarian weights were not collected in the F1, F2, or F3 generations at PND 1 or PND 8. 
Table represent means ± standard error of the mean from 3 – 24 dams per treatment group. *p ≤ 
0.05 (significant difference compared to the control); 0.05 > ^p ≥ 0.076 (borderline significant 
difference compared to the control). 
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Table 3.3 Effects of prenatal exposure to DEHP on uterine weights, measured in 
milligrams, in the F1, F2, and F3 generations of female mice.  











Control 7     1.0 ± 0.1 
DEHP 20 
µg/kg/day 7     1.1 ± 0.1 
DEHP 200 
µg/kg/day 3 no data no data  1.1 ± 0.1 
DEHP 200 
mg/kg/day 0    no data 
DEHP 500 
mg/kg/day 3     1.1 ± 0.2 
DEHP 750 





Control 8 - 15 56.1 ± 2.8 3.6 ± 0.2 4.4 ± 0.2 
DEHP 20 
µg/kg/day 5 - 7 49.3 ± 4.8 3.5 ± 0.2 4.1 ± 0.3 
DEHP 200 
µg/kg/day 3 - 8 56.2 ± 4.9 4.0 ± 0.2 4.6 ± 0.5 
DEHP 200 
mg/kg/day 7 -9 66.8 ± 3.4 3.1 ± 0.1 ^ no data 
DEHP 500 
mg/kg/day 3 - 5 61.3 ± 4.8 5.1 ± 0.8 * 4.0 ± 0.4 
DEHP 750 





Control 8 - 16 20.6 ± 1.8 16.4 ± 1.4 15.3 ± 1.0 
DEHP 20 
µg/kg/day 4 - 7 15.3 ± 2.5 9.3 ± 0.7 * 12.5 ± 1.2 
DEHP 200 
µg/kg/day 3 - 7 206.0 ± 26.9 * 14.2 ± 0.9 15.1 ± 1.3 
DEHP 200 
mg/kg/day 6 - 8 50.2 ± 17.1 16.4 ± 2.2 no data 
DEHP 500 
mg/kg/day 3 - 5 18.7 ± 2.5 21.2 ± 5.4 17.7 ± 1.6 
DEHP 750 




Table 3.3 (cont.) 
 











Control 6 - 7 111.2 ± 5.6 128.5 ± 15.8 106.0 ± 7.3 
DEHP 20 
µg/kg/day 4 - 7 123.2 ± 5.7 107.3 ± 7.5 116.2 ± 17.5 
DEHP 200 
µg/kg/day 4 131.7 ± 16.7 153.0 ± 19.6 95.8 ± 3.8 
DEHP 200 
mg/kg/day 0 no data no data no data 
DEHP 500 
mg/kg/day 2 - 7 110.3 ± 9.2 103.3 ± 15.2 145.1 ± 33.7 
DEHP 750 
mg/kg/day 4 - 6 no data 118.0 ± 28.3 99.2 ± 2.8 
 
Note: Uterine weights were not collected in the F1 and F2 generations at PND 1. Table represent 
means ± standard error of the mean from 2 – 16 dams per treatment group. *p ≤ 0.05 (significant 
difference compared to the control); 0.05 > ^p ≥ 0.084 (borderline significant difference 
compared to the control). 
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Table 3.4 Effects of prenatal exposure to DEHP on liver weights, measured in grams, in the 
F1, F2, and F3 generations of female mice.  











Control 5 - 17 0.0731 ± 0.0022 0.0745 ± 0.0053 0.0721 ± 0.0027 
DEHP 20 
µg/kg/day 3 - 7 0.0720 ± 0.0037 0.0710 ± 0.0045 0.0728 ± 0.0029 
DEHP 200 
µg/kg/day 3 - 6 0.0733 ± 0.0033 0.0679 ± 0.0032 0.0748 ± 0.0037 
DEHP 200 
mg/kg/day 9 0.0700 ± 0.0041 no data no data 
DEHP 500 
mg/kg/day 3 - 9 0.0840 ± 0.0024 * 0.0721 ± 0.0027 0.0723 ± 0.0037 
DEHP 750 





Control 8 - 17 0.1950 ± 0.0086 0.1234 ± 0.0088 0.1621 ± 0.0139 
DEHP 20 
µg/kg/day 5 - 9 0.1920 ± 0.0139 0.1207 ± 0.0076 0.1481 ± 0.0093 
DEHP 200 
µg/kg/day 3 - 10 0.1840 ± 0.0147 0.1491 ± 0.0097 0.1461 ± 0.0071 
DEHP 200 
mg/kg/day 8 - 9 0.1563 ± 0.0091 * 0.1137 ± 0.0053 no data 
DEHP 500 
mg/kg/day 4 - 10 0.1780 ± 0.0153 0.1577 ± 0.0085 * 0.1475 ± 0.0077 
DEHP 750 





Control 8 - 16 0.8154 ± 0.0256 0.6911 ± 0.0324 0.6654 ± 0.0505 
DEHP 20 
µg/kg/day 4 - 7 0.7607 ± 0.0599 0.4541 ± 0.0445 * 0.6280 ± 0.0327 
DEHP 200 
µg/kg/day 3 - 8 0.8220 ± 0.0496 0.6926 ± 0.0402 0.6305 ± 0.0708 
DEHP 200 
mg/kg/day 6 - 8 0.7438 ± 0.0385 0.5865 ± 0.0246 no data 
DEHP 500 
mg/kg/day 3 - 5 0.7565 ± 0.0206 0.9616 ± 0.1299 * 0.6928 ± 0.0413 
DEHP 750 




Table 3.4 (cont.) 











Control 7 - 23 1.6533 ± 0.0384 1.6236 ± 0.0940 1.7297 ± 0.0641 
DEHP 20 
µg/kg/day 6 - 8 1.6687 ± 0.0630 1.5593 ± 0.0425 1.5765 ± 0.0489 
DEHP 200 
µg/kg/day 4 - 7 1.5630 ± 0.1100 1.5649 ± 0.0901 1.7190 ± 0.1990 
DEHP 200 
mg/kg/day 8 1.5885 ± 0.0358 no data no data 
DEHP 500 
mg/kg/day 3 - 11 1.6264 ± 0.0609 1.7531 ± 0.1860 1.7792 ± 0.1131 
DEHP 750 
mg/kg/day 5 - 6 1.5357 ± 0.0761 1.6317 ± 0.1257 1.7854 ± 0.1110 
 
Note: Tables represent means ± standard error of the mean from 3 – 23 dams per treatment 
group. *p ≤ 0.05 (significant difference compared to the control). 
99 
 
Figure 3.1 The effects of prenatal DEHP exposure on ovarian follicle numbers in the F1 
generation 
 
The effects of prenatal exposure to DEHP on ovarian follicle numbers in the F1 generation at 
PND 1 (A), PND 8 (B), PND 21 (C), and PND 60 (D). Graphs represent means ± standard error 
of the mean from 2 – 14 dams per treatment group. *p ≤ 0.05 (significant difference compared to 
the control); 0.05 > ^p ≥ 0.084 (borderline significant difference compared to the control). 
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Figure 3.2 The effects of prenatal DEHP exposure on ovarian follicle percentages in the F1 
generation 
 
The effects of prenatal exposure to DEHP on ovarian follicle percentages in the F1 generation at 
PND 1 (A), PND 8 (B), PND 21 (C), and PND 60 (D). Graphs represent means ± standard error 
of the means from 2 – 14 dams per treatment group. *p ≤ 0.05 (significant difference compared 
to the control); 0.05 > ^p ≥ 0.085 (borderline significant difference compared to the control). 
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Figure 3.3 The effects of prenatal DEHP exposure on ovarian follicle numbers in the F2 
generation 
 
The effects of prenatal exposure to DEHP on ovarian follicle numbers in the F2 generation at 
PND 1 (A), PND 8 (B), PND 21 (C), and PND 60 (D). Graphs represent means ± standard error 
of the mean from 3 – 11 dams per treatment group. *p ≤ 0.05 (significant difference compared to 




Figure 3.4 The effects of prenatal DEHP exposure on ovarian follicle percentages in the F2 
generation 
 
The effects of prenatal exposure to DEHP on ovarian follicle percentages in the F2 generation at 
PND 1 (A), PND 8 (B), PND 21 (C), and PND 60 (D). Graphs represent means ± standard error 
of the means from 3 – 11 dams per treatment group. *p ≤ 0.05 (significant difference compared 
to the control); 0.05 > ^p ≥ 0.094 (borderline significant difference compared to the control). ND 
= no data 
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Figure 3.5 The effects of prenatal DEHP exposure on ovarian follicle numbers in the F3 
generation 
 
The effects of prenatal exposure to DEHP on ovarian follicle numbers in the F3 generation at 
PND 1 (A), PND 8 (B), PND 21 (C), and PND 60 (D). Graphs represent means ± standard error 
of the mean from 4 – 7 dams per treatment group. *p ≤ 0.05 (significant difference compared to 
the control); 0.05 > ^p ≥ 0.088 (borderline significant difference compared to the control). 
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Figure 3.6 The effects of prenatal DEHP exposure on ovarian follicle percentages in the F3 
generation 
 
The effects of prenatal exposure to DEHP on ovarian follicle percentages in the F3 generation at 
PND 1 (A), PND 8 (B), PND 21 (C), and PND 60 (D). Graphs represent means ± standard error 




Figure 3.7 The effects of prenatal DEHP exposure on corpora lutea in the F1 – F3 
generations 
 
The effects of prenatal exposure to DEHP on corpora lutea numbers at PND 60. Graph represents 
mean ± standard error of the means from 4 – 12 dams per treatment group. 
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Figure 3.8 The effects of prenatal DEHP exposure on serum sex steroid hormone levels in 
F1 – F3 generations 
 
The effects of prenatal exposure to DEHP on serum sex steroid hormone levels in the F1, F2, and 
F3 generations. Serum 17β-estradiol levels are shown at PND 8 (A), PND 21 (B) and PND 60 
(C) for the F1, F2, and F3 generations. Serum progesterone levels are shown at PND 21 (D) and 
PND 60 (E) for the F1, F2, and F3 generations. Serum testosterone levels are shown at PND 60 
(F) for the F1, F2, and F3 generations. The serum testosterone levels were at the limit of 
detection and therefore do not have error bars. Graphs represent means ± standard error of the 
mean from 2 – 8 dams per treatment group. *p ≤ 0.05 (significant difference compared to the 




Figure 3.9 The effects of prenatal DEHP exposure on serum gonadotropin hormone levels 
in the F1 – F3 generations 
The effects of prenatal exposure to DEHP on serum gonadotropin hormone levels in the F1, F2, 
and F3 generations at PND 60. Serum luteinizing hormone levels are shown in panel (A) and 
serum follicle stimulating hormone levels are shown in panel (B). Graphs represent means ± 
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Di(2-ethylhexyl) Phthalate Exposure During Prenatal Development Causes Adverse 
Transgenerational Effects on Female Fertility in Mice2 
4.1 Abstract 
 Di(2-ethylhexyl) phthalate (DEHP) is a ubiquitous environmental toxicant and endocrine 
disrupting chemical, but little is known about its effects on female reproduction. Thus, we tested 
the hypothesis that prenatal exposure to DEHP accelerates the onset of puberty, disrupts estrous 
cyclicity, disrupts birth outcomes, and reduces fertility in the F1, F2, and F3 generations of 
female mice. Pregnant CD-1 mice were orally dosed with corn oil (vehicle control) or DEHP (20 
and 200 µg/kg/day and 500 and 750 mg/kg/day) from gestation day 10.5 until birth. F1 females 
were mated with untreated males to obtain the F2 generation. F2 females were mated with 
untreated males to produce the F3 generation. In all generations, the onset of puberty, estrous 
cyclicity, select birth outcomes, and fertility-related indices were evaluated. In the F1 generation, 
prenatal DEHP exposure (200 µg, 500 mg, and 750 mg/kg/day) accelerated onset of puberty, it 
(200 µg/kg/day) disrupted estrous cyclicity, and it (20 µg and 200 µg/kg/day) decreased fertility-
related indices. In the F2 generation, ancestral DEHP exposure (200 µg and 500 mg/kg/day) 
accelerated onset of puberty, it (20 and 200 µg/kg/day) disrupted estrous cyclicity, it (20 µg and 
500 mg/kg/day) increased litter size, and it (500 mg/kg/day) decreased fertility-related indices. In 
the F3 generation, ancestral DEHP exposure (20 µg, 200 µg, and 500 mg/kg/day) accelerated 
onset of puberty, it (20 µg/kg/day) disrupted estrous cyclicity, and it (750 mg/kg/day) decreased 
female pup anogenital index. Collectively, these data indicate that prenatal DEHP exposure 
causes female reproductive problems in a multigenerational and transgenerational manner.  
2. This is a pre-copyedited, author-produced version of an article accepted for publication in Toxicological Sciences following peer review. The 
version of record S. Rattan, E. Brehm, L. Gao, and JA. Flaws. Di(2-ethylhexyl) phthalate exposure during prenatal development causes adverse 





Phthalate esters are a family of synthetic chemicals primarily used as plasticizers to 
confer flexibility, prevent plastics from becoming brittle, allow products to become transparent, 
and improve the longevity of products [1]. Di(2-ethylhexyl) phthalate (DEHP) in particular is a 
synthetic, high-molecular weight, organic phthalate compound. On average, 300 million pounds 
of DEHP are produced annually in the United States [1]. DEHP is incorporated in a multitude of 
products such as personal care products, medical equipment (e.g., blood and I.V. bags), car 
upholstery, food and beverage containers, and building materials [2, 3]. Because DEHP is 
noncovalently bound, it leaches from products and into the environment [4]. Due to the frequent 
use of products containing DEHP, the high volume of DEHP production, and the ability of 
DEHP to leach from products, humans are repeatedly and continuously exposed to DEHP [3]. 
The average range of human exposure to DEHP is between 3 – 30 µg/kg/day [5], and studies 
show that 100% of human urine samples test positive for DEHP and its metabolites [6]. 
Phthalate exposure is higher in women than men, likely due to the presence of phthalates 
in personal care products and the higher use of personal care products among women compared 
to men [7]. In women, DEHP can be found in developmental and reproductive tissues [3]. 
Specifically, DEHP and its metabolites have been found in cord blood samples from newborns, 
breast milk from nursing mothers, and human ovarian follicular fluid. Further, DEHP and its 
metabolites are present in amniotic fluid from fetuses, demonstrating that DEHP has the ability 
to cross the placenta [3]. This is concerning because a pregnant mother exposed to DEHP also 
risks exposure to her developing fetus. 
Of concern, DEHP acts as an endocrine disrupting chemical (EDC) and the developing 
fetus and the female reproductive tract are particularly susceptible to EDCs. Previous studies 
120 
 
have shown that prenatal exposure to DEHP adversely affects reproductive outcomes in rodents 
[2, 8, 9]. Specifically, our laboratory has shown that prenatal DEHP exposure (20 µg/kg/day) 
increased the time to pregnancy and it (750 mg/kg/day) increased the number of dead pups in the 
F1 generation of female mice [2]. Further, DEHP exposure (200 µg/kg/day) increased the male-
to-female sex ratio in litters of the F1 generation [2]. Prenatal exposure to DEHP (200, 500, and 
750 mg/kg/day) also decreased the percentage of atretic follicles in the ovary and it (20 
µg/kg/day, 500 mg/kg/day, and 750 mg/kg/day) increased serum estradiol levels at PND 8 in the 
F1 generation [10]. In addition, another study has shown that maternal DEHP exposure 
accelerates the rate of follicular recruitment in the F1 generation, which could deplete the 
primordial follicle reserve and lead to early reproductive senescence [9, 11]. 
Exposure to DEHP during development may have further implications for future 
generations [10, 12-14]. Studies have shown that DEHP exposure during embryonic 
development causes transgenerational inheritance of testicular disease in male mice [15, 16]. 
Transgenerational effects occur when the effects of DEHP are inherited and passed through the 
germ-line [17, 18]. Although few studies have investigated the transgenerational effects of 
DEHP exposure on female reproductive outcomes, one study has shown that maternal exposure 
to DEHP (0.05 – 5 mg/kg/day) accelerated folliculogenesis in the ovary in the F2 and F3 
generations of mice [9]. In addition, the results from another study indicated that ancestral 
exposure to a phthalate mixture, which included DEHP, increased uterine weight, decreased 
anogenital distance, and induced fertility complications in a transgenerational manner in mice 
[19]. Previously, our study has shown that ancestral exposure to DEHP decreased serum 




Although previous studies show that prenatal exposure to DEHP has adverse effects on 
ovarian follicle numbers and hormone levels, they have not assessed the effects of prenatal 
DEHP exposure on the onset of puberty, estrous cyclicity, and fertility [2, 9, 15]. Thus, we 
hypothesized that daily prenatal exposure to DEHP during the second half of pregnancy in the F0 
generation adversely affects reproductive outcomes in female mice in a transgenerational 
manner. Specifically, we investigated whether prenatal DEHP exposure accelerates the onset of 
puberty, disrupts estrous cyclicity, decreases the number of pregnancies and litters, adversely 
affects the birth outcomes of pups, and leads to an early age of reproductive senescence in the 
F1, F2, and F3 generations of female mice. 
 
4.3 Materials and Methods 
Chemicals 
DEHP (99% purity) was purchased from Sigma-Aldrich (St. Louis, MO). Stock solutions 
of DEHP (0.022, 0.224, 560, and 840 mg/mL) were prepared by diluting DEHP in tocopherol-
stripped corn oil (MP Biomedicals, Solon, OH). These stock solutions were diluted to create 
doses of 20 µg/kg/day, 200 µg/kg/day, 500 mg/kg/day, and 750 mg/kg/day of DEHP. DEHP 
concentrations were chosen based on previous studies and their environmental relevance [2, 8, 
16, 20-22]. Specifically, the 20 µg/kg/day dose of DEHP was selected because the U.S. 
Environmental Protection Agency established the chronic oral reference dose as 20 µg/kg/day of 
DEHP. The reference dose is an estimate of the daily oral exposure of DEHP in the general 
population that has a low risk of adverse effects during the lifetime [23]. In addition, 20 
µg/kg/day of DEHP falls within the estimated human exposure range based on urinary 
metabolite levels [5]. The 200 µg/kg/day dose of DEHP was used because it falls within the 
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estimated occupational range of exposure [3]. In addition, adult exposure to 200 µg/kg/day of 
DEHP has been shown to cause abnormal estrous cyclicity and accelerate primordial follicle 
recruitment in female CD-1 mice [22]. The 500 mg/kg/day dose of DEHP was selected because 
it has been shown to cause abnormalities in spermatogonial stem cells across multiple 
generations in male CD-1 mice [16]. The 750 mg/kg/day dose of DEHP was selected because 
adult exposure has been shown to cause abnormal estrous cyclicity and accelerate primordial 
follicle recruitment in adult female CD-1 mice [22]. 
 
Animals and dosing paradigm 
Adult female and male CD-1 mice (Charles River, USA) were housed at 25°C in 
conventional polysulfone, ventilated cages on 12L:12D cycles. The mice were fed Teklad 
Rodent Diet 8604 (Harlan) and provided highly purified water (reverse osmosis filtered water) in 
polysulfone water bottles ad libitum. All animal procedures were approved by the University of 
Illinois Institutional Animal Care and Use Committee and abide by the guidelines set forth by the 
National Institute of Health for the Care and Use of Laboratory Animals.  
At 8 weeks of age, female mice (F0) were mated with control male mice of the same age. 
The female mice were monitored twice a day for the presence of a copulatory vaginal sperm plug 
to confirm mating. Once a copulatory vaginal sperm plug was confirmed, the presence of which 
was considered gestational day (GD) 0.5, the females were removed, weighed, and individually 
housed. Subsequently, the mice were weighed twice a week to confirm successful pregnancy. 
From GD 10.5 until birth of the pups, 66 pregnant dams (F0 generation) were orally dosed (7 – 
27 dams/treatment group) once a day with the vehicle control (tocopherol-stripped corn oil) or 
with DEHP (20 µg/kg/day, 200 µg/mg/day, 500 mg/kg/day, 750 mg/kg/day) by placing a pipette 
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tip with the dosing solution into the cheek pouch of the mouse. This dosing regimen was selected 
to mimic oral exposure to DEHP in humans [1, 8, 22]. The doses were calculated and adjusted 
based on daily body weights, and delivered in 25 – 33 µL of tocopherol-stripped corn oil. The 
treatment window was chosen because it is a critical time period of ovarian development. 
Specifically, this is when primordial germ cells arrive at the gonad [24, 25], sex determination 
[26], global demethylation, and imprint erasure of primordial germ cells occurs [27]. 
Pregnant mice were allowed to deliver naturally and the day of birth was considered 
postnatal day (PND) 0. Mice born from the F0 generation were labeled the F1 generation. 
Female mice from the F1 generation were mated with non-treated male CD-1 mice to produce 
the F2 generation. Females from the F2 generation were mated with non-treated male CD-1 mice 
to produce the F3 generation. No mice were mated with family members. 
 
Onset of puberty 
 In all generations, female mice were weaned at PND 21. One female mouse from each 
litter was weighed and observed daily for the presence of a vaginal opening. Once a vaginal 
opening was observed, the age and weight of the female were recorded, and daily vaginal 




 In all generations, female mice were subjected to daily vaginal lavages at 3, 6, and 9 
months of age for 14 consecutive days to monitor estrous cyclicity. Following 14 days of 
consecutive vaginal lavages, female mice were weighed and paired with non-treated male CD-1 
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mice to test fertility. Female mice were monitored twice a day for the presence of a copulatory 
vaginal sperm plug to indicate successful mating. The latency to a copulatory vaginal sperm plug 
was recorded. All female mice were weighed twice a week to monitor weight gain associated 
with pregnancy regardless of a positive copulatory vaginal sperm plug. Once a copulatory 
vaginal sperm plug was observed, female mice were removed from the male cage and placed 
individually in a fresh cage, and weight gain was continuously monitored. Female mice were 
paired with non-treated CD-1 male mice for a maximum of 14 days for the fertility tests. If a 
vaginal sperm plug was not observed, female mice were housed individually and body weight 
gain was continuously monitored. Body weight gain was used to monitor pregnancy loss and/or 
maintenance of pregnancy. The number of total females, females with a copulatory plug, 
pregnant females, and females that delivered pups were recorded (Table 4.1). The total number 
of females was defined as females paired with males. Plugged females were defined as either: a) 
females that had a copulatory vaginal sperm plug or b) females that did not have a copulatory 
vaginal sperm plug, but gained at least 4 grams of weight. Pregnant females were defined as 
females that either: a) had a copulatory vaginal sperm plug and gained at least 4 grams of weight 
during their pregnancy, b) did not have a copulatory plug, but gained at least 4 grams of weight, 
or c) did not have a copulatory plug, but produced a litter. Females that delivered pups were 
defined as dams that gave birth to either live or dead pups. These definitions were used to 
calculate the mating index, pregnancy rate, fertility rate, and gestational index based on the 
following equations used by previous studies [19, 28, 29]: 
Mating index = number of females with copulatory vaginal sperm plugs/number of total females 
X 100 
Pregnancy rate = number of pregnant females/number of total females X 100 
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Fertility index = number of pregnant females/number of females with copulatory vaginal sperm 
plugs X 100 
Gestational index = number of females who delivered/number of pregnant females X 100 
Once a pregnant dam gave birth to pups, all pups were counted and sexed and live pups 
were weighed. At PND 21, male and female body weight and anogenital distance (AGD) were 
recorded. The anogenital index (AGI) was calculated as the AGD divided by the cubed root of 
body weight [30]. Any pup deaths between PND 0 and PND 21 were recorded and reported as 
the percent of dead pups per litter. 
 Infertility during early, mid-, or late gestation was recorded for all females. Early 
gestation infertility was classified as no observed copulatory vaginal sperm plug, or an observed 
copulatory vaginal sperm plug, but no significant weight gain. Mid-gestation infertility was 
defined as an observed copulatory vaginal sperm plug, body weight gain around GD 7 – 12, but 
loss of the gained weight and a return to pre-pregnancy weight without birth of pups. Late 
gestation infertility was defined as a successful completion of pregnancy, but no live pups were 
born, suggesting infertility may be caused by late gestation issues [31]. 
 
Statistical analyses 
Data were expressed as the mean ± standard error of the mean (SEM). In all generations, 
data from multiple female pups originating from the same litter were averaged and combined as 
n = 1, and data from at least 3 separate litters were used in the analyses. Data were analyzed by 
comparing treatment groups to control using SPSS software (SPSS Inc., Chicago, IL). Outliers 
were removed by the Grubb’s test using GraphPad outlier calculator software (GraphPad 
Software Inc., La Jolla, CA). Two cohorts (two groups of animals) were mated to produce the F3 
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generations. To test for cohort differences, data were tested using a general linear model 
univariate test. If there was an interaction between treatment and cohort in tests of between-
subjects effects, then the data from the first cohort was analyzed. If no interaction effect between 
treatment and cohort occurred, then both cohorts were analyzed together. Data that were 
continuous were assessed for normal distribution by Shapiro-Wilk analysis. If data met 
assumptions of normal distribution and homogeneity of variance, data were analyzed by one-way 
analysis of variance (ANOVA) followed by Dunnett (2-sided) post-hoc comparisons. If data 
were presented as percentages, were not normally distributed, and/or did not meet homogeneity 
of variance assumptions, the independent sample Kruskal-Wallis H followed by Mann-Whitney 
U non-parametric tests were performed. Data that were nominal were analyzed using the one-
tailed Fisher’s Exact test to compare individual treatment groups to control. For all comparisons, 
statistical significance was determined by a p-value ≤ 0.05. In instances in which p-values were 
greater than 0.05, but less than 0.1, data were considered to exhibit a trend towards significance. 
 
4.4 Results 
Effects of DEHP exposure on pubertal body weights, age of vaginal opening, and age of 
first estrus 
 To monitor puberty, the body weight at weaning, body weight at vaginal opening, age at 
vaginal opening, and age at first estrus were recorded. Our results indicate that in the F1, F2, and 
F3 generations, prenatal and ancestral exposure to DEHP did not affect the body weight of 
female mice at weaning (PND 21) (Figure 4.1A) or the body weight of female mice at vaginal 
opening (Figure 4.1B). 
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In the F1 generation, prenatal exposure to the 200 µg/kg/day dose of DEHP accelerated 
the age at vaginal opening, but this change was of borderline statistical significance compared to 
controls (Figure 4.1C, n = 5 – 16 dams/treatment group; p = 0.061). In contrast, exposure to the 
200 µg/kg/day dose of DEHP significantly accelerated the age at first estrus compared to 
controls (Figure 4.1D, n = 6 – 15 dams/treatment group; p ≤ 0.05). In the F2 generation, ancestral 
exposure to DEHP did not significantly affect the age at vaginal opening (Figure 4.1C), but the 
500 mg/kg/day dose of DEHP significantly accelerated the age at first estrus compared to 
controls (Figure 4.1D, n = 11 – 15 dams/treatment group; p ≤ 0.05). In the F3 generation, 
ancestral exposure to the 20 µg/kg/day, 500 mg/kg/day, and 750 mg/kg/day doses of DEHP 
significantly accelerated the age at vaginal opening compared to controls (Figure 4.1C, n = 7 – 
11 dams/treatment group; p ≤ 0.05), but DEHP exposure did not affect the age at first estrus 
(Figure 4.1D). 
 
Effects of DEHP exposure on post-pubertal cyclicity 
 To examine the effects of DEHP exposure on estrous cyclicity following the onset of 
puberty, estrous cyclicity was monitored for 30 consecutive days following vaginal opening. In 
the F1 generation, prenatal exposure to the 750 mg/kg/day dose of DEHP increased the percent 
of time in proestrus and the 200 µg/kg/day dose of DEHP increased the percent of time in estrus 
and decreased the percent of time in diestrus compared to controls, but the increases were 
borderline statistically significant (Figure 4.1E, n = 6 – 15 dams/treatment group; p = 0.068 for 
the increased percent of time in proestrus in the 750 mg/kg/day group vs. control; p = 0.078 for 
the increased percent of time in estrus in the 200 µg/kg/day group vs. control; p = 0.070 for the 
decreased percent of time in diestrus in the 200 µg/kg/day group vs. control). In the F2 
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generation, ancestral exposure to the 200 µg/kg/day and 500 mg/kg/day doses of DEHP 
increased the percent of time in estrus and decreased the percent of time that the mice spent in 
diestrus compared to controls (Figure 4.1E, n = 11 – 15 dams/treatment group; p ≤ 0.05 for the 
percent of time in diestrus in the 200 µg/kg/day group vs. control and for the percent of time in 
estrus and diestrus in the 500 mg/kg/day group vs. control; p = 0.078 for the percent of time in 
estrus 200 µg/kg/day group vs. control). In the F3 generation, ancestral DEHP exposure did not 
affect post-pubertal estrous cyclicity (Figure 4.1E). 
 
Effects of DEHP exposure on estrous cyclicity 
 To examine the effects of DEHP exposure on estrous cyclicity during adult life, estrous 
cyclicity was monitored for 14 consecutive days at 3, 6, and 9 months of age. In the F1 
generation, prenatal exposure to DEHP did not affect estrous cyclicity at 3 or 6 months of age, 
but the 500 mg/kg/day dose of DEHP borderline significantly increased the percent of time that 
mice spent in proestrus and the 200 µg/kg/day dose of DEHP significantly increased the percent 
of time that mice spent in estrus compared to controls at 9 months of age (Figure 4.2A, n = 4 – 7 
dams/treatment group; p = 0.071 for the 500 mg/kg/day group vs. control; p ≤ 0.05 for the 200 
µg/kg/day group vs. control). In the F2 generation, ancestral exposure to DEHP did not affect 
estrous cyclicity at 3 or 6 months of age. However, the 20 µg/kg/day dose of DEHP significantly 
increased the percent of time that the mice spent in estrus and the 200 µg/kg/day dose 
significantly decreased the amount of time that the mice spent in diestrus compared to controls at 
9 months of age (Figure 4.2B, n = 10 – 15 dams/treatment group; p ≤ 0.05). Further, the 200 
µg/kg/day dose of DEHP increased the time that the mice spent in estrus and the 20 µg/kg/day 
dose of DEHP decreased the that time the mice spent in diestrus at 9 months of age, but these 
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changes were borderline statistically significant (Figure 4.2B, n = 10 – 15 dams/treatment group; 
p = 0.086 for the 200 µg/kg/day group vs. control; p = 0.066 for the 20 µg/kg/day group vs. 
control). In the F3 generation, ancestral DEHP exposure did not affect estrous cyclicity at 3 
months of age, but the 20 µg/kg/day dose of DEHP significantly increased that the percent of 
time mice spent in estrus and decreased the percent of time that mice spent in diestrus compared 
to controls at 6 months of age (Figure 4.2C, n = 9 – 10 dams/treatment group; p ≤ 0.05). Further, 
the 20 µg/kg/day dose of DEHP decreased the time that the mice spent in diestrus at 9 months of 
age, but this was of borderline significance (Figure 4.2C, n = 0 dams/treatment group; p = 
0.089). 
 
Effects of DEHP exposure on birth outcomes 
 Select birth outcomes such as litter size, percentage of female pups, and mortality rates 
were monitored during the fertility tests. In the F1 and F3 generations, exposure to DEHP did not 
affect the litter size compared to controls. However, in the F2 generation, ancestral exposure to 
the 20 µg/kg/day and 500 mg/kg/day doses of DEHP increased the litter size compared to 
controls (Figure 4.3A, n = 7 – 26 dams/treatment group; p ≤ 0.05).  
In the F1 and F2 generations, prenatal and ancestral exposure to DEHP did not affect the 
percentage of female pups. However, in the F3 generation, ancestral exposure to the 20 
µg/kg/day dose of DEHP increased the percentage of female pups per litter, but the increase only 
trended towards significance (Figure 4.3B, n = 24 – 26 dams/treatment group; p = 0.080). In 
addition, in the F1, F2, and F3 generations, exposure to DEHP not affect the pup mortality rate 




Effects of DEHP exposure on anogenital index 
In the F1 and F2 generations, prenatal and ancestral DEHP exposure did not affect female 
pup anogenital index compared to controls (Figure 4.4A). However, in the F3 generation, 
ancestral exposure to the 750 mg/kg/day dose of DEHP decreased the female pup anogenital 
index in the 3 month old litter compared to controls (Figure 4.4A, n = 5 – 10 dams/treatment 
group; p ≤ 0.05), but it did not affect the female anogenital index in the 6 or 9 month old litters. 
In the F1, F2, and F3 generations, prenatal and ancestral exposure to DEHP did not affect the 
male pup anogenital index compared to controls (Figure 4.4B). 
 
Effects of DEHP exposure on fertility-related indices  
Exposure to DEHP did not affect the mating index in any generations. Specifically, the 
mating index ranged from 94 – 100 % in all treatment groups in the F1, F2, and F3 generations 
(Figure 4.5A). In the F1 generation, prenatal exposure to the 20 µg/kg/day and 200 µg/kg/day 
doses of DEHP decreased the pregnancy rate compared to controls, but the decrease only trended 
towards statistical significance (Figure 4.5B, n = 37 – 60 dams/treatment group; p = 0.082 and 
0.069, respectfully). Ancestral DEHP exposure did not significantly affect the pregnancy rate in 
the F2 or F3 generations. In the F1 generation, prenatal exposure to the 20 µg/kg/day and 200 
µg/kg/day doses of DEHP decreased the fertility index compared to controls (Figure 4.5C, n = 33 
– 58 dams/treatment group; p = 0.074 and p ≤ 0.05, respectfully). In contrast, ancestral exposure 
to DEHP did not affect the fertility index in the F2 or F3 generations. In the F1 and F3 
generations, prenatal and ancestral exposure to DEHP did not affect the gestational index. 
However, in the F2 generation, ancestral exposure to the 500 mg/kg/day dose of DEHP 
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significantly decreased the gestational index compared to controls (Figure 4.5D, n = 41 – 44 
dams/treatment group; p ≤ 0.05). 
 
Effects of DEHP exposure on types of infertility 
 In the F1 generation, prenatal exposure to the 20 µg/kg/day dose of DEHP increased the 
number of dams with early gestation infertility and the 200 µg/kg/day dose of DEHP increased 
the number of dams with early and mid-gestation infertility compared to controls (Table 4.2). In 
the F2 generation, ancestral exposure to the 500 mg/kg/day dose of DEHP increased the number 
of dams with mid-gestation infertility compared to controls (Table 4.2). In the F3 generation, 




Our data indicate that prenatal and ancestral exposure to DEHP negatively impacts 
reproductive outcomes across the F1, F2, and F3 generations of mice (Figure 6). Specifically, 
DEHP exposure accelerated puberty, interfered with normal estrous cyclicity, increased litter 
size, decreased anogenital index in female offspring, and decreased pregnancy rate, fertility 
index, and gestational index in multigenerational and transgenerational manners (Figure 6). 
It is interesting that prenatal DEHP exposure did not produce a linear dose response. 
DEHP is a known EDC, and a characteristic of EDCs is that the effects are not proportional to 
the dose and therefore, often do not follow a linear relationship [32]. It is also important to note 
that the effects of DEHP exposure were not always the same in each generation. The different 
effects of DEHP exposure in each generation are likely due to the different developmental 
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windows of exposure. During prenatal DEHP exposure, the F1 generation was exposed as the 
developing pup, the F2 generation was exposed as the developing ovaries within the F1 pup, and 
the F3 generation was not directly exposed to DEHP. Therefore, the effects of DEHP exposure in 
the F3 generation are considered transgenerational. 
Our data showed that DEHP exposure accelerated the onset of puberty in all three 
generations. It is likely that the ability of prenatal and ancestral DEHP exposure to accelerate 
puberty is not through a mechanism involving body weight because our data indicated that 
prenatal and ancestral DEHP exposure did not affect body weight. Further, it is likely that 
prenatal and ancestral exposure to DEHP did not accelerate the onset of puberty through the 
alteration of serum sex steroid hormone levels. Previously, our laboratory demonstrated that 
prenatal and ancestral exposure to DEHP did not significantly affect serum estradiol levels at 
PND 21, an age earlier than the observed pubertal onset [10]. Although we previously showed 
that ancestral DEHP (20 µg/kg/day and 500 mg/kg/day) exposure increased serum progesterone 
levels at PND 21 in the F2 generation [10], serum estradiol, but not progesterone, is critical for 
the onset of puberty [33, 34]. Although we did not detect differences in serum estradiol at PND 
21, it is possible that serum estradiol levels at other time points impacted the onset of puberty. 
One study demonstrated that ancestral exposure to a plasticizer mixture consisting of 750 
mg/kg/day of DEHP accelerated the age at vaginal opening in the F3 generation in rats [15]. 
However, our data differ from Manikkam et al. because that study showed that the mixture 
consisting of 750 mg/kg/day delayed vaginal opening in the F1 generation, whereas we did not 
observe a delay in vaginal opening in the 750 mg/kg/day DEHP dose group in the F1 generation. 
The reasons for differences between our F1 generation data and those from Manikkam et al. are 
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unclear, but they may be due to species differences between mice and rats or interactions 
between chemicals in the mixture that produced different effects than DEHP alone. 
In addition, our data showed that prenatal and ancestral exposure to DEHP disrupted 
post-pubertal cyclicity in the F1 generation and disrupted post-pubertal cyclicity and adult 
estrous cyclicity in the F2 and F3 generations. Our results agree with previous studies showing 
that adult exposure to DEHP (20 µg/kg/day) increased the percentage of days that the mice spent 
in estrus [8]. Previously, our laboratory showed that ancestral exposure to DEHP (200 
µg/kg/day, 500, and 750 mg/kg/day) decreased serum progesterone levels during the diestrus 
phase in the F2 generations [10]. Our current study showed that mice exposed to DEHP spent 
more time in diestrus when basal levels of progesterone are normally low [35]. Thus these data 
are consistent with our previous data showing that ancestral DEHP exposure decreased serum 
progesterone levels. Further, rodents undergoing reproductive senescence will experience a state 
of persistent estrus followed by complete acyclicity, or a chronic state of diestrus [36]. 
Therefore, our data suggest that ancestral DEHP exposure may accelerate the onset of 
reproductive senescence in the F2 and F3 generations and that it can have lasting effects on 
estrous cyclicity in both a multigenerational and transgenerational manner. 
Ancestral exposure to DEHP increased litter size in the F2 generation. These data were 
unexpected because previously we showed that ancestral exposure to DEHP did not affect the 
number of corpora lutea in mice [10]. Corpora lutea are used as indicators of ovulation, and no 
change in the number of corpora lutea suggests normal ovulation rates, and subsequently, normal 
litter sizes. However, this is the opposite of what was observed in the present study. 
Interestingly, previous literature has shown that direct exposure to DEHP (250 and 500 
mg/kg/day) reduced the number and size of corpora lutea in mice [37]. It is possible that direct 
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exposure to DEHP and ancestral exposure to DEHP impacts ovulation differently. The different 
ovulation rates may explain the difference in the results in our study versus the previous study. 
However, future studies should investigate the mechanism by which ancestral DEHP exposure 
increased litter size without affecting the number of corpora lutea. 
 Ancestral exposure to DEHP increased the female to male sex ratio in litters produced by 
the F3 generation. Although Niermann et al. showed that prenatal exposure to DEHP (750 
mg/kg/day) increased the male to female sex ratio in litters produced by the F1 generation [2], 
we observed a different trend in the F3 generation. Although the increase in the percentage of 
female pups per litter was only borderline statistically significant (p = 0.080), it appears that our 
control in the F3 generation was much lower than the expected 50% of female pups. The lower 
percentage of females in the control group may have influenced the observed borderline increase 
in percentage of female pups per litter observed in the F3 generation. In addition, random 
variation may have influenced the increased female to male ratio. 
Our data indicate that ancestral exposure to DEHP decreased female AGI at 3 months of 
age in the litters produced by the F3 generation, revealing a transgenerational effect of DEHP 
exposure on AGI. AGI is an indicator of androgen exposure to the fetus in utero. It is possible 
that androgen levels were decreased in the F3 mothers, therefore decreasing the AGI of the 
female pups, however future studies should test this hypothesis. Our findings are in contrast to 
another study that showed that maternal ancestral DEHP exposure (5 µg/kg/day) increased AGI 
in the F3 generation of female mice [38]. It is likely that our results differ from that study 
because we used different doses of DEHP. DEHP exerts non-monotonic dose responses, and 
therefore, different doses may affect the AGI differently. Further, the previous study observed a 
decrease in body weight in the 5 µg/kg/day pups, which likely drove the significant effects on 
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AGI [38]. However, in our study, we did not observe a significant difference in the body weights 
of the pups produced at 3 months of age in the F3 generation (data not shown). 
 The different fertility-related indices were calculated based on if a female mated, became 
pregnant, and gave birth. Our data indicate that DEHP exposure does not affect the mating index. 
Our data agree with previous studies that have shown that prenatal exposure to a phthalate 
mixture that included DEHP did not impact the mating index [19, 39]. In contrast, Quinnies et al. 
demonstrated that prenatal exposure to DEHP at 400 µg/kg/day caused females to be less 
interactive and potentially less interested in mating with males [38]. A lack of interest in mating 
with males should produce a low mating index, however, we did not observe this in our study. It 
is possible that inbred strain (C57BL/6J) used in the Quinnies et al. study and outbred strain 
(CD-1) used in our study contribute to the observed differences in results [40, 41].  
Our data indicate that prenatal exposure to DEHP reduced the pregnancy rate in the F1 
generation. The reduced pregnancy rate, but lack of an impact on mating index, indicates that 
DEHP exposure does not affect the ability of the mice to mate, but it affects the ability of the 
mice to become pregnant. Further, DEHP reduced the fertility index in the F1 generation, 
suggesting that DEHP decreases the number of females that became pregnant after mating. The 
exact mechanisms by which DEHP interferes with pregnancy and fertility are unknown. It is 
possible that DEHP exposure targets the ovary because DEHP exposure has been shown to 
decrease the ovarian reserve and increase atretic follicles in mice [8, 9, 42]. Additionally, it is 
possible that DEHP exposure interferes with uterine functions as indicated by previous literature 
demonstrating that exposure to a phthalate mixture, including DEHP (20 and 200 µg/kg/day 
phthalate mixture), increases uterine weight in young mice [39]. In our previous study, prenatal 
exposure to DEHP increased serum estradiol levels early in life [10], and this increase persisted 
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at one year of age in the F1 generation [43]. Although this increase in estradiol was not at the 
same age as the observed decreases in the pregnancy and fertility rates in the F1 generation, it is 
possible that estradiol levels were affected throughout life and impacted these fertility-related 
indices because estradiol is critical for normal fertility. 
Interestingly, ancestral DEHP exposure reduced the gestational index in the F2 
generation. The data indicate that although the females successfully mated and became pregnant, 
they had difficulty carrying the pregnancy to term in the F2 generation. The exact mechanism by 
which ancestral DEHP exposure affects the maintenance of pregnancy is not known, but 
previous literature has shown that exposure to DEHP (250 and 500 mg/kg/day) during pregnancy 
inhibited vascularization of corpora lutea and increased corpora lutea regression, suggesting that 
it might increase the risk of miscarriage by suppressing luteal function [37]. The potential for 
DEHP to cause miscarriages is supported by our data indicating that ancestral DEHP exposure 
increased mid-gestation infertility in the F2 generation. Further, the potential of DEHP to cause 
miscarriages is supported by a study showing that DEHP exposure (250 and 500 mg/kg/day) is 
teratogenic and has a lethal impact on the mouse fetus [44]. Further, we have previously shown 
that ancestral exposure to DEHP decreased serum progesterone levels in young adult mice [10] 
and at one year of age in the F2 generation [43]. Progesterone is important for thickening the 
lining of the uterus and maintaining a pregnancy [45]. Thus, DEHP-induced low levels of 
progesterone may contribute to the reduced gestational index observed in the F2 generation of 
our study. 
In our study, the F0 dams were orally exposed to DEHP, but previous studies have shown 
that the bioactive metabolite, MEHP, is responsible for the toxic effects [20, 46]. Therefore, it is 
likely that the bioactive metabolite, MEHP, affected the observed onset of puberty, estrous 
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cyclicity, and fertility related indices. In our study, we did not measure serum metabolite levels 
of DEHP in the F0 dams. However, future studies on the toxicokinetics of DEHP exposure are 
important and would be useful for comparison to human exposure levels. 
Collectively, our results indicate that prenatal DEHP exposure induced some 
multigenerational and transgenerational effects on female reproductive outcomes. 
Multigenerational effects on female reproductive outcomes were observed in the onset of 
puberty, estrous cyclicity, litter size, and fertility-related indices. Transgenerational effects on 
female reproductive outcomes were observed in the onset of puberty, estrous cyclicity, and 
anogenital index. Future studies should investigate the underlying mechanisms of the DEHP-
induced effects on reproductive outcomes in the F1, F2, and F3 generations. Given that DEHP is 
quickly metabolized and cleared from the body soon after birth [5, 47, 48] and the effects are 
observed in the adults of the F1 generation and into the F2 and F3 generations, these 
observations suggest that DEHP exposure causes toxicity via epigenetic mechanisms. Future 
studies should investigate whether ancestral exposure to DEHP influences the function of the 
ovary and if epigenetic changes contribute to the decrease in reproductive outcomes observed in 
our study. Further, recently, the use of DEHP replacements have steadily increased over the 
years [49, 50]. While phasing out DEHP would be ideal, few studies have investigated the effects 
of DEHP replacements on female reproduction. Therefore, we suggest that future studies 
investigate the effects of DEHP replacements on female reproduction before replacing DEHP 






4.6 Tables, Figures, and Legends 
Table 4.1 The number of mice used for the fertility related indices 
 
The number of females mated, number of females with copulatory plugs, number of pregnant 
females, and number of females that delivered pups recorded in the F1, F2, and F3 generations.
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Table 4.2 Different types of infertility in the F1 – F3 generations 
 
The number of female mice that experience infertility in early, mid-, or late gestation in the F1, 




Figure 4.1 The effects of DEHP exposure on pubertal outcomes in the F1 – F3 generations 
 
The effects of prenatal exposure to DEHP on pubertal outcomes in the F1, F2, and F3 
generations. The body weight at weaning (A), body weight at vaginal opening (B), age at vaginal 
opening (C), age at first estrus (D), and post pubertal cyclicity (E) are shown for the F1, F2, and 
F3 generations. Graphs represent mean ± standard error of the mean from 5 – 16 dams per 
treatment group. *p ≤ 0.05 (significant difference compared to the control); 0.05 < ^p ≤ 0.078 









Figure 4.2 (cont.) 
The effects of prenatal exposure to DEHP on estrous cyclicity are shown for the F1 generation 
(A), F2 generation (B), and F3 generation (C) at 3, 6, and 9 months of age. Graphs represent 
mean ± standard error of the mean from 2 – 15 dams per treatment group. *p ≤ 0.05 (significant 
difference compared to the control); 0.05 < ^p ≤ 0.086 (borderline difference compared to the 
control); ND = no data. 
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Figure 4.3 The effects of DEHP exposure on birth outcomes in the F1 – F3 generations 
 
The effects of prenatal exposure to DEHP on birth outcomes such as litter size (A), percentage of 
females per litter (B), and mortality rate (C) are shown for the F1, F2, and F3 generations. 
Graphs represent mean ± standard error of the mean from 7 – 44 dams per treatment group. *p ≤ 
0.05 (significant difference compared to the control); ^p = 0.080 (borderline difference compared 
to the control). 
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Figure 4.4 The effects of DEHP exposure on female pup anogenital index in the F1 – F3 
generations 
 
The effects of prenatal exposure to DEHP on female pup anogenital index (A) and male pup 
anogenital index (B) are shown for the F1, F2, and F3 generations at 3, 6, and 9 months of age. 
Graphs represent mean ± standard error of the mean from 2 – 13 dams per treatment group. *p ≤ 
0.05 (significant difference compared to the control); ND = no data. 
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Figure 4.5 The effects of DEHP exposure on fertility related indices in the F1 – F3 
generations 
 
The effects of prenatal exposure to DEHP on the fertility related indices the F1, F2, and F3 
generations. The mating index (A), pregnancy rate (B), fertility index (C), and gestational index 
(D) are represented. Graphs represents mean ± standard error of the mean from 12 – 60 dams per 
treatment group. * p ≤ 0.05 (significant difference compared to the control); 0.05 < ^p ≤ 0.082 
(borderline difference compared to the control). 
146 
 
Figure 4.6 The effects of DEHP exposure on female fertility summarized 
 
The effects of DEHP on female fertility at each dose are summarized for the F1, F2, and F3 
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Prenatal and Ancestral Exposure to Di(2-ethylhexyl) Phthalate Alters Gene Expression and 
DNA Methylation in Mouse Ovaries 
5.1 Abstract 
Di(2-ethylhexyl) phthalate is a commonly used plasticizer in polyvinyl chloride products 
to induce flexibility and stability in plastic products. However, DEHP is a known endocrine 
disrupting chemical and studies show that it causes transgenerational reproductive toxicity in 
female rodents. However, the mechanism of action in the F3 generation is not understood. 
Therefore, the purpose of this study was to determine the effects of prenatal and ancestral DEHP 
exposure on various ovarian pathways critical for cell growth, proliferation, and function, and to 
determine the effects on DNA methylation pathways in mouse ovaries from the F1, F2, and F3 
generations. Pregnant CD-1 dams were orally exposed to tocopherol-stripped corn oil (vehicle 
control) or DEHP (20 µg/kg/day, 200 µg/kg/day, 500 mg/kg/day, or 750 mg/kg/day) daily from 
gestation day 10.5 until birth. Once the pregnant dams gave birth to the F1 generation, DEHP 
exposure ceased. Female mice from the F1 generation were mated with non-treated male mice to 
produce the F2 generation. Females from the F2 generation were used to produce the F3 
generation. At postnatal day 21 for each generation, mice were euthanized and ovaries were 
removed for gene expression analysis of various ovarian pathways via qPCR and 5-methyl 
cytosine (5-mC) quantification. The results show that in the F1 generation, prenatal DEHP 
exposure disrupted the expression of cell cycle regulators, decreased the expression of 
peroxisome-proliferator activating receptors, and increased the percentage of 5-mC in the ovary 
compared to control. In the F2 generation, exposure to DEHP decreased the expression of 
steroidogenic enzymes, dysregulated the expression of PI3K-pathway factors, decreased the 
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expression of apoptosis factors, and decreased the expression of Tet compared to controls. In the 
F3 generation, ancestral DEHP exposure decreased the expression of steroidogenic enzymes, 
decreased the expression of PI3K-pathway factors, decreased the expression of cell cycle 
regulators, decreased the expression of apoptosis factors, decreased the expression of Esr2, 
decreased the expression of DNA methylation factors, and decreased the percentage of 5-mC 
compared to controls. Overall, the data show that prenatal and ancestral DEHP greatly 
suppresses gene expression of pathways required for folliculogenesis and steroidogenesis in the 
ovary in a transgenerational manner and that gene expression may be in influenced by DNA 
methylation. These results provide insight into some of the mechanisms of DEHP-mediated 
toxicity in the ovary across generations. Supported by NIH P01 ES022848, EPA RD-83459301, 
T32 ES007326, F31 ES030467, and the Billie A. Field Fellowship. 
 
5.2 Introduction 
Phthalates are a family of synthetic chemicals that act as plasticizers to confer flexibility 
and prevent plastics from becoming brittle [1]. Phthalates are critical for the production of 
consumer goods. Many types of phthalates exist, but di(2-ethylhexyl) phthalate (DEHP) is a 
common plasticizer found in polyvinyl chloride products. DEHP is incorporated into a multitude 
of products including personal care products, medical equipment (i.e., blood and I.V. bags), car 
upholstery, food and beverage containers and packaging, and building materials, particularly 
vinyl products [1-3]. DEHP is noncovalently bound to the polymer chains within these products; 
therefore, DEHP may migrate from the products and into the environment after repeated use, 
heating, and cleaning [4]. Humans are exposed to DEHP by oral ingestion, inhalation, and 
dermal contact. However, the most common route of exposure to DEHP and phthalates in 
155 
 
general is by ingestion. The estimated range of human exposure to DEHP is between 3 – 30 
µg/kg/day [2, 5-7]. Human urine samples persistently test positive for DEHP and its metabolites, 
indicating that humans are repeatedly and continuously exposed to DEHP [8]. This is further 
supported by the detection of DEHP in human tissues such as blood, amniotic fluid, umbilical 
cord blood, breast milk, and ovarian follicular fluids in humans [2, 9-12].  
DEHP is an endocrine disrupting chemical (EDC) [2, 13, 14], and reproductive tissues 
such as the gonads are particularly susceptible to EDCs. In humans, in utero exposure to DEHP 
is associated with decreased free testosterone and free testosterone:estradiol ratio the in cord 
blood of both male and female newborns [15, 16]. DEHP exposure has been shown to interfere 
with obstetrical outcomes, puberty, and gonadal function [17]. DEHP exposure is also associated 
with an early age of pubic hair development in young girls, an indicator of precocious puberty 
[18]. Further, in utero exposure to DEHP metabolites is associated with an earlier age of 
menarche, or first menstruation in young girls [19]. Finally, urinary concentrations of DEHP 
metabolites are negatively associated with total oocytes, mature oocytes, fertilized oocytes, and 
top quality embryos, indicating that DEHP impairs oocyte parameters [20].  
The ability of DEHP to cause adverse reproductive outcomes is a major concern for the 
F1 and subsequent generations. Changes in the ovary may be inherited by the subsequent 
generations through the female germ cells [21]. Transmission of disease due to direct prenatal 
DEHP exposure may cause multigenerational effects and ancestral exposure to DEHP may cause 
transgenerational effects in the F3 generation. This is because during a developmental exposure 
window, the pregnant mouse (F0 generation) is exposed to DEHP via ingestion. Therefore, the 
F1 generation is directly exposed to DEHP as a fetus, and the F2 generation is directly exposed 
to DEHP as the developing germ cells in the F1 fetus, causing multigenerational effects in the F1 
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and F2 generations [22]. Effects observed in the F3 generation are not due to direct exposure, but 
instead are due to ancestral exposure, meaning they are transgenerational effects [22].  
Experimental studies show that DEHP exposure causes numerous multigenerational and 
transgenerational phenotypes in female reproduction. Specifically, prenatal DEHP exposure 
decreases the percentage of dams that give birth in the F2 generation of mice [23]. Ancestral 
DEHP exposure accelerates the onset of puberty and reproductive senescence in the F3 
generation of female mice [23, 24]. Further, DEHP exposure during prenatal development 
dysregulates folliculogenesis, alters sex steroid hormone levels, and increases the presence of 
ovarian cysts in a multigenerational manner [24, 25]. In addition, ancestral exposure to DEHP 
accelerates early folliculogenesis in a transgenerational manner [25]. Although studies 
demonstrate that phthalate exposure causes transgenerational effects on the ovary, the 
mechanisms underlying these effects are not well understood.  
Epigenetic modification is thought to be the mechanism by which transgenerational 
effects are inherited [26]. Epigenetics are mitotically and meiotically heritable changes in gene 
function, without changing DNA sequences [27, 28]. These heritable changes in the epigenome 
define and control cell and tissue development by controlling gene expression [29]. Multiple 
molecular mechanisms alter the epigenome, however, DNA methylation is the most commonly 
studied epigenetic mechanism [30]. DNA methylation patterns are placed and removed by DNA 
methyltransferases (DNMTs) and ten-eleven translocation (TET) enzymes [31-33]. DNMTs are 
a family of enzymes that methylate CpG dinucleotides in DNA. DNMT1 is the maintenance 
DNMT that maintains original DNA methylation patterns in a cell lineage; it methylates CpG 
sites during DNA replication so that both daughter cells have the same DNA methylation 
patterns [34-36]. DNMT3A and DNMT3B methylate CpG sites on naked DNA outside of DNA 
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replication and are required for genome-wide de novo methylation [31]. TETs are enzymes that 
oxidize 5-methyl cytosine (5-mC) as a demethylation mechanism [32, 37]. TET1 is primarily 
responsible for oxidizing 5-mC into 5-hydroxymethyl cytosine (5-hmC), whereas TET2 and 
TET3 primarily oxidize 5-hmC into further oxidized versions which are eventually replaced with 
an unmethylated, unmodified cytosine [32, 38]. 
Studies have demonstrated that DEHP exposure modulates DNA methylation. 
Specifically, prenatal DEHP exposure induces a long-lasting and robust promoter methylation-
related silencing of fundamental genes in sperm physiology [39]. Further, in utero DEHP 
exposure is associated with an enrichment of DNA methylation levels of genes involved in the 
androgen response, estrogen response, and spermatogenesis [40]. Prenatal exposure to DEHP 
differentially expressed 406 genes related to reproductive processes in rat ovaries [41]. These 
studies indicate that DEHP acts through methylation, however, these studies do not indicate if 
the effects of DEHP on methylation status continue throughout generations. Therefore, the 
current study was designed to evaluate the pathways and mechanisms by which prenatal and 
ancestral exposure to DEHP influence key ovarian functions in the F1, F2, and F3 generations of 
mice. Specifically, this study tested the hypothesis that prenatal and ancestral DEHP exposure 
disrupt ovarian functions via DNA methylation and subsequently alters gene expression of 
several ovarian pathways critical for cell growth, proliferation, and function (i.e., the sex steroid 
hormone synthesis pathway, phosphoinositide 3-kinase pathway (PI3K), cell cycle regulators, 
apoptosis and oxidative stress factors, steroid hormone receptors, and insulin-like growth factors) 
[25, 42-49] and DNA methylation effectors such as DNMTs and TET enzymes. 
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5.3 Materials and Methods 
Chemicals 
DEHP (99% purity) was purchased from Sigma-Aldrich (St. Louis, MO). Stock solutions 
of DEHP (0.022, 0.224, 560, and 840 mg/mL) were prepared by diluting DEHP in tocopherol-
stripped corn oil (MP Biomedicals, Solon, OH). These stock solutions were diluted to create 
doses of 20 µg/kg/day, 200 µg/kg/day, 500 mg/kg/day, and 750 mg/kg/day of DEHP. DEHP 
concentrations were chosen based on previous studies and their environmental relevance [45, 46, 
50-53]. Specifically, the 20 µg/kg/day dose of DEHP was selected because the U.S. 
Environmental Protection Agency established the chronic oral reference dose as 20 µg/kg/day of 
DEHP. The reference dose is an estimate of the daily oral exposure of DEHP in the general 
population that has a low risk of adverse effects during the lifetime [54]. In addition, 20 
µg/kg/day of DEHP falls within the estimated human exposure range based on urinary 
metabolite levels [5]. The 200 µg/kg/day dose of DEHP was used because it falls within the 
estimated occupational range of exposure [2]. In addition, adult exposure to 200 µg/kg/day of 
DEHP has been shown to cause abnormal estrous cyclicity and accelerate primordial follicle 
recruitment in female CD-1 mice [45]. The 500 mg/kg/day dose of DEHP was selected because 
it has been shown to cause abnormalities in spermatagonial stem cells across multiple 
generations in male CD-1 mice [52]. The 750 mg/kg/day dose of DEHP was selected because 
adult exposure has been shown to cause abnormal estrous cyclicity and accelerate primordial 
follicle recruitment in adult female CD-1 mice [45]. 
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Animals and dosing paradigm 
Adult female and male CD-1 mice (Charles River, USA) were housed at 25°C in 
conventional polysulfone, ventilated cages on 12L:12D cycles. The mice were fed Teklad 
Rodent Diet 8604 (Harlan) and provided highly purified water (reverse osmosis filtered water) in 
polysulfone water bottles ad libitum. All animal procedures were approved by the University of 
Illinois Institutional Animal Care and Use Committee and abide by the guidelines set forth by the 
National Institute of Health for the Care and Use of Laboratory Animals.  
At 8 weeks of age, female mice (F0) were mated with control male mice of the same age. 
The female mice were monitored twice a day for the presence of a copulatory vaginal sperm plug 
to confirm mating. Once a copulatory vaginal sperm plug was confirmed, the presence of which 
was considered gestational day (GD) 0.5, the females were removed, weighed, and individually 
housed. Subsequently, the mice were weighed twice a week to confirm successful pregnancy. 
From GD 10.5 until birth of the pups, pregnant dams (F0) were orally dosed once a day with the 
vehicle control (tocopherol-stripped corn oil) or with DEHP (20 µg/kg/day, 200 µg/kg/day, 500 
mg/kg/day, 750 mg/kg/day) by placing a pipette tip with the dosing solution into the cheek pouch 
of the mouse. This dosing regimen was selected to mimic oral exposure to DEHP in humans [1, 
45, 51]. The doses were calculated and adjusted based on daily body weights, and delivered in 25 
– 33 µL of tocopherol-stripped corn oil. The treatment window was chosen because it is a critical 
time period of ovarian development. Specifically, this is when primordial germ cells arrive at the 
gonad [55, 56], sex determination occurs [57], and global demethylation and imprint erasure of 
primordial germ cells occur [58]. 
Pregnant mice were allowed to deliver naturally and the day of birth was considered 
postnatal day (PND) 0. Mice born from the F0 generation were labeled the F1 generation. 
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Female mice from the F1 generation were mated with non-treated male CD-1 mice to produce 
the F2 generation. Females from the F2 generation were mated with non-treated male CD-1 mice 
to produce the F3 generation. No mice were mated with family members. At PND 21, mice were 
euthanized by CO2 affiliation followed by cervical dislocation. PND 21 was selected because 
mice are juvenile and not sexually mature. Further, sex steroid hormones are not actively 
produced in the ovary and no corpora lutea are present. Whole ovaries were collected from each 
mouse. One ovary was fixed in Dietrich’s fixative for immunohistochemistry and the second 
ovary was immediately frozen in liquid nitrogen and stored at -80C for RNA and DNA 
extraction. 
 
RNA sequencing analysis 
Frozen whole ovaries collected at PND 21 from control and 20 µg/kg/day (n = 3 
ovaries/treatment group) from the F3 generation were used for RNA sequencing. Raw reads were 
checked for quality using FASTQC (v 0.11.5) then trimmed and filtered using Trimmomatic (v 
0.36) to remove residual adapter content, low quality bases (Phred quality score < 28), and 
resulting reads shorter than 30 nt. Trimmed/filtered reads were aligned to NCBI’s Mus musculus 
GRCm38.p6 genome and gene model annotation release 106 using STAR (v 2.5.3a). Post-
alignment gene counts were then determined for each NCBI EntrezGene ID using featureCounts 
from Subread (v 1.5.2-pl) with multi-mapping reads excluded. 
The raw read counts were input into R [59] (v 3.4.3) for pre-processing and analysis 
together using Bioconductor [60] packages as listed below. Approximately ~23 million reads 
aligned uniquely within the 41,595 M. musculus genes. We used TMM method [61] in the edgeR 
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package [62] (v 3.20.5) to normalize the counts to log2-transformed counts per million 
(logCPM), using the cpm() function with prior.count = 3.  Specifically, 25,141 genes did not 
have logCPM > log2(0.5) in at least three samples and were filtered out, leaving 16,454 genes to 
be analyzed for differential expression. TMM-values and logCPM normalized values were re-
calculated with prior.count = 3 after gene filtering. Principle components analysis clustering of 
the samples (Data not shown) indicated one of the treatment replicates was more variable than 
the other two. Rather than remove this sample completely, we did a surrogate variables analysis 
[63, 64] on the logCPM values, which estimated one surrogate variable that corrected for the 
difference in this replicate (data not shown). This surrogate variable was added to edgeR’s quasi-
likelihood negative binomial generalized log-linear model [65], which was fit on the original 
read counts + TMM values to find differential expression between the treated and control groups. 
Multiple hypothesis test correction was done using the False Discovery Rate method [66]. 
Data obtained from RNA sequencing were functionally analyzed using The Database of 
Annotation, Visualization, and Integrated Discovery Bioinformatics (DAVID) 6.8 following the 
previously published protocol [67, 68]. Genes with a false discovery rate < 0.62 and p < 0.007 
were entered into DAVID for functional annotation analysis for a total of 177 genes. 
“Gene_Ontology” and “Pathways” and the denoted DAVID defined defaults were selected for 
functional annotation clustering. To determine if functional gene groups were valuable, 




Gene expression analysis 
Frozen whole ovaries collected at PND 21 were used for quantitative real-time 
polymerase chain reaction (qPCR) analysis (n= 3 – 6 ovaries/treatment group). Total RNA (>100 
ng) was extracted from the whole ovaries using the AllPrep DNA/RNA Mini Kit (Qiagen, 
Austin, TX, USA) according to the manufacturer’s protocol, including DNase digestion. Total 
RNA (100 ng) was reverse transcribed to complementary DNA (cDNA) using the iScript RT Kit 
(Bio-Rad Laboratories, Inc., Hercules, CA, USA) according to the manufacturer’s protocol. Each 
cDNA sample was diluted 1:8 using nuclease-free water prior to qPCR analysis. Analysis of 
qPCR was performed using the CFX96 C1000 Real-Time PCR Detection System and CFX 
Manager Software (Bio-Rad Laboratories, Inc., Hercules, CA, USA) according to the 
manufacturer’s protocol. Each qPCR reaction was done in duplicates using 2 µL of cDNA, 
forward and reverse primers (5 pmol) for select genes, nuclease-free water, and 
SsoFastEvaGreen Supermix for a final reaction volume of 10 µL. Target genes were analyzed in 
reference to the housekeeping gene, beta-actin (Bactin). A list of gene primers (Integrated DNA 
Technologies, Coralville, IA, USA) and the housekeeping gene, beta-actin, are included in the 
supplementary files (Table S1). 
The CFX96 C1000 Real-Time PCR Detection machine quantifies the amount of PCR 
product generated by measuring SsoFastEvaGreen dye (Bio-Rad Laboratories, Inc., Hercules, 
CA) that fluoresces when bound to double-stranded DNA. The qPCR program consisted of an 
enzyme activation step (95 °C for 1 min), an amplification and quantification program (40 cycles 
of 95 °C for 10 s, 60 °C for 10 s, single fluorescence reading), a 72 °C for 5 min, a melt curve 
(65 °C–95 °C heating 0.5 °C/s with continuous fluorescence readings), and a final step at 72 °C 
for 5 min as per the manufacturer's protocol. All gene expression data were normalized to the 
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housekeeping gene. Relative fold changes were calculated as the ratio to control group level and 
were analyzed using a mathematical model for relative quantification of real-time PCR data 
developed by Pfaffl [69]. 
 
DNA methylation analysis 
 DNA was extracted from frozen whole PND 21 ovaries using the AllPrep DNA/RNA 
Mini Kit (Qiagen, Austin, TX, USA) per the manufacturer’s protocol. DNA was extracted, eluted 
in 100 µL of EB buffer, and stored in -80 C until further DNA methylation testing. To measure 
global DNA methylation status, the enzyme-linked immunosorbent assay MethylFlash 
Methylated DNA 5-mC Quantification Kit (Colorimetric assay, Epigentek Group Inc., 
Farmingdale, NY, USA) was used according to the manufacturer’s protocol. Briefly, ovarian 
DNA (100 ng) was added to high affinity strip wells. Methylated DNA was detected using 
capture and detection antibodies for 5-methyl cytosine (5-mC) and quantified by reading 
absorbance at 450 nm using a 354 Multiskan Ascent Microplate Reader (Thermo Electron Corp., 
Shanghai, China). The absolute amount and percentage of methylated DNA were calculated 
using the absolute quantification method per the manufacturer’s protocol. Briefly, a standard 
curve was calculated from five known concentrations of methylated DNA (0.5, 1, 2, 5, 10 ng). 
The slope of the standard curve was quantified and used in the provided formulas per the 





Data were expressed as the mean ± standard error of the mean (SEM). In all generations, 
data from multiple female pups originating from the same litter were averaged and combined as 
n = 1, and data from at least 3 separate litters were used in the analyses. Data were analyzed by 
comparing treatment groups to control using IBM SPSS version 24 software (SPSS Inc., 
Chicago, IL, USA). Outliers were removed by the Grubb’s test using GraphPad outlier calculator 
software (GraphPad Software Inc., La Jolla, CA, USA). Data that were continuous were assessed 
for normal distribution by Shapiro-Wilk analysis. If data met assumptions of normal distribution 
and homogeneity of variance, data were analyzed by one-way analysis of variance (ANOVA) 
followed by Tukey HSD or Dunnett 2-sided post-hoc comparisons. However, if data met 
assumptions of normal distributions, but not homogeneity of variance, data were analyzed by 
ANOVA followed by Games-Howell or Dunnett’s T3 post-hoc comparisons. If data were 
presented as percentages or were not normally distributed, the independent sample Kruskal-
Wallis H followed by Mann-Whitney U non-parametric tests were performed. For all 
comparisons, statistical significance was determined by a p-value ≤ 0.05. In instances in which 






The effects of ancestral exposure to DEHP on gene expression in the F3 generation as 
determined by RNA sequencing and The Database of Annotation, Visualization, and Integrated 
Discovery Bioinformatics 
Functional annotation gene clustering analysis via DAVID provided 5 annotation clusters 
from the “Gene_Ontology” selection (Figure 5.1A). Within the annotation cluster containing the 
highest enrichment score was insulin-like growth factor binding, regulation of cell growth, and 
growth factor binding (Figure 5.1A). Functional annotation gene clustering from the “Pathway” 
selection provided 1 annotation cluster (Figure 5.1B). Within the annotation cluster, extra 
cellular matrix-receptor interaction, amoebiasis, focal adhesion, and the PI3K-Akt signaling 
pathway were listed (Figure 5.1B). Based on these results, subsequent qPCR was conducted to 
assess the effects of DEHP exposure on ovarian gene expression. 
 
The effects of DEHP exposure on hormone receptors and insulin-like growth factor gene 
expression in ovaries from the F1 – F3 generations 
Several studies suggest that DEHP and its many metabolites act through steroid hormone 
receptors and peroxisome proliferator-activated receptors (PPAR) [70, 71]. Therefore, the 
current study examined the effects of prenatal and ancestral exposure to DEHP on the expression 
of hormone receptors and PPARs. Further, based on the RNA sequencing results, the insulin-like 
growth factor (IGF) family was examined.  In the F1 generation, prenatal exposure to DEHP did 
not affect the expression of Ppara, Fshr, or Igfbp4 compared to controls (Figures 5.2A, 5.2E, 
and 5.2G). However prenatal exposure to DEHP decreased the expression of Pparg in the 20 
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µg/kg/day and 750 mg/kg/day groups, increased Esr2 expression in the 750 mg/kg/day group, 
decreased the expression of Ar in the 20 µg/kg/day group, and increased the expression of Igf1 in 
the 500 mg/kg/day group compared to controls (Figures 5.2B, 5.2C, 5.2D, and 5.2F, n = 3 – 5 
ovaries/treatment group, p ≤ 0.05). In the F2 generation, exposure to DEHP did not affect the 
expression of Ppara, Pparg, Ar, Fshr, or Igf1 compared to controls (Figures 5.2A, 5.2B, 5.2D, 
5.2E, and 5.2F). In contrast, exposure to DEHP decreased the expression of Esr2 in the 20 
µg/kg/day group and decreased Igfbp4 expression in the 500 mg/kg/day group compared to 
controls (Figures 5.2C and 5.2G, n = 3 ovaries/treatment group, p ≤ 0.05). In the F3 generation, 
ancestral exposure to DEHP did not affect the expression of Ppara, Pparg, Fshr, Igf1, or Igfbp4 
compared to controls (Figures 5.2A, 5.2B, 5.2E, 5.2F, and 5.2G). However ancestral exposure to 
DEHP decreased the expression of Esr2 in the 20 µg/kg/day, 200 µg/kg/day, and 750 mg/kg/day 
groups, and decreased the expression of Ar in the 200 µg/kg/day group compared to controls 
(Figures 5.2C and 5.2D, n = 3 – 6 ovaries/treatment group, p ≤ 0.05 but p = 0.071 for Ar in 200 
µg/kg/day). 
 
The effects of DEHP on steroidogenic enzyme gene expression in ovaries from the F1 – 
F3 generations 
Our previous work showed that prenatal DEHP exposure dysregulated steroid hormone 
levels in F2 generations, but not the F1 and F3 generations of mice at PND 21 [25]. The current 
work was performed to examine estrogen synthesis and expand our knowledge of DEHP 
dysregulation of steroid hormones by determining if it is due to prenatal or ancestral DEHP 
effects on expression of steroidogenic enzymes.  In the F1 generation, prenatal exposure to 
DEHP did not affect the expression of Star, Hsd17b1, Cyp11a1, Cyp17a1, Cyp19a1, Cyp1a1, or 
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Cyp1b1 (Figures 5.3A, 5.3C, 5.3D, 5.3E, 5.3F, 5.3G, and 5.3H), but  DEHP at 750 mg/kg/day 
increased the expression of Hsd3b1 compared to controls (Figure 5.3B, n = 3 – 5 
ovaries/treatment group, p ≤ 0.05). In the F2 generation, exposure to DEHP decreased the 
expression of Star in the 20 µg/kg/day group, decreased Hsd3b1 expression in the 20 µg/kg/day 
group, decreased Hsd17b1 expression in the 20 µg/kg/day, 500 mg/kg/day, and 750 mg/kg/day 
groups, and decreased Cyp19a1 expression in the 20 µg/kg/day and 500 mg/kg/day groups 
compared to controls (Figures 5.3A, 5.3B, 5.3C, and 5.3F, n = 3 ovaries/treatment group, p ≤ 
0.05, but p = 0.081 for Star in 20 µg/kg/day). In the F3 generation, ancestral exposure to DEHP 
did not affect the expression of Star, Hsd3b1, Cyp11a1, Cyp17a1, Cyp19a1, or Cyp1a1 
compared to controls (Figures 5.3A, 5.3B, 5.3D, 5.3E, 5.3F, and 5.3G), but ancestral exposure 
decreased the expression of Hsd17b1 in the 20 µg/kg/day and 750 mg/kg/day groups and 
decreased Cyp1b1 expression in the 200 µg/kg/day, 500 mg/kg/day, and 750 mg/kg/day 
treatment groups compared to controls (Figures 5.3C and 5.3H, n = 3 – 6 ovaries/treatment 
group, p ≤ 0.05, but p = 0.068 and 0.069 for Cyp1b1 in 500 mg and 750 mg/kg/day, 
respectfully). 
 
The effects of DEHP exposure on phosphoinositide 3-kinase pathway gene expression 
ovaries from the F1 – F3 generations 
Our previous work showed that ancestral exposure to DEHP accelerated primordial 
follicle recruitment in the F3 generation, but not in the F1 and F2 generations of mice [25]. 
Previous studies also indicate that adult exposure to DEHP dysregulates the PI3K pathway, a 
critical pathway for primordial follicle recruitment [45]. Thus, we examined the effects of 
prenatal and ancestral exposure to DEHP on the PI3K factors in the F1 – F3 generations. In the 
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F1 generation, prenatal exposure to DEHP did not affect the expression of Foxl2, Kitl, Mtorc1, 
Foxo3a, Pdk1, Kit, Tsc1, or Rps6 compared to controls (Figures 5.4A, 5.4B, 5.4C, 5.4D, 5.4F, 
5.4G, 5.4H, and 5.4J). However, prenatal exposure to 20 µg/kg/day of DEHP increased the 
expression of Pten compared to controls (Figure 5.4E, n = 3 – 5 ovaries/treatment group, p ≤ 
0.05). In the F2 generation, exposure to DEHP did not affect the expression of Foxl2, Kitl, Pdk1, 
Kit, Tsc1, or Rps6 compared to controls (Figures 5.4A, 5.4B, 5.4F, 5.4G, 5.4H, and 5.4J), but 
DEHP exposure increased the expression of Mtorc1 at 20 µg/kg/day and 750 mg/kg/day and 
decreased Mtorc1 expression at 200 µg/kg/day, decreased the expression of Foxo3a in the 20 
µg/kg/day group and increased Foxo3a expression in the 750 mg/kg/day group, and decreased 
the expression of Pten in the 20 µg/kg/day group compared to controls (Figures 5.4C, 5.4D, and 
5.4E, n = 3 ovaries/treatment group, p ≤ 0.05). In the F3 generation, ancestral exposure to DEHP 
did not affect the expression of Foxl2, Kitl, Mtorc1, Foxo3a, Kit, or Tsc1 compared to controls 
(Figures 5.4A, 5.4B, 5.4C, 5.4D, 5.4G, and 5.4H). Ancestral exposure to DEHP decreased the 
expression of Pten in all treatment groups, decreased Pdk1 expression in the 20 µg/kg/day, 200 
µg/kg/day, and 750 mg/kg/day groups, and decreased Rps6 expression in the 20 µg/kg/day group 
compared to controls (Figures 5.4E, 5.4F, and 5.4J, n = 3 – 6 ovaries/treatment group, p ≤ 0.05). 
 
The effects of DEHP exposure on cell cycle regulator gene expression in ovaries from the 
F1 – F3 generations 
 Our previous work showed the prenatal exposure to DEHP dysregulated folliculogenesis 
at PND 21 in all three generations of mice [25]. Folliculogenesis is regulated by many factors, 
but the cell cycle regulators are heavily involved in cell proliferation and follicle growth [49, 72]. 
Therefore, we measured the mRNA expression levels of cyclins, cyclin dependent kinases, and 
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cyclin dependent kinase inhibitors. In the F1 generation, prenatal exposure to DEHP increased 
the expression of Ccna2 in the 500 mg/kg/day group, decreased the expression of Ccnd2 in the 
750 mg/kg/day group, decreased the expression of Cdkn1a in the 750 mg/kg/day group, 
increased the expression of Cdkn1c in the 200 µg/kg/day group, and increased the expression of 
Cdkn2a expression in the 20 µg/kg/day, 200 µg/kg/day, and 750 mg/kg/day groups compared to 
controls (Figure 5.5A, 5.5C, 5.5F, and 5.5H n = 3 – 6 ovaries/treatment group, p ≤ 0.05, but p = 
0.076 for Ccna2 in 500 mg/kg/day, p = 0.101 for Ccnd2 in 20 µg/kg/day, and p = 0.055 for 
Cdkn2a for 750 mg/kg/day). In the F1 generation, prenatal exposure to DEHP did not affect the 
expression of Ccnb1, Ccne1, Cdk4, or Cdkn1c compared to controls (Figures 5.5B, 5.5E, 5.5D, 
and 5.5G). In the F2 generation, exposure to DEHP did not affect the expression of Ccna2, 
Ccnd2, Ccne1, Cdk4, Cdkn1a, Cdkn1c, or Cdkn2a compared to controls (Figures 5.5A, 5.5C, 
5.5D, 5.5E, 5.5F, 5.5G, and 5.5H). However, exposure to DEHP at 500 mg/kg/day decreased the 
expression of Ccnb1 compared to controls, but it was borderline statistically significant (Figure 
5.5B, n = 3 ovaries/treatment group, p = 0.057). In the F3 generation, ancestral exposure to 
DEHP decreased the expression of Ccna2 in the 20 µg/kg/day, 200 µg/kg/day, and 750 
mg/kg/day groups, decreased Ccnb1 expression in the 750 mg/kg/day group, decreased Ccnd2 
expression in the 20 µg/kg/day, 200 µg/kg/day, and 750 mg/kg/day groups, decreased Cdk4 
expression in the 750 mg/kg/day group, and decreased the expression of Cdkn2a in the 20 
µg/kg/day and 200 µg/kg/day groups compared to controls (Figures 5.5A, 5.5B, 5.5C, 5.5E, and 
5.5H n = 3 – 6 ovaries/treatment group, p ≤ 0.05, but p = 0.084 and 0.060 for Ccnd2 in 200 
µg/kg/day and 750 mg/kg/day, respectfully). Further, in the F3 generation, ancestral exposure to 
DEHP did not affect the expression of Ccne1, Dckn1a, or Cdkn1c compared to controls (Figures 
5.5D, 5.5F, and 5.5G). 
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The effects of DEHP exposure on apoptosis and oxidative stress pathway gene expression 
in ovaries from the F1 – F3 generations 
Our previous study showed the prenatal exposure to DEHP decreased the percentage of 
atretic follicles in the F1 generation [25]. The B-cell lymphomas/leukemia-2 (Bcl-2) family 
includes inhibitors and promoters of apoptosis in the ovary [47]. The balance of promotors and 
inhibitors of apoptosis is critical for the healthy development and maintenance follicular cells. 
The Bcl-2 family has been shown to directly regulate apoptosis in the ovary [47, 73]. In addition, 
oxidative stress is an imbalance of pro-oxidant molecules and anti-oxidant defenses and the 
balance of these factors are critical for adequate growth and development of follicles [48]. Thus, 
we examined the effects of prenatal and ancestral exposure to DEHP on the expression of the 
Bcl-2 family and oxidative stress factors in the ovary of the F1 – F3 generations. 
In the F1 generation, prenatal exposure to DEHP did not affect the expression of Bcl2, 
Bax, Bad, Casp3, Casp8, Catalase, Gpx, or Gsr compared to controls (Figures 5.6A, 5.6B, 5.6C, 
5.6E, 5.6F, 5.6H, 5.6J, and 5.6K). In contrast, prenatal exposure to DEHP at 750 mg/kg/day 
decreased the ratio of Bax/Bcl2 and DEHP at 500 mg/kg/day increased the expression of Bok 
compared to controls, but it was borderline statistically significant (Figure 5.6D and 5.6G, n = 3 
– 5 ovaries/treatment group, p ≤ 0.05 and p = 0.076 for Bok). In the F2 generation, exposure to 
DEHP did not affect the expression of Bcl2, Bax, Bax/Bcl2 ratio, Bok, Catalase, or Gsr 
compared to controls (Figures 5.6A, 5.6B, 5.6D, 5.6E, 5.6H, and 5.6K). However, exposure to 
20 µg/kg/day of DEHP decreased the expression of Bad, Casp3, and Casp8, and exposure to 500 
mg/kg/day of DEHP increased the expression of Gpx compared to controls (Figures 5.6C, 5.6E, 
5.6F, and 5.6J, n = 3 ovaries/treatment group, p ≤ 0.05). In the F3 generation, ancestral exposure 
to DEHP decreased the expression of Bcl2 in all treatment groups, increased the expression of 
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Bax/Bcl2 ratio in the 20 µg/kg/day, 200 µg/kg/day, and 500 mg/kg/day groups, decreased the 
expression of Casp3 in the 20 µg/kg/day, 200 µg/kg/day, and 500 mg/kg/day groups, decreased 
the expression of Casp8 in all treatment groups, decreased the expression of Bok in the 20 
µg/kg/day group, decreased the expression of Gpx in the 750 mg/kg/day group, and decreased 
the expression of Gsr in the 20 µg/kg/day, 200 µg/kg/day, and 750 mg/kg/day groups compared 
to controls (Figures 5.6A, 5.6D, 5.6E, 5.6F, 5.6G, 5.6J, and 5.6K, n = 3 – 6 ovaries/treatment 
group, p ≤ 0.05, but p = 0.071 for Casp8 in 750 mg/kg/day, p = 0.088 for Bok in 20 µg/kg/day, 
and p = 0.067 for Gsr in 200 µg/kg/day). 
 
The effects of DEHP exposure on DNA methyltransferases and ten-eleven translocation 
enzyme gene expression in ovaries from the F1 – F3 generations 
 Although previous studies demonstrate that DEHP exposure causes transgenerational 
inheritance of ovarian dysfunction [25, 74, 75], the DNA methylation mediators underlying these 
changes have not been well studied. Therefore, we examined the expression levels of DNA 
methyltransferases (DNMT) and ten-eleven translocation enzyme (TET) gene expression in the 
F1 – F3 generations. In the F1 generation, prenatal exposure to DEHP did not affect the 
expression of Dnmt3a, Dnmt3b, Tet1, Tet2, and Tet compared to controls (Figures 5.7B, 5.7C, 
5.7D, 5.7E, and 5.7F). However, prenatal exposure to DEHP at 750 mg/kg/day increased the 
expression of Dnmt1 compared to controls, but it was borderline statistically significant (Figure 
5.7A, n = 3 – 5 ovaries/treatment group, p = 0.068). In the F2 generation, exposure to DEHP did 
not affect the expression of Dnmt1, Dnmt3a, or Dnmt3b compared to controls (Figures 5.7A, 
5.7B, and 5.7C). In contrast, DEHP exposure decreased the expression of Tet1 in all groups, 
decreased the expression of Tet2 in the 20 µg/kg/day group, and decreased the expression of Tet3 
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in the 500 mg/kg/day group compared to control, but it was borderline statistically significant 
(Figures 5.7D, 5.7E, and 5.7F, n = 3 ovaries/treatment group, p ≤ 0.05, but p = 0.085 for Tet3 in 
500 mg/kg/day). In the F3 generation, ancestral exposure to DEHP decreased the expression of 
Dnmt1 in all groups compared to control, but some of the decreases were borderline statistically 
significant (Figure 5.7A, n = 3 – 6 ovaries/treatment group, p ≤ 0.05, but p = 0.097 for 200 
µg/kg/day, p = 0.095 for 500 mg/kg/day, and p = 0.059 for 750 mg/kg/day). Further, ancestral 
exposure to DEHP decreased the expression of Dnmt3a in the 750 mg/kg/day group, decreased 
the expression of Dnmt3b in all groups, decreased Tet2 expression in the 200 µg/kg/day and 750 
mg/kg/day groups, and decreased Tet3 expression in the 200 µg/kg/day and 750 mg/kg/day 
groups compared to controls (Figures 5.7B, 5.7C, 5.7E, and 5.7F, n = 3 – 6 ovaries/treatment 
group, p ≤ 0.05, but p = 0.064 for Tet2 in 750 mg/kg/day and p = 0.063 for Tet3 in 200 
µg/kg/day). In the F3 generation, ancestral exposure to DEHP did not affect the expression of 
Tet1 compared to controls (Figure 5.7D). 
 
The effects of DEHP exposure on DNA methylation percentage in whole ovaries from 
the F1 – F3 generations 
 Previous studies determined that prenatal exposure to DEHP causes both 
multigenerational and transgenerational inheritance in ovarian dysfunction [23-25]. 
Transgenerational inheritance is thought to be mediated by epigenetic mechanisms, and DNA 
methylation is a commonly studied epigenetic mechanism. Therefore, the current study measured 
the percentage of 5-mC in the whole ovary in the F1 – F3 generations. In the F1 generation, 
prenatal exposure to 20 µg/kg/day of DEHP increased the percentage of 5-mC compared to 
controls and in the F3 generation, ancestral exposure to 500 mg/kg/day and 750 mg/kg/day of 
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DEHP decreased the percentage of 5-mC in the whole ovary compared to controls (Figure 5.8, n 
= 3 – 7 ovaries/treatment group, p ≤ 0.05).  
 
5.5 Discussion 
Our previous study showed that prenatal and ancestral exposure to DEHP disrupted sex 
steroid hormone levels in the F1 and F2 generations, disrupted ovarian follicle counts in the F1 – 
F3 generations, and altered select reproductive outcomes in the F1 – F3 generations [24, 25]. Our 
current study provides additional information on the multigenerational and transgenerational 
effects of DEHP exposure on the ovary. We show that prenatal exposure to DEHP disrupts the 
expression of the sex steroid hormone synthesis pathway, factors in the PI3K pathway, steroid 
hormone receptors, DNA demethylation processes, and DNA methylation in the F1 and the F2 
generations of the ovary. Further, we show that ancestral exposure to DEHP disrupts the 
expression of estrogen metabolism, PI3K pathway, cell cycle regulators, apoptosis and oxidative 
stress factors, estrogen receptor beta, DNA methylation and demethylation factors, and DNA 
methylation in the F3 ovary. This study provides potential mechanisms and pathways explaining 
how both prenatal and ancestral exposure to DEHP disrupt ovarian functions in the F1 – F3 
generations of mice. 
In this study, mice were orally exposed daily to DEHP starting at embryonic day 10.5 and 
ending at birth. During this exposure window, primordial germ cells in the fetus (F2 generation) 
migrate to the genital ridge and undergo mitosis, meiosis, methylation, and demethylation 
processes [76-79]. We anticipate that this window of exposure targets epigenetic inheritance and 
likely causes transgenerational phenomenon in the F3 generation [79]. This window of exposure 
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is critical because the F1, F2, and F3 generations receive exposure at different developmental 
windows. The F1 generation is exposed as a developing pup, and therefore, the hypothalamus-
pituitary-gonadal axis is directly exposed to DEHP. The F2 generation is exposed as the 
developing germ cells in the gonad. The F3 generation is not directly exposed to DEHP and thus, 
it is the first generation to experience transgenerational inheritance.  Each generation is at 
different developmental time points, therefore, we anticipated that the effects of DEHP on 
ovarian functions would be different in each generation. 
Our results indicate that DEHP exposure altered the expression of sex steroid hormone 
receptors in the F1, F2, and F3 generations. DEHP is a known endocrine disrupting chemical 
with studies showing that it acts through PPAR, estrogen receptors, and the androgen receptor 
[70, 80, 81]. Our study showed that in the F1 generation, prenatal DEHP exposure decreased the 
expression of Pparg and Ar, but increased the expression of Esr2. In the F2 generation, DEHP 
exposure decreased the expression of Esr2. In the F3 generation, ancestral DEHP exposure 
decreased the expression of Esr2 and Ar. A previous study demonstrated that direct DEHP 
inhibited ERα, ERβ, and AR and that DEHP metabolites activated PPARα and PPARγ [70]. 
However, in our study, DEHP exposure only affected the expression of Pparg, Ar, and Esr2 in 
the F1 generation. The other study was performed in vitro and our current study was performed 
in vivo and therefore, it is likely that the experimental set up contributes to the differences in 
receptor activation. A different study demonstrated that DEHP exposure represses Esr1 gene 
expression via PPARα-dependent pathways in a multigenerational manner [80]. However, in our 
study, we did not observe a significant change in Ppara gene expression in any generation. It 
was surprising that we did not see changes in Ppar expression in the F3 generation because the 
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endocrine disrupting effects of DEHP are thought to be mediated through PPAR action [80, 82-
84].  
 Our study showed that DEHP exposure increased the expression of Igf1 in the F1 
generation and decreased the expression of Igfbp4 in the F2 generation, but did not affect the 
gene expression in the F3 generation. Our data indicate that prenatal DEHP exposure caused 
multigenerational changes on gene expression on insulin-like growth factor (Igf). Mice lacking 
IGF1 are infertile with follicles arrested in the preantral stage, suggesting that it is important for 
follicular development and proliferation and differentiation of granulosa cells [85]. Therefore, an 
increase in Igf1 expression suggests that ovaries would have contained mature follicle types. 
However, we observed the opposite in the F1 generation; we observed that DEHP exposure 
decreased antral follicle numbers [25]. It is likely that the increased Igf1 expression by DEHP 
exposure is a compensatory mechanism to encourage the growth of mature follicle types in the 
ovary.  
The insulin-like growth factor binding proteins (IGFBPs) are necessary to transport IGFs 
into the bloodstream and ultimately determine IGF bioavailability [85]. Therefore, a decrease in 
Igfbp4 expression may induce a decrease in bioavailability of IGFs. Further, Igfbp4 expression is 
restricted to apoptotic and atretic follicles [47]. Interestingly, in our previous study, we did not 
observe changes in atretic follicle numbers [25] even though we observed decreased Igfbp4 
expression.  
Our results show that DEHP exposure disrupted steroidogenesis in the F2 and F3 
generations, but not in the F1 generation. According to our previous study, prenatal DEHP 
exposure did not affect serum 17β-estradiol levels in the F1 generation at PND 21 [25]. 
Therefore, it is not surprising that prenatal DEHP exposure did not significantly affect the 
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expression of sex steroid hormone synthesis enzymes in the F1 generation. However, in the F2 
generation, our previous study showed that prenatal exposure to DEHP borderline decreased 
serum 17β-estradiol levels and increased serum progesterone levels in the 20 µg/kg/day 
treatment group compared to control [25]. In our current study, DEHP exposure at 20 µg/kg/day 
decreased the expression of Star, Hsd3b1, Hsd17b1, and Cyp19a1 in the F2 generation. This 
decrease in enzymes correlates well with the previously observed serum sex steroid hormone 
levels. Likely, the increase in serum progesterone level is due to the decrease of enzymes 
necessary to further biotransform it to androgens and estrogens. Further, the decrease of 
Hsd17b1 and Cyp19a1 likely leads to a decrease in serum 17β-estradiol levels because these two 
enzymes biotransform estrone and testosterone into 17β-estradiol, respectfully [86]. Finally, in 
the F3 generation, we observed a decrease with DEHP exposure in Hsd17b1 expression, which is 
important for biotransforming androstenedione into testosterone and estrone into 17β-estradiol 
[86]. However, in our previous study, we did not observe a serum sex steroid hormone change 
[25], but we observed a DEHP-induced decrease in Cyp1b1, an enzyme important for 
hydroxylation of 17β-estradiol [87, 88]. It may be that the decreases in Hsd17b1 and Cyp1b1 are 
compensatory mechanisms in the ovary to keep serum 17β-estradiol levels at a normal and 
healthy level.  
Interestingly, our results are in contrast with another study that exposed mice to DEHP 
during an early developmental time period. Specifically, Pocar et al. perinatally dosed mice 
throughout gestation and lactation with low doses of DEHP and observed decreases in 
steroidogenic enzyme expression in the F1 generation and not the F2 or F3 generations [75]. The 
reason why our results and Pocar et al. vary may be due to the many differences between the 
experiments. In our study, we dosed animals only during the second half of gestation and our 
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doses varied (20 µg/kg/day – 750 mg/kg/day), whereas Pocar et al. dosed animals throughout 
lactation and gestation with different doses (50 µg/kg/day and 5 mg/kg/day) [75]. Due to DEHP 
and its endocrine disrupting activities, the timing and dose of exposure greatly influences the 
observed effects [79, 89]. 
Results from out study indicate that prenatal and ancestral DEHP exposure disrupted the 
PI3K pathway in the F1, F2, and F3 generations. In the F1 generation, prenatal DEHP exposure 
increased Pten expression in the PI3K pathway but it did not affect other factors in the pathway. 
Pten is a gene that encodes the PI3K negative regulator; if deleted, the entire pool of primordial 
follicles activate [42]. Therefore, an increase in Pten expression suggests a primordial follicle 
quiescence. Interestingly, in our previous study, we observed data supporting primordial follicle 
quiescence. At PND 21, prenatal DEHP exposure decreased the number of antral follicles in the 
F1 generation, suggesting primordial follicle quiescence [25, 90]. Additionally, at PND 60, 
prenatal DEHP exposure decreased the number of primary and preantral follicle numbers further 
suggesting that primordial follicle activation may be impeded in the F1 generation, though we 
did not measure gene expression at this time point [25]. In our study, the increased Pten 
expression supports follicle count numbers observed in our previous study in the F1 generation 
[25]. These data are similar to a study by Hannon et al. in which mice were exposed to DEHP 
during adulthood and the expression of Pten was measured in whole ovaries. Hannon et al. found 
that DEHP exposure decreased the expression of Pten in mice exposed to DEHP [45]. Although 
our study and Hannon et al. did not use the same exposure window, it is interesting that DEHP 
exposure has a strong effect on Pten expression. In the F2 generation, exposure to DEHP altered 
the expression of Mtorc1 and Foxo3a, but decreased the expression of Pten compared to control. 
Similar to Pten, Foxo3a is responsible for primordial follicle quiescence and a lack of Foxo3a 
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promotes primordial follicle activation [91]. In contrast, Mtorc1 is involved in primordial follicle 
activation and regulates protein synthesis and cell growth, whereas a decrease in Mtorc1 
expression promotes primordial follicle quiescence [90, 92]. In the F3 generation, ancestral 
exposure to DEHP decreased the expression of Pten, Pdk1, and Rps6. PI3K signaling is mediated 
through Pdk1 and it signals to activate AKT to maintain primordial follicles survival [93]. 
Further, Rps6 encodes for a ribosomal protein necessary to maintain the survival of primordial 
follicles in relation to PDK1-AKT signaling [93]. Our previous data showed that at PND 21, 
ancestral DEHP exposure decreased primordial follicle numbers [25]. A correlated decrease in 
Pten, Pdk1, and Rps6 expression correlates well with decreased primordial follicle numbers 
because decreased Pten expression suggests that primordial follicles activate and continue 
folliculogenesis [42]. Further, decreased Pdk1 and Rps6 expression decreases primordial follicle 
survival [93]. Therefore, decreased expression of these factors supports follicle count numbers in 
the F3 generation and provides a potential mechanism for follicle count disruption at PND 21. 
Prenatal and ancestral exposure to DEHP significantly decreased gene expression of cell 
cycle regulators in the F1 and F3 generations. In somatic cells, the cell cycle is made of four 
phases with different cyclin-dependent kinases and cyclins to control the cell cycle [94]. Cyclin 
A2 is expressed during the S phase and is critical for DNA replication [49]. Cyclin B1 is 
necessary for cell cycle progression through mitosis [49]. Cyclin D2 binding to CDK4 is a 
critical positive regulator for ovarian granulosa cell proliferation in response to follicle-
stimulating hormone (FSH) [72, 95]. In the F1 generation, DEHP exposure increased Ccna2, 
Cdkn1c, and Cdkn2a but decreased Ccnd2 and Cdkn1a expression. It is likely that prenatal 
DEHP exposure inhibits the cell cycle progression by decreasing promotors of the cell cycle such 
as Ccnd2 and increasing the expression of inhibitors of cell cycle such as Cdkn2a and Cdkn1c 
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[96, 97]. Although the expression of Cdkn1a, another cell cycle inhibitor, was decreased in the 
F1 generation, it is likely that it was not biologically significant enough to counteract the 
expression of the other inhibitors. The cell cycle changes in the F1 generation support previous 
data that prenatal DEHP exposure decreases the number of antral follicles at PND 21. Further, 
the effects of prenatal DEHP exposure on cell cycle regulators is somewhat similar to studies 
that directly exposed the ovary to DEHP. Direct exposure to DEHP in vitro increased the 
expression of Ccna2, Ccnb1, Ccnd2, Cdk4, and Ccne1 after 72 hours of exposure in the antral 
follicle [50]. Both experimental models observed increased Ccna2 expression, however, the two 
experimental models are vastly different because of the route of exposure (direct in vitro vs. 
prenatal in vivo). In the F3 generation, ancestral DEHP exposure decreased the expression of 
Ccna2, Ccnb1, Ccnd2, and Cdk4. Decreases in these cyclins and cyclin-dependent kinase suggest 
that ancestral DEHP exposure reduces cell cycle progression and proliferation and likely leaves 
these cells in cell cycle arrest. Specifically, Ccna2, Ccnb1, Ccnd2, and Cdk4 encode for cyclin 
A2, cyclin B1, cyclin D2, and Cdk4 and decreases in these factors decrease the progression of 
the G1 phase, S phase, G2 phase, and they decrease transition from G2 to M phase [49, 72, 98]. 
Our study observed significant increases in cell cycle inhibitors in the F1 generation and 
significant decreases in cell cycle regulation in the F3 generation showing that prenatal DEHP 
exposure causes transgenerational changes in gene expression. 
Our data indicate that DEHP exposure decreased the expression of apoptosis factors in 
the F2 and F3 generations, but not the F1 generation. Apoptosis is mediated by a balance of pro-
apoptotic factors and anti-apoptotic factors [47]. Specifically, Bad is a pro-apoptotic factor that 
utilizes caspases proteases [99]. Some caspases include initiator caspases (Casp8) and effector 
caspases (Casp3) that cleave enzymes and proteins necessary for cell viability [47]. In the F2 
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generation, exposure to DEHP at 20 µg/kg/day decreased the expression of Bad, Casp3, and 
Casp8. Interestingly, decreases in these genes suggest that DEHP exposure decreases pro-
apoptotic factors and favors cell viability without significantly affecting anti-apoptotic factors. In 
the F3 generation, ancestral DEHP exposure decreases the expression of Bcl2, an anti-apoptotic 
factor [47], decreases the expression of Bok, a pro-apoptotic factor [47], and decreases the 
expression of both Casp3 and Casp8. Although ancestral exposure decreases both pro- and anti-
apoptotic factors, it is the ratio of the two that drives either cell survival or death [47]. In the F3 
generation, ancestral DEHP exposure increased the ratio of Bax to Bcl2 showing that cells are 
driven towards an apoptotic fate, however, the expression of both caspases are decreased in the 
F3 generation. The caspases are cell regulatory enzymes that control cell death [100]. Therefore, 
the gene expression of the enzymes necessary for cell death is not consistent in our results and is 
likely that the pro-apoptotic actions are unable to activate the expression of both caspases in the 
F3 generation. 
Our data also indicate that exposure to DEHP did not affect oxidative stress factors in the 
F1 generation, increased oxidative stress factors in the F2 generation, and decreased oxidative 
stress factors in the F3 generation. A balance of pro-oxidants and anti-oxidants is necessary for 
physiological processes, but an imbalance can cause damage to DNA and proteins [48]. A 
healthy balance is achieved by changing reactive oxygen species, reactive nitrogen species, or 
anti-oxidant defense mechanism [48, 101]. In our study, in the F2 generation, DEHP exposure 
increased the expression of Gpx, which encodes for an enzyme that degrades hydrogen peroxide 
into water [48]. In the F3 generation, ancestral DEHP exposure decreased the expression of both 
Gpx and Gsr. Although Gpx is an anti-oxidant, Gsr is necessary to recycle glutathione (GSH) so 
that it can be recruited to reduce peroxidase [102]. A significant reduction of Gpx and Gsr may 
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result in DNA damage and high hydrogen peroxide concentrations, although this current study 
did not measure DNA damage or reactive oxygen species. However, these data suggest that 
ancestral DEHP exposure disrupted oxidative stress factors in a transgenerational manner. 
 Epigenetic modifications are commonly thought to be the mode of action for 
transgenerational changes. Specifically, we examined DNA methylation mechanisms in all 
generations. Our data indicate that prenatal exposure to DEHP slightly increased the expression 
of Dnmt enzymes in the F1 generation, but decreased the expression in the F3 generation. 
Interestingly, we did not observe Dnmt expression changes in the F2 generation. Although 
previous studies demonstrated Dnmt expression changes in the F1 generation, no studies to our 
knowledge have measured Dnmt expression changes in the ovary of the F3 generation. One 
study has perinatally exposed rats to methoxychlor, a well-known endocrine disruptor, and it 
increased the expression of Dnmt3b in PND 50 – 60 ovaries [103]. In another study, rats 
prenatally exposed to DEHP increased Dnmt expression in testicular Leydig cells, increased 
methylation in promoter regions of steroidogenic transcription factors, and decreased gene 
expression of steroidogenic enzymes in the F1 generation [104]. This study clearly demonstrated 
that DNA methylation altered adult testicular function, however, our data do not clearly 
demonstrate such a connection. Prenatal DEHP exposure slightly increased Dnmt1 expression, 
but not significantly, and therefore suggesting that DNA methylation may contributed as a mode 
of action for altered steroidogenesis and folliculogenesis in the F1 generation at PND 21. 
Additionally, in the F3 generation, ancestral DEHP exposure decreased Dnmt expression, 
suggesting that DNA methylation plays a major role in regulating gene expression in the ovary. 
 Next, we measured the gene expression of DNA demethylation contributors in all 
generations. Our results indicate that prenatal DEHP exposure did not affect the expression of 
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Tet enzymes in the F1 generation, but DEHP exposure decreased the expression in the F2 
generation and ancestral DEHP exposure decreased the expression of Tet enzymes in the F3 
generation. Tet expression correlates to the level of 5-mC because TET oxidized 5-mC into 5-
hmC as a demethylation process [32]. In our study, prenatal DEHP exposure increased the 
percentage of 5mC in the F1 generation and ancestral DEHP exposure decreased the percentage 
of 5mC in the F3 generation. Although a previous study has shown that overexpression of TET1 
reduces genomic 5-mC [105], we did not observe a decrease in Tet1 expression in the F1 
generation that correlates with increased 5-mC in the ovary. Therefore, the increased 5-mC in the 
F1 generation may not be due to only gene expression of Tet1 or Dnmt, but instead it may be due 
to changes in protein levels. Interestingly, another study analyzed DNA methylation changes in 
the rat ovary after prenatal DEHP exposure and found that 406 genes were either hyper- or 
hypomethylated [106]. Although we did not specifically measure methylation status in genes, our 
results are similar in that we observed increased 5-mC in prenatally exposed mouse ovaries. In 
the F2 generation, the percentage of 5-mC was not affected, however, Tet expression was 
decreased with DEHP exposure. The decreased Tet expression suggests that DEHP modulates 
DNA demethylation pathways, but it may not be biologically significant enough to affect 5-mC 
levels. In the F3 generation, ancestral DEHP exposure decreased Tet expression, suggesting that 
less TET is available to oxidize 5-mC and subsequently, increased 5-mC in the ovary. However, 
ancestral DEHP exposure decreased the percentage of 5-mC in the ovary. Therefore, Tet 
expression in the ovary may not drive decreased 5-mC. Instead, we anticipate that the decreased 
Dnmt3b expression in the F3 generation results in the decreased 5-mC levels in the ovary. In our 
study, the changes in 5-mC percentage in the F1 and F3 generations may contribute to some of 
the gene expression changes observed [40, 107-109], however, additional studies are necessary 
183 
 
to determine if global 5-mC translates to altered methylation in promoters of transcripts for 
critical ovarian functions. It is critical to selectively measure 5-mC and 5-mhC to adequately 
determine the roles of Dnmts and Tets in the DNA methylation in the ovary. Without 
determining the correct percentage of 5-mC and 5-mhC, it is difficult to determine whether the 
expression levels of Dnmts and Tets are biologically relevant to DNA methylation and 
demethylation processes. 
In summary, our observations indicate that prenatal and ancestral DEHP exposure causes 
differential gene expression in multiple pathways necessary for healthy ovarian function in the 
F1, F2, and F3 generations. Further, results from our study suggest that DNA methylation may 
serve as an epigenetic mechanism, causing some of the transgenerational effects of DEHP. 
Additional studies are required to understand the developmental epigenetic effects of DEHP and 
other endocrine disrupting chemicals on ovarian health. In addition, future studies should 
examine cell types targeted by DEHP exposure. Phthalates, like DEHP, are associated with DNA 
methylation in cord blood of newborns making studies that examine epigenetic changes 
extremely important to human medicine [40]. DNA methylation is not the only epigenetic 
mechanism, thus additional studies should examine other epigenetic mechanisms, such as histone 
modifications, imprinted genes, and the recently discovered DNA methylation mechanism 
involving N6-methyladenine [110]. The understanding of epigenetic mechanisms and the 
understanding of endocrine disruptors on the ovary will help with future pharmaceuticals and 
devices to combat the toxicant effects on the ovary. 
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5.6 Table, Figures, and Legends 
Table 5.1 Sequences of primers sets used for gene expression analysis 
Gene name Symbol Forward primer Reverse primer 
Actin, beta Bactin 5'-AGCACAGCTTCTTTGCAGCTCCTT-3' 5'-CAGCGCAGCGATATCGTCATCCAT-3' 
Steroidogenic acute regulatory protein Star 5'-CAGGGAGAGGTGGCTATGCA-3' 5'-CCGTGTCTTTTCCAATCCTCTG-3' 
3β-hydroxysteroid dehydrogenase 1 Hsd3b1 5'-CAGGAGAAAGAACTGCAGGAGGTC-3' 5'-GCACACTTGCTTGAACACAGGC-3' 
17β-hydroxysteroid dehydrogenase 1 Hsd17b1 5'-ACTGTGCCAGCAAGTTTGCG-3' 5'-AAGCGGTTCGTGGAGAAGTAG-3' 
Cytochrome P450 11A1 Cyp11a1 5'-AGATCCCTTCCCCTGGTGACAATG-3' 5'-CGCATGAGAAGAGTATCGACGCATC-3' 
Cytochrome P450 17A1 Cyp17a1 5'-CCAGGACCCAAGTGTGTTCT-3' 5'-CCTGATACGAAGCACTTCTCG-3' 
Cytochrome P450 aromatase Cyp19a1 5'-CATGGTCCCGGAAACTGTGA-3' 5'-GTAGTAGTTGCAGGCACTTC-3' 
Cytochrome P450 1A1 Cyp1a1 5'-TGTCAGATGATAAGGTCATCACG-3' 5'-TCTCCAGAATGAAGGCCTCCAG-3' 
Cytochrome P450 1B1 Cyp1b1 5'-GCGACGATTCCTCCGGGCTG-3' 5'-TGCACGCGGGCCTGAACATC-3' 
Forkhead box protein L2 Foxl2 5'-GATGGCCAGCTACCCCGAGC-3' 5'-CGCGGGGTCTGGTTTCTCCG-3' 
Kit ligand Kitl 5'-AGTGCTTCGCTGTGAACCCTGC-3' 5'-CCAAGCCATGCAAACGGTGCAA-3' 
Mammalian target of rapamycin complex 1  Mtorc1 5'-GAACCTCAGGGCAAGATGCT-3' 5'-TCTTCAGTCCACTGGCGAAC-3' 
Forkhead box O3  Foxo3a 5'-AGGAGAGAGCAAGAGCCCAAGC-3' 5'-TCGAACTCTGGGTCCAGCTCCA-3' 
Phosphatase and tensin homolog  Pten 5'-GCAGAGCAAGCTCAGTGTGGGT-3' 5'-AGGGGGCAAGGTAGGTACGCAT-3' 
3-phosphoinositide dependent protein kinase-1  Pdk1 5'-AAAAGCAAGCCGGTGGAAAC-3' 5'-CTTGTGAGCATTCCCGCTTG-3' 
Mast/stem cell growth factor receptor  Kit 5'-AACAACAAAGAGCAAATCCAGGCCC-3' 5'-TGAGCACCATCACAATGATCCCCAT-3' 
Tuberous sclerosis 1  Tsc1 5'-ATGCTGCCTGTGGGTGGGTGTA-3' 5'-AGGGTGGAACCATGACCAGCCA-3' 
Ribosomal protein S6 Rps6 5'-GAAGCCAAAGAAAAGCGCCA-3' 5'-TCTCCCCATATTCTAGCAGTCCT-3' 
Cyclin A2 Ccna2 5'-GCTCTACTGCCCGGAGGCTGA-3' 5'-TGGCCTACATGTCCTCTGGGGAA-3' 
Cyclin B1 Ccnb1 5'-TGCATTCTCTCAGTGCCCTCCACA-3' 5'-AGACAGGAGTGGCGCCTTGGT-3' 
Cyclin D2 Ccnd2  5'-CCTTTGACGCAGGCTCCCTTCT-3' 5'-ACCCTGGTGCACGCATGCAAA-3' 
Cyclin E1 Ccne1 5'-GGTGTCCTCGCTGCTTCTGCTT-3' 5'-CCGGATAACCATGGCGAACGGA-3' 
Cyclin-dependent kinase 4  Cdk4 5'-AGAAACCCTCGCTGAAGCGGCA-3' 5'-TGGGGGTGAACCTCGTAAGGAGA-3' 
Cyclin-dependent kinase inhibitor 1A Cdkn1a 5'-TTAGGCAGCTCCAGTGGCAACC-3' 5'-ACCCCCACCACCACACACCATA-3' 
Cyclin-dependent kinase inhibitor 1C Cdkn1c 5'-CTGGACAGGACAAGCGATCC-3' 5'-GCTGTTCTGCTGCGGAGGTA-3' 
Cyclin dependent kinase inhibitor 2A  Cdkn2a 5'-GCTCTGGCTTTCGTGAACAT-3' 5'-CGAATCTGCACCGTAGTTGA-3' 
B cell leukemia/lymphoma 2 Bcl2 5'- ATGCCTTTGTGGAACTATATGGC-3' 5'- GGTATGCACCCAGAGTGATGC-3' 
BCL2-associated X protein Bax 5'- TGAAGACAGGGGCCTTTTTG-3' 5'- AATTCGCCGGAGACACTCG-3' 
BCL2-associated agonist of cell death Bad 5'- AAGTCCGATCCCGGAATCC-3' 5'- GCTCACTCGGCTCAAACTCT-3' 
Caspase 3 Casp3 5'-TGGTGATGAAGGGGTCATTTATG-3' 5'-TTCGGCTTTCCAGTCAGACTC-3' 
Caspase 8 Casp8 5'- GTGAGCCGGCGTGGAACAGG-3' 5'- AGAGCTGTAACCTGTGGCCGAGT-3' 
BCL2-related ovarian killer Bok 5'- CTGCCCCTGGAGGACGCTTG-3' 5'- CCGTCACCACAGGCTCCGAC-3' 
Catalase Cat 5'-GCAGATACCTGTGAACTGTC-3' 5'-GTAGAATGTCCGCACCTGAG-3' 
Glutathione peroxidase Gpx 5'-TTCGGACACCAGGAGAATGG-3' 5'-TAAAGAGCGGGTGAGCCTTC-3' 
Glutathione reductase Gsr 5'- CAGTTGGCATGTCATCAAGCA-3' 5'-CGAATGTTGCATAGCCGTGG-3' 
Peroxisome proliferator-activated receptor alpha Ppara 5'-TGAACAAAGACGGGATG-3' 5'-TCAAACTTGGGTTCCATGAT-3' 
Peroxisome proliferator-activated receptor gamma Pparg 5'-TGTGAGACCAACAGCCTGACGG-3' 5'-GTCCTGAATATCAGTGGTTCACCGC-3' 
Estrogen receptor 2 Esr2 5'-GGAATCTCTTCCCAGCAGCA-3' 5'-GGGACCACATTTTTGCACTT-3' 
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Table 5.1 (cont.) 
Gene name Symbol Forward primer Reverse primer 
Follicle-stimulating hormone receptor Fshr 5'-AGCAAGTTTGGCTGTTATGAGG-3' 5'-GTTCTGGACTGAATGATTTAGAGG-3' 
Insulin-like growth factor 1 Igf1 5'-ATCCCAAGCCCTGTTTGGTT-3' 5'-TGCCCCCAGTGTTTTGAAGT-3' 
insulin-like growth factor binding protein 4 Igfbp4 5'-TTCTCAACTCAAGGCCCACG-3' 5'-GGGCGTTCAATGTTCACCAC-3' 
DNA methyltransferase 1 Dnmt1 5'-GGAAGGCTACCTGGCTAAAGTCAAG-3' 5'-ACTGAAAGGGTGTCACTGTCCGAC-3' 
DNA methyltransferase 3a Dnmt3a 5'-TGGAGAATGGCTGCTGTGTGAC-3' 5'-CACTCATCCCGTTTCCGTTGG-3' 
DNA methyltransferase 3b Dnmt3b 5'-AGTGACCAGTCCTCAGACACGAAG-3' 5'-ATCAGAGCCATTCCCATCATCTAC-3' 
Ten-eleven translocation enzyme 1 Tet1 5'-ACATCCCACAGACCGAAGAT-3' 5'-TTCTGGGGTTTTCACTCCTC-3' 
Ten-eleven translocation enzyme 2 Tet2 5'-AGAGCCTCAAGGCAACCAAAA-3' 5'-ACATCCCTGAGAGCTCTTGC-3' 
Ten-eleven translocation enzyme 3 Tet3 5'-CCGGATTGAGAAGGTCATCTAC-3' 5'-AAGATAACAATCACGGCGTTCT-3' 




Figure 5.1 The Database of Annotation, Visualization, and Integrated Discovery functional 
analysis 
 
Data obtained from the RNA sequencing were functionally analyzed using The Database of 
Annotation, Visualization, and Integrated Discovery (DAVID) Bioinformatics version 6.8. A 
total of 177 genes were entered into DAVID (false discovery rate < 0.62 and p < 0.007) for 
functional annotation analysis. “Gene_Ontology” results yield 5 annotation clusters (A) and 
“Pathways” results yield 1 annotation cluster (B) with a significant enrichment score ≥ 1. 
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Figure 5.2 The effects of DEHP exposure on steroid hormone receptors and insulin-like 
growth factors in the F1 – F3 generations 
 
The effects of prenatal and ancestral DEHP exposure on steroid hormone receptors and insulin-
like growth factors in PND 21 ovaries in the F1 – F3 generations. All gene expression is relative 
to the housekeeping gene, Bactin, and the relative fold change is normalized to 1 for control. 
Graphs represent mean ± SEM from 3 – 6 ovaries per treatment group. * p ≤ 0.05 (significant 
difference compared to control with generation), 0.05 < ^ p < 0.10. 
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Figure 5.3 The effects of DEHP exposure on steroidogenesis and estradiol metabolism in 
the F1 – F3 generations 
 
 
The effects of prenatal and ancestral DEHP exposure on steroidogenesis and estradiol 
metabolism in PND 21 ovaries in the F1 – F3 generations. All gene expression is relative to the 
housekeeping gene, Bactin, and the relative fold change is normalized to 1 for control. Graphs 
represent mean ± SEM from 3 – 6 ovaries per treatment group. * p ≤ 0.05 (significant difference 
compared to control with generation), 0.05 < ^ p < 0.10. 
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Figure 5.4 The effects of DEHP exposure on the phosphoinositide 3-kinase pathway in the 
F1 – F3 generations 
 
The effects of prenatal and ancestral DEHP exposure on the phosphoinositide 3-kinase pathway 
in PND 21 ovaries in the F1 – F3 generations. All gene expression is relative to the housekeeping 
gene, Bactin, and the relative fold change is normalized to 1 for control. Graphs represent mean 
± SEM from 3 – 6 ovaries per treatment group. * p ≤ 0.05 (significant difference compared to 
control with generation), 0.05 < ^ p < 0.10. 
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Figure 5.5 The effects of DEHP exposure on cell cycle regulators in the F1 – F3 generations 
 
The effects of prenatal and ancestral DEHP exposure on cell cycle regulators in PND 21 ovaries 
in the F1 – F3 generations. All gene expression is relative to the housekeeping gene, Bactin, and 
the relative fold change is normalized to 1 for control. Graphs represent mean ± SEM from 3 – 6 
ovaries per treatment group. * p ≤ 0.05 (significant difference compared to control with 
generation), 0.05 < ^ p < 0.10. 
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Figure 5.6 The effects of DEHP exposure on the B-cell lymphomas/leukemia-2 family and 
oxidative stress factors in the F1 – F3 generations 
 
The effects of prenatal and ancestral DEHP exposure on the B-cell lymphomas/leukemia-2 
family and oxidative stress factors in PND 21 ovaries in the F1 – F3 generations. All gene 
expression is relative to the housekeeping gene, Bactin, and the relative fold change is 
normalized to 1 for control. Graphs represent mean ± SEM from 3 – 6 ovaries per treatment 
group. * p ≤ 0.05 (significant difference compared to control with generation), 0.05 < ^ p < 0.10. 
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Figure 5.7 The effects of DEHP exposure on DNA methyltransferases and ten-eleven 
translocation enzymes in the F1 – F3 generations 
 
The effects of prenatal and ancestral DEHP exposure on DNA methyltransferases and ten-eleven 
translocation enzymes in PND 21 ovaries in the F1 – F3 generations. All gene expression is 
relative to the housekeeping gene, Bactin, and the relative fold change is normalized to 1 for 
control. Graphs represent mean ± SEM from 3 – 6 ovaries per treatment group. * p ≤ 0.05 
(significant difference compared to control with generation), 0.05 < ^ p < 0.10. 
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Figure 5.8 The effects of DEHP exposure on the percentage of 5-methyl cytosine in the F1 – 
F3 generations 
 
The effects of prenatal and ancestral DEHP exposure on the percentage of 5-methyl cytosine in 
whole ovaries at PND 21 in the F1 – F3 generations. Graphs represent mean ± SEM from 3 – 7 
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Summary, Conclusions, and Future Directions 
6.1 Summary, Conclusions, and Future Directions 
 My doctoral dissertation work was designed to determine the developmental and 
reproductive toxicity of DEHP exposure in female mice. DEHP is a widely used plasticizer in 
consumer products and is a known developmental and reproductive toxicant [1-3]. DEHP and its 
bioactive metabolites are found in human tissues such as amniotic fluid, cord blood, breast milk, 
and human follicular fluid [4]. The presence of DEHP in tissues vital for reproduction and 
development suggests that DEHP exposure occurs at various developmental stages; thus, posing 
as a potential toxicant for several generations. Many studies have been conducted on the toxic 
effects of DEHP on the female reproduction. However, most of these studies focused on one 
generation or focus on adult exposure [1, 2, 5, 6]. Understanding the effects of environmentally 
relevant DEHP exposure on female reproduction across generations is critical so that we can 
better understand the potential risks of DEHP on human and animal health. Collectively, my 
study shows that environmentally relevant levels of DEHP disrupts ovarian functions, impairs 
reproductive outcomes, and decreases expression of genes necessary for normal ovarian 
functions across generations in female mice. 
 In Chapter 3, I tested the hypothesis that prenatal DEHP exposure disrupts ovarian 
functions in a transgenerational manner. I found that prenatal and ancestral DEHP exposure 
disrupted folliculogenesis in a multigenerational manner and accelerated germ cell transition in a 
transgenerational manner. Specifically, in the F1 generation, prenatal DEHP exposure decreased 
folliculogenesis and decreased the percentage of atretic follicles. In the F2 generation, DEHP 
exposure disrupted folliculogenesis. In the F3 generation, ancestral DEHP exposure accelerated 
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transition of germ cells to primordial follicles in neonatal ovaries. The altered folliculogenesis in 
the ovary suggests that DEHP exposure directly targets maturing follicles and the changes in 
germ cell numbers suggest that DHEP targets ovarian development. Future studies should test 
the health of ovarian follicles by isolating and culturing them to monitor their growth and 
hormone production. Additionally, studies should test the health of the oocyte by performing in 
vitro fertilization on isolated follicles. Further, future studies should investigate the effects of 
folliculogenesis at older ages and determine if DEHP induces premature ovarian failure. 
 In Chapter 3, I measured serum hormone levels and found that prenatal DEHP exposure 
disrupted serum sex steroid hormone levels in female mice. In the F1 generation, prenatal DEHP 
exposure increased serum 17β-estradiol. In the F2 generation, DEHP exposure disrupted serum 
progesterone levels. The altered steroidogenesis suggests that DEHP exposure targets serum sex 
steroid hormone levels either through synthesis or metabolism. These hormones are critical for 
normal reproductive health and function and are also critical for bone, heart, and mental health 
[7-13]. Additional studies should determine whether DEHP exposure disrupts enzymes that 
metabolize sex steroid hormones in the liver. Enzymes that metabolize sex steroid hormones can 
have an impact on the serum sex steroid hormone level in the body [14]. In addition, studies 
should determine the impact of DEHP exposure on other sex steroid hormone synthesizing 
organs such as the adrenals, which secrete precursor hormones such as progesterone and 
androgens [15], so that we can better understand the impact of DEHP on steroidogenesis. 
Further, additional studies should measure serum steroid hormone levels at all phases of the 
estrous cycle to determine if DEHP exposure targets a particular phase. 
In Chapter 4, I hypothesized that prenatal and ancestral exposure to DEHP disrupts 
female reproductive outcomes in both a multigenerational and transgenerational manner. I found 
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that prenatal and ancestral DEHP exposure accelerated the onset of puberty and estrous cyclicity. 
In the F1 generation, prenatal DEHP exposure accelerated the onset of puberty and disrupted 
post-pubertal cyclicity. In the F2 generation, DEHP exposure accelerated the onset of puberty 
and disrupted post-pubertal cyclicity and adult estrous cyclicity. In the F3 generation, ancestral 
DEHP exposure accelerated the onset of puberty and disrupted post-pubertal cyclicity and adult 
estrous cyclicity. Our data show that DEHP exposure disrupts pubertal onset in female mice. 
Pubertal onset is governed by a feedback loop between the hypothalamus, pituitary, and gonads 
[16]. Additional studies are needed to better understand the mechanism by which DEHP induces 
precocious puberty. Specifically, future studies should determine whether DEHP exposure 
disrupts GnRH firing and production of gonadotropin hormones around the time of puberty. 
In Chapter 4, I found that prenatal DEHP exposure disrupts birth outcomes and decreases 
fertility-related indices in a multigenerational manner. In the F1 generation, prenatal DEHP 
exposure decreased the mating index and pregnancy index. In the F2 generation, DEHP exposure 
increased litter size and decreased the gestational index. My data show that DEHP exposure 
directly affects the fertility of female mice. Additional studies are necessary to determine the 
mechanism of action. Specifically, additional studies should investigate the effects of DEHP on 
mating behavior and determine if the decreased mating index is due to a behavioral change 
caused by DEHP. My study found that the majority of infertility issues caused by DEHP were 
due to mid-gestation infertility. Possible causes of mid-gestation infertility include disrupted 
uterine function, immune response, fetal development, or hormone signaling. Therefore, it is 
critical for future studies to examine the cause of breeding and pregnancy complications. Future 
studies that investigate the uterus are critical because the uterus is fundamental for the 
maintenance of a pregnancy. 
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In Chapter 5, I hypothesized that prenatal and ancestral DEHP disrupted gene expression 
of pathways critical for ovarian health and DNA methylation mechanisms. I found that prenatal 
and ancestral DEHP exposure disrupted gene expression of various pathways in the ovary in a 
multigenerational and transgenerational manner. In the F1 generation, prenatal DEHP exposure 
dysregulated the expression of genes in the cell cycle regulators and peroxisome-proliferator 
activated receptors in the whole ovary. In the F2 generation, DEHP exposure decreased the 
expression of steroidogenic enzymes, disrupted the expression of PI3K factors, and decreased the 
expression of pro-apoptotic factors in the whole ovary. In the F3 generation, ancestral DEHP 
exposure decreased the expression of PI3K factors, cell cycle regulators, apoptotic factors, 
oxidative stress factors, and estrogen receptor 2 in the whole ovary. Future studies should 
investigate the effects of DEHP exposure on protein expression in the ovary. Although my data 
show that DEHP exposure decreases gene expression in the ovary, it is critical to know if DEHP 
disrupts the expression of proteins. 
In Chapter 5, I also found that prenatal and ancestral DEHP exposure dysregulated the 
expression of Dnmts and Tets and altered DNA methylation levels in both a multigenerational 
and transgenerational manner. In the F1 generation, prenatal DEHP exposure increased the 
expression of Dnmt1 and increased the percentage of 5-mC in the whole ovary. In the F2 
generation, DEHP exposure decreased the expression of Tets. In the F3 generation, ancestral 
DEHP exposure decreased the expression of Dnmts, Tets, and decreased the percentage of 5-mC 
in the whole ovary. Future studies should investigate the effects of DEHP exposure on gene 
expression and DNA methylation in single cells. The ovary is a heterogeneous organ and it is 
critical to know which cells gene expression changes are occurring. It is especially important to 
know if DEHP induces DNA methylation changes in the germ cell. Additionally, future studies 
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should determine the protein expression of DNMT and TET in the ovary. Protein expression and 
activity of DNMT and TET are critical for the execution of DNA methylation [17-24]. Further 
studies should determine the methylation profile of promoter regions of genes that were 
differentially expressed due to DEHP exposure. Such studies would determine whether DNA 
methylation specifically targets gene expression changes. However, it is necessary that additional 
studies determine whether DEHP acts through additional epigenetic pathways. 
Further studies should investigate the effects of prenatal and ancestral exposure to DEHP 
on the ovary in older mice. Although I observed significant changes in ovarian function and 
health and early reproductive outcomes in the female mice, it is critical to observe the life-long 
effects of DEHP exposure. Therefore, future studies should examine the health of the ovary in 
mice significantly older than postnatal day 60. Additionally, given that humans and animals are 
continuously exposed to DEHP on a daily basis, it is critical to have future studies that expose 
animals to DEHP on a daily basis to better understand the effects of DEHP on female 
reproductive health. Future analyses should also investigate different developmental exposure 
windows to DEHP to determine the mechanisms that causes transgenerational inheritance of 
disease and dysfunction. Although there are studies that expose mice to DEHP during gestation 
and the neonatal time period [25], it is important to determine the most sensitive window of 
exposure to induce transgenerational inheritance of disease in females. 
Overall, my doctoral dissertation work indicates that prenatal and ancestral DEHP 
exposure disrupts female reproductive outcomes in a multigenerational and transgenerational 
manner. Specifically, DEHP exposure disrupts ovarian health and function by altering 
steroidogenesis in a multigenerational manner and folliculogenesis in a transgenerational 
manner. Moreover, DEHP exposure disrupts female reproductive outcomes in all generations of 
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female mice. Further, DEHP exposure dysregulates the expression of Dnmts and Tets and alters 
DNA methylation levels in both a multigenerational and transgenerational manner. These 
findings are important for the public health because humans and animals are continuously 
exposed to DEHP and our findings show that the effects of DEHP on female reproduction span 
generations. Further, the environmentally relevant doses of DEHP used in my doctoral 
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